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Abstract 
The discovery that the three ring polyamide Im-Py-Py-Dp containing imidazole 
(Im) and pyrrole (Py) carboxamides binds the DNA sequence 5'-(A,T)G(A,T)C(A,T)-3' 
as an antiparallel dimer offers a new model for the design of ligands for specific 
recognition of sequences in the minor groove containing both G,C and A,T base pairs. In 
Chapter 2, experiments are described in which the sequential addition of five N-
methylpyrrolecarboxamides to the imidazole-pyrrole polyamide Im-Py-Py-Dp affords a 
series of six homologous polyamides, Im-(Py)2_7-Dp, that differ in the size of their binding 
site, apparent first order binding affinity, and sequence specificity. These results 
demonstrate that DNA sequences up to nine base pairs in length can be specifically 
recognized by imidazole-pyrrole polyamides containing three to seven rings by 2:1 
polyamide-DNA complex formation in the minor groove. Recognition of a nine base pair 
site defines the new lower limit of the binding site size that can be recognized by 
polyamides containing exclusively imidazole and pyrrolecarboxamides. The results of this 
study should provide useful guidelines for the design of new polyamides that bind longer 
DNA sites with enhanced affinity and specificity. 
In Chapter 3 the design and synthesis of the hairpin polyamide Im-Py-Im-Py-y-
Im-Py-Im-Py-Dp is described. Quantitative DNase I footprint titration experiments reveal 
that Im-Py-Im-Py-y-Im-Py-Im-Py-Dp binds six base pair 5'-(A,T)GCGC(A,T)-3 ' 
sequences with 30-fold higher affinity than the unlinked polyamide Im-Py-Im-Py-Dp. The 
hairpin polyamide does not discriminate between A•T and T·A at the first and sixth 
positions of the binding site as three sites 5'-TGCGCT-3', 5'-TGCGCA-3', and 5 '-
AGCGCT-3' are bound with similar affinity. However, Im-Py-Im-Py-y-Im-Py-Im-Py-
Dp is specific for and discriminates between G·C and C·G base pairs in the 5'-GCGC-3 ' 
vu 
core as evidenced by lower affinities for the mismatched sites 5'-AACGCA-3', 5'-
TGCGTT-3' , 5'-TGCGGT-3', and 5'-ACCGCT-3'. 
In Chapter 4, experiments are described in which a kinetically stable hexa-aza 
Schiff base La3+ complex is covalently attached to a Tat(49-72) peptide which has been 
shown to bind the HIV-1 TAR RNA sequence. Although these metallo-peptides cleave 
TAR site-specifically in the hexanucleotide loop to afford products consistent with 
hydrolysis, a series of control experiments suggests that the observed cleavage is not 
caused by a sequence-specifically bound Tat(49-72)-La(L)3+ peptide. 
Vlll 
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DNA Recognition in Biological Systems. Deoxyribonucleic acid (DNA) 
functions as the chemical blueprint for life by encoding all of the proteins and ribonucleic 
acid (RNA) necessary for cellular function. The specific recognition of particular DNA 
sequences by proteins is critical for a variety of cellular processes including gene 
replication, transcription, and cell division. The critical importance of DNA in these 
processes makes the genetic material an attractive target for the development of chemical 
approaches to sequence-specific recognition. The design of materials for the specific 
recognition of particular DNA sequences may afford a new class of reagents that are 
capable of controlling gene expression and that may be useful in human therapeutics. 
DNA Structure. The structure of B-form right-handed double helical DNA 1s 
well-established.1· 2 The DNA double helix is composed of two antiparallel polydeoxy-
ribonucleotide strands which associate via Watson-Crick hydrogen bonds between 
complementary heterocyclic bases on opposite strands and is stabilized by vertical n:-n: 
stacking interactions between bases on the same strand (Figure 1.1 ). In double helical 
DNA the sugar-phosphate backbone is displaced away from the helical axis, creating a 
wide and shallow major groove and a narrow and deep minor groove along the cylindrical 
double helix. The edges of the base pairs are located at the bottom of the grooves and 
present different chemical functionalities capable of interacting with DNA-binding ligands 
(Figure 1.2). In the major groove the distinct pattern of hydrogen bond donor and acceptor 
groups allows all four base pairs to be distinguished. Base pair discrimination in the 
2 
Figure 1.1. Structure of B-form double helical DNA. The DNA is represented as a line 
model (white) with an overlaid van der Waals surface (magenta). The wide and shallow 
major groove and the narrow and deep minor groove are clearly visible. 
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Major Groove Major Groove 
Minor Groove Minor Groove 
Figure 1.2. Structure of the four natural Watson-Crick base pairs showing the functional 
groups displayed in the major and minor grooves. Lone pairs that function as potential 
hydrogen bond acceptors are represented as black lobes and potential hydrogen bond 
donors are indicated as gray spheres. 
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minor groove is less distinct. The A,T base pair presents two hydrogen bond acceptors, 
the purine N3 and the pyrimidine 02 atoms (Figure 1.3). Due to the approximate two-fold 
symmetry of these atoms, the minor groove surfaces of A•T and T•A base pairs are 
approximately degenerate. The GC base pair retains these two hydrogen bond acceptors 
but also presents the 2-amino group of guanine as a hydrogen bond donor. Because this 
hydrogen bond donor lies closer to the guanine-containing strand, G•C and C•G base pairs 
are distinguishable in the minor groove. In addition to the groove edges of the base pairs 
sequence-dependent structural variations, conformational properties, and counterion 
organization can all distinguish particular DNA sequences. DNA-binding ligands 
generally recognize their target sites by a combination of hydrogen bonding interactions 
with the functional groups displayed on the floor of the grooves and electrostatic, van der 
Waals interactions with the sugar-phosphate backbone, and overall shape complementarity 
with the binding site.3 
Protein-DNA Complexes. High resolution structural data from x-ray and NMR 
studies of protein-DNA complexes has dramatically enhanced our understanding of 
sequence-specific recognition of DNA by native proteins. Several different structural 
motifs for sequence-specific DNA binding have been identified including the zinc finger, 
leucine zipper, homeodomain, and helix-tum-helix motifs.4 These proteins generally 
recognize their binding sites by a combination of hydrogen bonding interactions between 
the protein backbone and side chains with the bases in the major and/or minor groove, salt 
bridges between positively charged side chains and specific phosphate groups, as well as 
the overall shape complementarity between the protein and the DNA binding site (Figure 
1.4). Due to the complexity of DNA-protein interactions the design of proteins for 
recognition of designated DNA sequences remains a major challenge although progress is 
being made in this area, particularly with the zinc finger motif.5 
6 
Figure 1.3. Base pair discrimination in the minor groove of B-form double helical DNA. 
The A•T and T•A base pairs (top) and G•C and C•G base pairs (bottom) are shown. The 
DNA is shown in CPK form (yellow) with N3 of A and G and N2 of G colored blue and 
02 ofT and C colored red. The hydrogen atom of N2 of G is colored white. 
7 
8 
Figure 1.4. High resolution x-ray crystal structure of the 52 amino acid residue DNA 
binding domain of Hin recombinase bound to a DNA recombination half-site.4d The DNA 
is represented as a line model (white) with an overlaid van der Waals surface (magenta). 
The protein is a member of the helix-turn-helix family and is represented as a yellow 
ribbon. The side chains of the residues comprising the DNA recognition helix bound in 
the major groove are shown as well as the side chains of the N-terminal arm residues 
bound in the adjacent minor groove. 
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Oligonucleotide-Directed Triple Helix Formation. In 1987 Moser and Dervan 
demonstrated that a short homopyrimidine oligodeoxynucleotide could sequence-
specifically bind in the major groove of double helical DNA parallel to a homopurine tract 
(Figure 1.5).6"7 Specificity within the triple-helical complex arises from the formation of 
T• AT and c+•GC base triplets via hydrogen bonding interactions between the pyrimidine 
bases on the third strand and the Hoogsteen face of the purine bases of the Watson-Crick 
base pairs. The sequence specificity of triple helix formation has been powerfully 
demonstrated in a series of experiments where pyrimidine oligonucleotides were capable of 
single-site binding to bacteriophage, yeast, and human chromosomal DNA.8 Additional 
experiments have been performed to determine the effects of oligonucleotide length,6·9 
modified pyrimidines,10 single base mismatches,6·9·11 pH, 10b·12 cation concentration and 
valence,13 temperature, 14 backbone composition,15 cooperativity,16 and sequence 
composition 17 on the stability and specificity of triple helix formation in the pyrimidine 
motif. Purine-rich oligonucleotides have been shown to bind in the minor groove of 
double helical DNA antiparallel to a homopurine strand by the formation of specific G•GC, 
A•AT, and T•AT base triplets.18 More recently, a third nonnatural motif for recognition of 
DNA by triple helix formation has been discovered. 19 In the parallel purine motif the 
putative base triplet geometry of the antiparallel purine motif is maintained while the third 
strand orientation is reversed by moving the third strand deoxyribose from the natural N9 
position to N7. Experiments have shown that A•T and G•C base pairs can be recognized 
by the formation of 7 A • AT and 7 G•GC base triplets. Current efforts are directed towards 
the synthesis of oligonucleotides containing exclusively N7 purines that bind with high 
affinity and specificity. While these three triple-helical motifs provide a versatile method 
for binding homopurine sequences, the recognition of mixed purine-pyrimidine sequences 

































Figure 1.5. Oligonucleotide-directed triple helix formation. Ribbon model of a triple-
helical complex between a 15 base pair purine sequence and a 15mer pyrimidine 
oligonucleotide on a 4 .06-kbp DNA restriction fragment. 
base pairs via new hydrogen bonding patterns and favorable steric interactions with the 
major groove edges of these base pairs is an ongoing effort.20' 21 Progress has been 
hampered by the lack of high-resolution structural data and an incomplete understanding of 
the forces that stabilize triple helix formation, particularly base stacking interactions in the 
third strand.22 Protein-mediated triple helix formation with RecA nucleoprotein filaments 
that appear to bind in the minor groove may become a versatile method for recognizing 
DNA sequences containing all four of the natural base pairs.23.24 
Small Molecule Recognition of DNA. A wide variety of small molecules (MW 
< 1500) bind double helical DNA sequence specifically.25 Examples include distamycin, 
12 
Figure 1.6. Structure of netropsin and distamycin A. 
netropsin, chromomycin, and the enediyne antibiotics neocarzinostatin, calicheamycin, and 
dynemycin. These ligands generally recognize DNA by binding in the minor groove 
and/or intercalating between the base pairs.26 Netropsin and distamycin are di- and tri-N-
methylpyrrolecarboxarnides, respectively, isolated from Streptomyces (Figure 1.6).27 
Netropsin contains an N-terrninal guanadinium group and a C-terrninal amidinium group 
while distamycin contains an N-terminal formamide group and a C-terrninal arnidinium 
group. These compounds exhibit antifungal, antimitotic, and antiviral properties in vivo 
presumably by binding A,T-rich DNA sequences.28. 29 The ability to synthesize analogs of 
these natural products coupled with direct assays for DNA binding provides chemists with 
the opportunity to study sequence-specific molecular recognition of double helical DNA. 
The development of ligands that bind in the minor groove of DNA with high affinity and 
sequence specificity may afford new materials that have use in controlling gene expression 
and as human therapeutics. 
13 
A B 
Figure 1.7. 1:1 Models for netropsin (A) and distamycin (B) binding to A,T-rich DNA. 
Structure of 1:1 Polyamide-DNA Complexes. High-resolution x-ray30 and 
NMR31 studies of netropsin- and distamycin-DNA complexes reveal how sequence-
specific binding to four and five base pair A,T-rich sequences, respectively, is 
accomplished. The crescent-shaped polyamides are bound in the center of the minor 
groove of an A,T -rich sequence with the N-methylpyrrolecarboxamides twisting in a screw 
sense to match the walls of the minor groove, giving a favorable shape complementarity 
for the ligand. The carboxamide NH' s form bifurcated hydrogen bonds with adenine N3 
and thymine 02 atoms on the floor of the minor groove (Figure 1.7). The pyrrole rings fill 
the groove and form extensive van der Waals contacts with the walls of the minor groove 
(Figure 1.8). The aromatic hydrogens of the N-methylpyrrole rings are set too deeply in 
the minor groove to accommodate the guanine 2-amino group of a G,C base pair, 
affording binding specificity for A,T-rich sequences. The positively charged amidinium 
and guanadinium groups of the polyamides lie along the floor of the groove and provide 
favorable electrostatic interactions with the negatively-charged phosphodiester backbone of 
DNA.32-33 
14 
Figure 1.8. High resolution x-ray crystal structure of the 1:1 complex between distamycin 
and a 5'-AAATTT-3 ' site.30d The DNA is represented as a line model (white) with an 
overlaid van der Waals surface (magenta). The N-methylpyrrolecarboxamides and the 
positively charged arnindinium group are colored cyan and green, respectively. 
15 
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Assays for Sequence-Specific DNA Binding. Two complementary techniques, 
affinity cleaving and footprinting, are routinely used for determining the binding affinity 
and sequence specificity of DNA-binding ligands.34 In affinity cleaving a non-specific 
DNA cleaving agent is covalently attached to a sequence-specific DNA binding molecule 
to afford a sequence-specific DNA cleaving molecule. A commonly used non-specific 
cleaving moiety is EDTA•Fe(II) which in the presence of reducing agents such as 
dithiothreitol or sodium ascorbate generates a diffusible oxidant, presumably hydroxyl 
radical, capable of hydrogen atom abstraction from the sugar-phosphate backbone at 
locations near the ligand binding site. Analysis of the cleavage products from an 32P end-
labeled DNA restriction by high-resolution denaturing polyacrylamide gel electrophoresis 
provides information about the location and size of the binding site and the orientation of 
the affinity cleaving analog on the DNA (Figure 1.9). Analysis of the asymmetric pattern 
of the cleavage bands provides direct information on the groove location of EDT A • Fe(II) 
(Figure 1.10). EDTA•Fe(II) positioned in the major groove affords cleavage products that 
are asymmetrically shifted in the 5' direction, whereas if the cleaving agent is located in the 
minor groove the cleavage products are 3' shifted. Affinity cleaving has been used in 
studies of sequence specific DNA recognition by proteins,35 oligonucleotides,9•36 and small 
molecules.37 In DNA footprinting a 32P-end labeled restriction fragment and the DNA-
binding ligand are incubated in solution, after which they are treated with a non-specific 
DNA cleaving agent such as DNase I38 or the synthetic reagent methidiumpropyl-
EDTA•Fe(II)39 (MPE•Fe(II)) which cleave DNA at positions not bound by the ligand. 
Analysis of the cleavage products by high-resolution denaturing polyacrylamide gel 
electrophoresis reveals the location and size of the binding site (Figure 1.9). 
Quantitative DNase I Footprint Titration Experiments. The apparent first 
order equilibrium binding affinities of ligands for discreet DNA sequences can be 
17 
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Figure 1.9. Affinity cleaving (left) and footprinting (right) techniques for the analysis of 
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Models for the asymmetric DNA cleavage pattern generated by 
EDTA•Fe(II) positioned in the major and minor grooves of right-handed double helical 
DNA. 
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measured by quantitative DNase I footprint titration experiments. This technique has been 
well-developed by Ackers and coworkers for measuring the binding affinity of proteins 
and small molecules.40"41 In a quantitative DNase I footprint titration experiment, 
footprinting reactions are carried out over a five order of magnitude range of ligand 
concentration. After limited digestion with DNase I the cleavage products are separated on 
a high-resolution denaturing polyacrylamide gel along with cleavage products from a 
control reaction where no ligand was added (Figure 1.11). The gel is imaged using storage 
phosphor autoradiography and the data is analyzed by performing volume integrations of 
the ligand binding site and a reference site at which DNase I cleavage is invariant.42 The 
fractional occupation of the site, e app' is calculated by comparing the extent of protection at 
the target site to that of the reference site and normalizing to the control lane. The ([L]
10
t> 
eapp) data points are fit to Langmuir binding isotherm by minimizing the difference between 
eapp and er.r using the modified Hill equation: 
f) f) ( (} _ (} . ) K a n [L] n tot 





corresponds to the total ligand concentration, Ka corresponds to the apparent 
monomeric association constant, n is the Hill coefficient, and emax and emin represent the 
experimentally determined site saturation values when the binding site is unoccupied or 
saturated, respectively (Figure 1.12). 
Polyamides for Binding Longer A,T Tracts. The 1:1 polyamide-DNA models 
derived from high-resolution netropsin- and distamycin-DNA structures aided in the 
design of polyamides that bind larger sequences of A,T-rich DNA.43. 47 Youngquist and 
Dervan demonstrated that a series of polyamides containing three to nine N-
methylpyrrolecarboxamides are capable of binding four to eleven A ,T base pairs, 
19 
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Figure 1.11. Illustrative gel from a quantitative DNase I footprint titration experiment. 
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[Ligand] (M. 1) 
Figure 1.12. Example of a binding isotherm generated from a quantitative DNase I 
footprint titration experiment where the fractional occupancy, 8 norm' and log[L] are reported 
on the vertical and horizontal axes, respectively. The curve through the data points is the 
best-fit Langmuir binding isotherm. The ligand concentration at half-occupancy is the first 
order dissociation constant. 
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respectively .44 In subsequent work a polyamide containing three tetra-N-methylpyrrole-
carboxamide units coupled head-to-tail with ~-alanine specifically bound 16 contiguous 
A,T base pairs, a tum and a half of the double helix, in the minor groove.45 
Polyamides Designed to Bind Mixed Sequences from 1:1 Models. One 
approach to the design of polyarnides for recognition of G,C base pairs based on 1:1 
polyamide-DNA models involved incorporating hydrogen bond acceptor atoms on ligands 
which could form specific hydrogen bonds with the 2-arnino group of guanine on the floor 
of the minor groove.48 Distamycin analogs in which the pyrrole rings were substituted 
with imidazole and thiazole rings displayed increased tolerance for G,C base pairs in their 
binding site, but with an overall loss of specificity.49 Two polyamides designed from 1:1 
models are specific for mixed sequences. Footprinting and affinity cleavage experiments 
reveal that the pyridine- (Pyr) and imidzaole (Im)-pyrrole (Py) polyamides Pyr-Py-Py-Dp 
and Im-Py-Py-Dp specifically recognize five base pair 5'-(A,T)G(A,T)C(A,T)-3' 
sequences (Figure 1.13). 50-51 However, 1: 1 polyamide-DNA models were inadequate for 
rationalizing the presence of G,C base pairs in the second and fourth positions of the 
binding site. 
Figure 1.13. Structure of Pyr-Py-Py-Dp and Im-Py-Py-Dp. 
21 
2:1 Distamycin-DNA Complexes. Two-dimensional NMR studies by Pelton and 
Wemmer have demonstrated that distamycin at high concentrations is capable of binding in 
the minor groove of a 5' -AAATT-3' sequence as a side-by-side antiparallel dimer (Figures 
1.14, 1.15). 52.53 Molecular modeling suggests that the minor groove must expand 
significantly relative to 1: 1 complexes in order to accommodate both ligands. As in 1:1 
distamycin-DNA complexes the dimeric polyamides fill the minor groove and maintain 
favorable van der Waals contacts with the walls of the groove. The stacked distamycin 
ligands are staggered with the carboxamides of one ligand overlapping the pyrrole rings of 
the second ligand in the 2: 1 complex. In this 2:1 complex the positively charged 
amidinium groups are oriented towards the 3' ends of the binding site. The recent x-ray 
crystal structure of a 2:1 distamycin-5' -ICICICIC-3' complex confirms these results and 
emphasizes the importance of polyamide-polyamide stacking interactions in stabilizing 2:1 
complexes.54 Detailed thermodynamic analysis of distamycin binding to a 5 ' -AAATT -3' 
site reveals that the first ligand binds with high affinity (Kb = 3.1 x 107) in an enthalpically 
driven process (l1Hb = -12.3 kcal/mol) while the second ligand binds with lower overall 
affinity (Kb = 3.3 x 106) but with a larger enthalpy of binding (l1Hb = -18.8 kcal/mol).55 
Rentzeperis and co-workers suggest that this 6.5 kcallmol increase in the enthalpy of 
binding for the second distamycin ligand in the 2: 1 complex is primarily a result of the 
increase in van der Waals interactions from the side-by-side stacking of the ligands in the 
minor groove. 55 Other experiments have shown that the cooperativity of distamycin 
binding is highly dependent on DNA sequence and may depend on both sequence-
dependent minor groove width and flexibility.56 
Recognition of Mixed Sequences by 2:1 Antiparallel Polyamide Dimers. The 
2:1 model derived from the studies above adequately explains the specificity of Pyr-Py-Py-
Dp and Im-Py-Py-Dp for 5 ' -(A,T)G(A,T)C(A,T)-3' sequences.50.5 1 The 2-amino group 
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Figure 1.14. High resolution structure the 2:1 complex between distamycin and a 5'-
AAATT-3 ' site derived from NMR data.52 The DNA is represented as a line model 
(white) with an overlaid van der Waals surface (magenta). The N-
methylpyrrolecarboxamides and the positively charged amindinium group are colored cyan 
and green, respectively. 
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Figure 1.15. Binding model of the 2:1 complex between distamycin and a 5'-AAATT-3' 
site derived from NMR data. Circles with dots represent lone pairs of N3 of purines and 
02 of pyrimidines and circles containing a H represent the 2-amino group of guanine. 
Putative hydrogen bonds are indicated by dashed lines. 
of each guanine in the binding site could participate m specific hydrogen bonds with 
pyridine or imidazole nitrogen atoms on each of the polyamides in the 2 :1 complex (Figure 
1.16). The carboxamide NH's are predicted to participate in hydrogen bonds with N3 of 
adenine and 02 of thymine and cytosine. NMR experiments have confirmed these 
predictions and reveal that Pyr-Py-Py-Dp and Im-Py-Py-Dp bind a 5'-TGACT-3' site in 
the minor groove as side-by-side anti parallel dimers (Figure 1.17). 57.58 As in 1:1 and other 
2:1 polyamide-DNA complexes, dimeric binding of Pyr-Py-Py-Dp and Im-Py-Py-Dp to 
5'-TGACT -3 ' is likely stabilized by a combination of specific hydrogen bonding, 
electrostatic, and van der Waals interactions between the ligands and the DNA and stacking 
of the ligands in the minor groove. NMR titration experiments demonstrate that binding of 
the second ligand is highly cooperative with only resonances for the 2: 1 complex observed 
even at low ligand concentrations. This result is consistent with the observation 
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A B 
Figure 1.16. 2:1 models for (A) Pyr-Py-Py-Dp and (B) Im-Py-Py-Dp bound at a 5'-
TGTCA-3 ' site. Circles with dots represent lone pairs of N3 of purines and 02 of 
pyrimidines and circles containing a H represent the 2-amino group of guanine. Putative 
hydrogen bonds are indicated by dashed lines. 
that distamycin binds exclusively as a dimer to a 5'-IIICC-3' site. For mixed sequences 
which generally have inherently wider minor grooves than A,T-rich sequences expansion 
of the minor groove to accommodate binding of polyamide dimers may be more 
energetically favorable than clamping down on one ligand in a 1:1 complex.57·59 
Antiparallel Side-by-Side Heterodimer. The most significant difference between 
2:1 and 1: 1 polyamide-DNA complexes is that each ligand in the dimeric motif interacts 
with only one of the DNA strands in the minor groove. The side-by-side combination of 
one imidazole ring on one ligand and a pyrrolecarboxamide on the second ligand is specific 
for G•C, while a pyrrolecarboxarnide/imidazole pair targets a C•G base pair. A 
pyrrolecarboxamide/ pyrrolecarboxamide pair is partially degenerate and binds A•T or T•A 
base pairs. Based on this revised 2:1 model a polyamide heterodimer consisting of Im-Py-
Py-Dp and distamycin should was designed to specifically bind 5'-(A,T)G(A,Tk3' 
sequences (Figure 1.18). 60 Footprinting and affinity cleavage experiments demonstrate that 
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Figure 1.17. High resolution structure of the (Im-Py-Py-Dp)2•5'-TGTCA-3' complex 
derived from NMR data.57 The DNA is represented as a line model (white) with an 
overlaid van der Waals surface (magenta). The imidazole rings, N-
methylpyrrolecarboxarnides, and the positively charged dimethylarninopropyl groups are 
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Figure 1.18. Model of the (lm-Py-Py-Dp/distamycin)•5'-TGTT A-3 ' complex. Circles 
with dots represent lone pairs of N3 of purines and 02 of pyrimidines and circles 
containing a H represent the 2-amino group of guanine. Putative hydrogen bonds are 
indicated by dashed lines. 
both ligands simultaneously bind a five base pair 5'-TGTT A-3' sequence and reveal that 
the ligands are oriented as predicted by the 2:1 model for polyamide-DNA recognition. 
Structural characterization of this heterodimeric complex by two-dimensional NMR 
confirms these results and as observed for the (lm-Py-Py-Dp)2•5'-TGACT-3 ' complex no 
1:1 binding is observed.61 In a related study, Lown, Wemmer, and coworkers reported that 
a Py-lm-Py polyamide in combination with distamycin recognizes a 5 ' -AAGTT-3' site in 
the minor groove as an antiparallel heterodimer.62 These studies of homo- and 
heterodimeric polyamide-DNA complexes suggest that the 2:1 motif will be useful in the 
design of polyamides for specific recognition of a variety of other mixed sequences in the 
minor groove. 
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Figure 1.19. Structure of Im-Py-Im-Py-Dp and the affinity cleaving analog Im-Py-Im-
Py-EDTA•Fe(II). 
Recognition of 5'-GCGC-3' Sequences. Based on 2:1 polyamide-DNA models, 
the alternating four ring polyamide Im-Py-Im-Py-Dp was designed to bind six base pair 
5' -(A,T)GCGC(A,T)-3' sequences as an antiparallel homodimer in the minor groove 
(Figure 1.19).63 Each imidazole N3 in the ligands was designed to form a hydrogen bond 
to one guanine amino group on the floor of the minor groove. MPE•Fe(II) footprinting 
and affinity cleaving experiments reveal that Im-Py-Im-Py-Dp specifically binds 5'-
TGCGCA-3 ' , 5'-AGCGCT-3', and 5 ' -AACGCA-3' sites consistent with 2:1 binding.63b 
Quantitative DNase I footprint titration experiments demonstrate that the alternating 
polyamide binds match sites 5'-TGCGCA-3' and 5 '-AGCGCT-3' with equal affinity (Ka 
= 4.0 x 105) suggesting that Im-Py-Im-Py-Dp does not discriminate between A•T and T•A 
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base pairs in the first and sixth position of the binding site. Binding of Im-Py-Im-Py-Dp 
to the mismatch 5'-AACGCA-3' site occurs with three-fold lower affinity. The 
observation that 5'-TGGCGT-3' and 5'-TCGGCA-3' sites are not bound demonstrates 
that the four ring polyamide discriminates between G•C and C•G base pairs in the center of 
the binding site. NMR characterization of an (Im-Py-Im-Py-Dp)2•5 ' -TGCGCA-3' 
complex indicates that the polyamide binds in the minor groove as a side-by-side 
antiparallel dimer with positive cooperativity (Figure 1.20).633 Modeling of the complex 
with constraints from the NMR data affords a model in which each imidazole of the 
dimeric polyamides forms a hydrogen bond to a unique guanine amino group (Figure 
1.21). The binding of Im-Py-Im-Py-Dp to a 5 ' -GCGC-3' core sequence represents a 
complete reversal of the specificity of distamycin and netropsin and demonstrates the 
versatility of the 2:1 polyamide-DNA motif for recognition of mixed sequences. 
Expansion of the 2: 1 motif to other mixed sequences continues to be an area of ongoing 
research. 
Covalently Linked Polyamides. Polyamides that bind as side-by-side dimers in 
the minor groove can be covalently tethered to afford a new class of polyamides that bind 
with higher affinity and sequence specificity. The free energy of binding for linked 
polyarnides is expected to be more favorable entropically than binding of two side-by-side 
polyarnides. Linking the polyarnides in a heterodimeric complex should disfavor binding 
at homodimeric sites and hence increase sequence specificity. Connecting the nitrogen 
atoms of the central pyrrole rings in the 2:1 Pyr-Py-Py-Dp and Im-Py-Py-Dp/distamycin 
complexes with butyl linkers affords the linked polyarnides (Pyr-Py-Py-DpkC4 and Im-
Py-Py-Dp-C4-Py-Py-Py-Dp, respectively (Figure 1.22).64-65 Quantitative DNase I footprint 
titration experiments reveal that (Pyr-Py-Py-DpkC4 binds a 5'-TGTCA-3' site with a 
binding affinity at least 10-fold greater than Pyr-Py-Py-Dp.64 The ratio of binding affinities 
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Figure 1.20. High resolution structure of the (lm-Py-lm-Py-Dp)2•5'-TGCGCA-3' 
complex derived from NMR data.63a The DNA is represented as a line model (white) with 
an overlaid van der Waals surface (magenta). The imidazole rings, N-methylpyrrole-
carboxarnides, and the positively charged dimethylaminopropyl groups are colored yellow, 
cyan, and green, respectively. 
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Figure 1.21. Model of the (Im-Py-Im-Py-Dp)2•5'-TGCGCA-3' complex derived from 
NMR data. Circles with dots represent lone pairs of N3 of purines and 02 of pyrimidines 
and circles containing a H represent the 2-amino group of guanine. Putative hydrogen 
bonds are indicated by dashed lines. 
Figure 1.22. Structure of the covalently linked polyamides (Pyr-Py-Py-Dp)z-C4 and Im-
Py-Py-Dp-C4-Py-Py-Py-Dp. 
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for a 5'-TGTCA-3' to a 5'-TTTTT-3' is 25:1 for (Pyr-Py-Py-DpkC4 compared to 1:1 for 
unlinked Pyr-Py-Py-Dp. The polyamide heterodimer Im-Py-Py-Dp-C4-Py-Py-Py-Dp also 
binds the match site 5'-TGTTA-3' with higher affinity than Im-Py-Py-Dp or Py-Py-Py-
Dp.65 Sequence specificity of the linked heterodimer is also improved as evidenced by the 
lower affinity for the Im-Py-Py-Dp and Py-Py-Py-Dp binding sites 5'-TGTCA-3' and 5'-
TTTTT-3', respectively. Lown and coworkers have subsequently reported that a 
polyamide composed of two Py-Py-Py units linked through the central pyrroles with a ~ 
alkyl linker binds A,T-rich DNA with enhanced affinity.66 While these examples are 
encouraging, the formidable syntheses of centrally linked polyamides may limit the utility 
of this dimeric motif. 
Hairpin and Cyclic Polyamides. More recently, polyamides in a 2:1 complex 
have been head-to-tail linked with simple amino acids that function as a tum in the minor 
groove without disturbing the geometry of the polyamide-DNA complex to afford hairpin 
polyamides that bind with enhanced affinity and specificity.67 The hairpin polyamide Im-
Py-Py-y-Py-Py-Py-Dp in which the C-terminus of Im-Py-Py and theN-terminus of Py-
Py-Py-Dp are linked with y-aminobutyric acid (y) binds a match 5' -TGTTA-3' site with 
high affinity (Ka = 8 x 107 M"1) and binds a single base pair mismatch 5'-TGACA-3' site 
with 24-fold lower affinity (Ka = 3 x 106 M-1 ) (Figure 1.23a). Hairpin-linking Im-Py-Py-
Dp and Py-Py-Py-Dp increases their binding affinity by approximately 2 orders of 
magnitude relative to the unlinked 2:1 complex. Coupling of the N- and C-terrnini of Im-
Py-Py-y-Py-Py-Py-Dp with an additional GABA linker affords the corresponding cyclic 
polyamide that binds the match 5'-TGTT A-3 ' site with even higher affinity (Ka = 3 x 109 
M-1) (Figure 1.23b).68 Comparing the binding affinities for the single base pair mismatch 
5'-TGACA-3' site reveals that the cycle is considerbly less specific than the hairpin 
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polyamide. Use of the hairpin and cyclic motifs for the design of polyamides that bind 
other sequences with 
A 
B 
Figure 1.23. Models of (A) the hairpin polyamide Im-Py-Py-y-Py-Py-Py-Dp and (B) 
cyclo-(Im-Py-Py-y-Py-Py-Py) binding to a 5'-TGTTA-3' site. Circles with dots represent 
36 
lone pairs of N3 of purines and 02 of pyrimidines and circles containing a H represent the 
2-amino group of guanine. Putative hydrogen bonds are indicated by dashed lines. 
high affinity and specificity is a major goal in the area of polyamide-DNA recognition. 
Description of this Work. In Chapter 2, experiments are described in which the 
sequential addition of five N-methylpyrrolecarboxarnides to the imidazole-pyrrole 
polyamide Im-Py-Py-Dp affords a series of six homologous polyamides, Im-(Py)2_7-Dp, 
that differ in the size of their binding site, apparent first-order binding affinity, and 
sequence specificity. These results demonstrate that DNA sequences up to nine base pairs 
in length can be specifically recognized by irnidazole-pyrrole containing polyamides 
containing three to seven rings by 2:1 polyamide-DNA complex formation in the minor 
groove. Recognition of a nine base pair site defines the new lower limit of the binding site 
size that can be recognized by polyamides containing exclusively imidazole and 
pyrrolecarboxamides. The results of this study should provide useful guidelines for the 
design of new polyamides for that bind longer DNA sites with enhanced affinity and 
specificity. 
In Chapter 3 the design and synthesis of the hairpin polyamide Im-Py-Im-Py-y-
Im-Py-Im-Py-Dp is described. Quantitative DNase I footprint titration experiments reveal 
that Im-Py-Im-Py-y-Im-Py-Im-Py-Dp binds six base pair 5'-(A,T)GCGC(A,T)-3' 
sequences with 30-fold higher affinity than the unlinked polyamide Im-Py-Im-Py-Dp. The 
hairpin polyamide does not discriminate between A•T and T•A at the first and sixth 
positions of the binding site as three sites 5'-TGCGCT-3', 5' -TGCGCA-3', and 5'-
AGCGCT-3' are bound with similar affinity. However, Im-Py-Im-Py-y-Im-Py-Im-Py-
Dp is specific for and discriminates between G·C and C ·G base pairs in the 5' -GCGC-3' 
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core as evidenced by lower affinities for the mismatched sites 5'-AACGCA-3', 5 '-
TGCGTT-3 ', 5'-TGCGGT-3', and 5'-ACCGCT-3' on the same DNA fragment. 
In Chapter 4, experiments are described in which a kinetically stable hexa-aza 
Schiff base La>+ complex is covalently attached to a Tat( 49-72) peptide which has been 
shown to bind the HIV -1 TAR RNA sequence. Although these metallo-peptides cleave 
TAR site-specifically in the hexanucleotide loop to afford products consistent with 
hydrolysis, a series of control experiments suggests that the observed cleavage is not 
caused by a sequence-specifically bound Tat(49-72)-La(L)3+ peptide. 
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Binding Site Size Limitations of Imidazole-Pyrrole Polyamides 
for Recognition in the Minor Groove of DNA 
Introduction 
1:1 Polyamide-DNA Motif. The natural products netropsin and distamycin are 
crescent shaped di- and tripyrrolecarboxamides, respectively, that bind in the minor groove 
of DNA at sites of four or five successive A,T base pairs. 1•3 The structures of a number of 
polyamide-DNA complexes have been determined by X-ray diffraction4 and NMR 
spectroscopy5, and the thermodynamic profiles have been studied for these complexes.6 
Analyses of these 1: 1 complexes suggests that favorable electrostatic interactions and 
extensive van der Waals contacts between the polyamide and the floor and walls of the 
minor groove contribute to complex stability. Although this model has aided in the design 
of polyamides for recognition of longer tracts of A,T-rich sites/ efforts based on the 1:1 
polyamide-DNA motif to design ligands capable ofbinding sequences containing A,T and 
G,C base pairs have met with limited success.8·9 
2:1 Polyamide-DNA Motif. Recent examples of 2:1 polyamide-DNA complexes 
have created new models for the design of nonnatural ligands for sequence-specific 
recognition of mixed sequences in the minor groove of DNA. 10-15 The imidazole (lm)-
pyrrole (Py) polyamide Im-(Py)z-Dp was shown to specifically bind five base pair 5'-
(A ,T)G(A,T)C(A,T)-3' sequences12 while the alternating polyamide Im-Py-Im-Py-Dp was 
shown to bind six base pair 5'-(A,T)GCGC(A,T)-3' sites14 as side-by-side antiparallel 
dimers in the minor groove (Figure 2.1). In addition to the sequence-dependent groove 
width being a determinant of specificity, the 2: 1 model allows specific contacts with 
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A 
(Im-(Pyh-Dph • TGTCA 
B 
(Im-Py-Im-Py-Dph • TGCGCA 
Figure 2.1. Binding models for the 2: 1 complexes formed between (A) Im-(Py)2-Dp with 
a 5'-TGTCA-3' sequence and (B) Im-Py-Im-Py-Dp with a 5'-TGCGCA-3' sequence. 
Circles with dots represent lone pairs of N3 of purines and 02 of pyrimidines and circles 
containing a H represent the 2-amino group of guanine. Putative hydrogen bonds are 
indicated by dashed lines. 
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each strand on the floor of the mmor groove. The side-by-side combination of one 
imidazole ring on one ligand and a pyrrolecarboxamide on the second ligand is specific for 
G•C, while a pyrrolecarboxamide/imidazole pair targets a C•G base pair.12. 15 A 
pyrrolecarboxamide/ pyrrolecarboxamide pair is partially degenerate binds A •T or T• A 
base pairs.10. 15 
A major goal of our efforts in evaluating the scope and limitations of the 2:1 
polyamide-DNA motif is to extend specific recognition to larger binding sites. In the 
examples described above the three ring polyamide Im-(Py)z-Dp binds five base pair sites 
while the four ring polyamide Im-Py-Im-Py-Dp is specific for six base pair sites 
suggesting that incorporation of an additional ring in the ligand lengthens the binding site 
size by one base pair. In order to determine the effect of polyamide length on binding site 
size, binding affinity, and sequence specificity in the 2:1 polyamide-DNA motif a series of 
imidazole-pyrrole polyamides containing three to eight rings was synthesized 
Experimental Design. The polyamide series is based on Im-(Py)z-Dp (1) with 
pyrrolecarboxamide moieties added sequentially to the C-termini to afford Im-(PykDp 
(2), Im-(Pyk Dp (3), Im-(Py)s-Dp (4), Im-(PykDp (5) and Im-(PykDp (6) which are 
designed to bind, five six, seven, eight, nine and ten base pair sites, respectively, as side-
by-side antiparallel dimers (Figures 2.2, 2.3). The DNA binding sites are based on 5'-
TGACA-3' and contain a sequentially longer A,T tract in the center of the binding sites that 
will be recognized by the additional pyrrolecarboxamides. This combination of 
polyamides and DNA binding site sequences was chosen to satisfy several criteria. The 
imidazole rings at the N-termini of the poly ami des will provide specificity in 2:1 
polyamide-DNA complex formation by recognizing, m combination with a 
pyrrolecarboxamide from the other polyamide, the G·C and C·G base pairs in the binding 





Figure 2.2. Structure of the imidazole-pyrrole polyamides Im-(PykDp, Im-(Pyk Dp, 
Im-(PykDp, Im-(Py)s-Dp, Im-(Pyk Dp, and Im-(PykDp. 
51 
5'-T G A C A-3' 
e-0-0--<· 
·rO-D-e 
3'-A C T G T-5' 
5'-T G T A C A-3' 
e-o-o-D-<· 
·:rO-O-O-e 
3'-A CAT G T-5' 
5'-T G T A A C A-3' 
e-o-o-o-o+ 
·>-0-0--0-0-e 
3'-A CAT T G T-5 ' 
5'-T G T T A A C A-3' 
.o-o-o-o--0-<· 
·>-0-0-0-0-0-e 
3' - A C A AT T G T-5' 
5'-T G T T A A A C A-3' 
e-o--o-o-o-o-o<· 
·>--0-0-0-0-0-0-
3 '-A C A AT T T G T-5' 
5'-T G T T T A A A C A-3' 
3 '-A C A A AT T T G T-5' 
e = Imidazole 
0 = Pyrrole 
Figure 2.3. Proposed 2:1 binding models of Im-(PykDp, Im-(PykDp, Im-(PykDp, 
Im-(Py)s-Dp, Im-(PykDp and Im-(Py)7-Dp binding to five, six, seven, eight, nine and ten 
base pair match sites, respectively. The imidazole and pyrrole rings are represented as 
shaded and unshaded spheres, respectively. The amide linkage between the heterocyclic 
rings are represented by line segments. 
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to lock the polyamides in the designed binding sites by preventing them from binding in 
undesired slipped conformations on the DNA. 12• 14 The mixed A,T tract in the center of the 
binding sites is designed to favor 2: 1 binding in contrast to pure A-tracts which generally 
favor 1:1 polyamide-DNA complex formation. 16 The binding site size, apparent first-order 
binding affinity, and sequence specificity of each polyamide was determined by 
MPE•Fe(II) footprinting and quantitative DNase I footprint titration experiments on a 
series of restriction fragments containing a match site and a single base pair mismatch site 
for each polyamide. 
Results 
Polyamide Synthesis. The polyamides were synthesized by solution-phase 
methods (Figure 2.4). In each case the oligo-(N-methylpyrrole)carboxamide moiety was 
prepared by condensation (HBTU, DIEA) of a 4-tert-butoxycarbonylamino-N-
methylpyrrole carboxylic acid derivative with the appropriate 4-amino-N-methylpyrrole 
derivative followed by introduction of the dimethylarninopropyl group at the C-terrninus as 
necessary. Deprotection (TFA) of the N-terminal amino group afforded the 4-amino-
oligo-(N-methylpyrrole)carboxamide derivatives 11, 15, 18, 20 and 21. Condensation with 
1-methylimidazle-2-carboxylic acid afforded the imidazole-pyrrole containing polyamides 
Im-(PykDp (2), Im-(Pyk Dp (3), Im-(Py)s-Dp (4), Im-(PykDp (5) and Im-(Py)7-Dp 
(6) which were purified by reverse phase HPLC. 17 
MPE•Fe(II) Footprinting. Binding site sizes were determined by MPE•Fe(II) 
footprinting (25 mM Tris-acetate, pH 7 .0, 10 mM NaCI, 100 J.LM bp calf thymus DNA, 22 
°C) of Im-(Py)z-Dp, Im-(PykDp, Im-(PykDp, Im-(Py)s-Dp, Im-(Pyk Dp and Im-
(Pyk Dp on the 32P end-labeled Eco RIJPvu II restriction fragments from plasmids pJK5, 
pJK6, pJK7, pJK8, pJK9 and pJKlO, respectively (Figures 2.5, 2.6).2 Each restriction 
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Figure 2.4. Synthetic scheme for the synthesis of polyamides (A) Im-(PykDp, (B) Im-
(PykDp, (C) Im-(Py)s-Dp, (D) Im-(Py\-Dp and, (E) Im-(Py)7-Dp. Reagents: (a) 4-tert-
butoxycarbonyl-amino-N-methylpyrrole-2-carboxylic acid hydroxybenzotriazole ester, 
DIEA; (b) NaOH, H20, EtOH; (c) 3-dimethylaminopropylamine, HBTU; (d) TFA, 
CH2Cl2; (e) 1-methylimidazole-2-carboxylic acid, HBTU, DIEA; (f) 4-tert-
butoxycarbonylamino-bis-N-methylpyrrole-2-carboxylic acid 12, HBTU, DIEA; (g) 9, 
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Figure 2.5. lllustration of the Eco RI!Pvu II restriction fragments from plasmids pJK5, 
pJK6, pJK7, pJK8, pJK9 and pJKlO. The plasmids were prepared by inserting the 
sequences shown into plasmid pUC19 restricted with Bam HI and Hind III. The 
sequences of the match and single base pair mismatch site on each restriction fragment are 
shown in bold. 
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Figure 2.6. MPE•Fe(Il) footprinting experiments with (A) Im-(PykDp, (B) Im-(Pyk 
Dp, (C) Im-(PykDp, (D) lm-(Py)s-Dp, (E) Im-(PykDp, and (F) Im-(PykDp on the 
Eco RI!Pvu II restriction fragments from plasmids pJK5, pJK6, pJK7, pJK8, pJK9 and 
pJKIO, respectively. Gray-scale representations of storage phosphor autoradiograms of 
8% denaturing polyacrylamide gels. All reactions contain 25 mM Tris·AcOH pH 7.0, 10 
mM NaCl, 100 J..LM bp calf thymus DNA, 5 J..LM MPE-Fe(II), 5 mM DTT, and 20-30 
kcpm of 5'- or 3'-32P-labeled restriction fragment as indicated. Lanes 1-4 in (A)-(F) 
correspond to intact DNA, A reaction, G reaction, and a MPE•Fe(II) control to which no 
polyamide was added, respectively. In (A) lanes 5-7, 10 J..LM, 20 1-1M, and 50 1-1M Im-
(Py)z-Dp, respectively; (B) lanes 5-6, 21-1M and 5 J..LM Im-(PykDp, respectively; (C) lanes 
5-7, 2 J..LM, 51-1M, and 10 J..LM Im-(PykDp, respectively; (D) lanes 5-7, 2 J..LM, 5 J..LM, and 
10 1-1M Im-(Py)s-Dp, respectively; (E) lanes 5-7, 2 1-1M, 5 1-1M, and 10 1-1M Im-(Py)6-Dp, 
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fragment contains a match site and a single base pair mismatch site in which a G•C base 
pair replaces an A•T or T•A base pair separated by ten base pairs. Analysis of the 
MPE• Fe(II) protection patterns reveals that the sequential addition of pyrrolecarboxamide 
moieties to the C-terrnini of the polyamides increases the preferred DNA binding site size 
by one base pair with Im-(Py)2-Dp, Im-(PykDp, Im-(PykDp, Im-(Py)s-Dp, Im-(Pyk 
Dp and Im-(Py)7-Dp binding specifically to five, six, seven, eight, nine, and ten base pair 
sites, respectively (Figure 2.7). For all six polyamides the observed MPE•Fe(II) protection 
patterns are 3'-shifted consistent with 2:1 polyamide-DNA complex formation in the minor 
groove.2 
Quantitative DNase I Footprint Titration Experiments. The apparent first-
order binding affinity for the match and single base pair mismatch sites for the six 
polyamides was determined by quantitative DNase I footprint titration experiments (10 
mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgC12, 5 mM CaC12, 22 oq in the absence of 
unlabeled carrier DNA (Figure 2.8). 18 The eapp points for each polyamide were steep and 
were adequately fit by a cooperative binding isotherm consistent with 2: I polyamide-DNA 
complex formation (Figure 2.9).12c Analysis of the match site data reveals that Im-(Pyk 
Dp binds the five base pair 5'-TGACA-3' site with an affinity of 1.3 x 105 M-1 while Im-
(PykDp binds the six base pair 5'-TGTACA-3' site with an affinity of 8.6 x 106 M-1 , 
corresponding to a 66-fold enhancement in affinity for the added pyrrolecarboxamide 
recognizing the additional T•A base pair in the binding site (Table I). The five ring 
polyamide Im-(PykDp binds the seven base pair 5'-TGTAACA-3' with an affinity of 4.5 
x 107 M-1 , a modest five-fold gain in affinity for recognition of a seven over the six base 
pair site. Binding affinity levels off with Im-(Py)s-Dp binding the eight base pair 5'-
TGTTAACA-3' site (Ka = 5.3 x 107 M-1 ) and Im-(PykDp binding the nine base pair 5'-
TGTTAAACA-3' site (K, = 4.7 x 107 M-1) with the same affinity as Im-(Py)4-Dp for a 
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Figure 2.7. Histograms of cleavage protection from MPE•Fe(II) for Im-(PykDp, Im-
(PykDp, Im-(Py)4-Dp, Im-(Py)s-Dp, Im-(Py)6-Dp and Im-(Pyk Dp binding to the Eco 
RI!Pvu II restriction fragments from plasmids pJK5, pJK6, pJK7, pJK8, pJK9 and 
pJKlO, respectively. The individual bar heights are proportional to the protection from 
MPE• Fe(II) cleavage at each nucleotide. The match and mismatch sites are indicated by 
boxes. 
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Im-(Pyh-Dp (20 ~) ... 
5 ' -GCGAGCTCA~CGAGCTCA~GCGAGCTCAT-3' 
3 '-CGCTCGAG CTCGAGT~CGCTCGAGTA-5' 
Im-(Py)3-Dp (5 !-lM) .... ... 
5' -GCGAGCTCA~CGAGCTCA~GGAC~CGAGCTCAT-3' 
3'-CGCTCGAG GCTCGAGT ... or' GCTCGAGTA- 5' 
Im-(PykDp (5 J.!M) .... .... 
5' -GCGAGCTCA~TAAC~CGAGCTCA~GGAAC~CGAGCTCAT-3' 
3'-CGCTCGAGT ~ATTG GCTCGAGT ACCTTG GCTCGAGTA-5' .... ... 
Im-(Py)s-Dp (5 J.!M) .... 
5' -GCGAGCTCA~GTTAAC~CGAGCTCA~GTGAAC~CGAGCTCAT-3' 
3'-CGCTCGAGT ACAATTG GCTCGAGTCACTTG GCTCGAGTA-5' 
.... ¥ 
Im-(Py)6-Dp ( 10 !-lM) 
5 ' -GCI:;A(;C~'CA,'I!r 
3 ' - CGC:TC(;AG' 
Im-(Py)J-Dp (20 J.!M) 
5 ' - Gi:GJI.GC:TC 
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Figure 2.8b. Quantitative DNase I footprint titration experiment with Im-(PykDp on the 
Eco RI!Pvu II restriction fragment from plasmid pJK6. Gray-scale representation of a 
storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel. All reactions 
contain 10 mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgC12, 5 mM CaC12 and 1-2 x 10
5 
cpm of 3'-32P-end labeled restriction fragment. Lane 1, intact DNA; lane 2, A reaction; lane 
3, G reaction; lane 4, DNase I control lane to which no polyamide was added; lanes 5- 18, 
0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM, 50 nM, 0.1 ).l.M, 0.2 ).l.M, 0.5 
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Figure 2.8c. Quantitative DNase I footprint titration experiment with Im-(PykDp on the 
Eco RI!Pvu II restriction fragment from plasmid pJK7. Gray-scale representation of a 
storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel. All reactions 
contain 10 mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgC12, 5 mM CaC12 and 1-2 x 10
5 
cpm of 3'-32P-end labeled restriction fragment. Lane 1, intact DNA; lane 2, A reaction; lane 
3, G reaction; lane 4, DNase I control lane to which no polyamide was added; lanes 5-19, 
20 pM, 50 pM, 0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM, 50 nM, 0.1 
~-tM, 0.2 ~-tM, 0.5 ~-tM , 1 ~-tM Im-(PykDp, respectively. 
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Figure 2.8d. Quantitative DNase I footprint titration experiment with Im-(Py)s-Dp on the 
Eco RI!Pvu II restriction fragment from plasmid pJK8. Gray-scale representation of a 
storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel. All reactions 
contain 10 mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgC12, 5 mM CaCl2 and 1-2 x 10
5 
cpm of 3'-32P-end labeled restriction fragment. Lane 1, intact DNA; lane 2, A reaction; lane 
3, G reaction; lane 4, DNase I control lane to which no polyamide was added; lanes 5-20, 1 
pM, 2 pM, 5 pM, 10 pM, 20 pM, 50 pM, 0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 
nM, 20 nM, 50 nM, 0.1 ~-tM Im-(Py)s-Dp, respectively. 
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Figure 2.8e. Quantitative DNase I footprint titration experiment with Im-(PykDp on the 
Eco RI!Pvu II restriction fragment from plasmid pJK9. Gray-scale representation of a 
storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel. All reactions 
contain 10 mM Tris·HCl pH 7.0, 10 mM KCI, 5 mM MgC12, 5 mM CaC12 and 1-2 x 10
5 
cpm of 3'-32 P-end labeled restriction fragment. Lane 1, intact DNA; lane 2, A reaction; lane 
3, G reaction; lane 4, DNase I control lane to which no polyamide was added; lanes 5-20, 
10 pM, 20 pM, 50 pM, 0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM, 50 
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Figure 2.8f. Quantitative DNase I footprint titration experiment with Im-(PykDp on the 
Eco RI!Pvu II restriction fragment from plasmid pJK10. Gray-scale representation of a 
storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel. All reactions 
contain 10 mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgCl2, 5 mM CaC12 and 1-2 x 10
5 
cpm of 3'-32 P-end labeled restriction fragment. Lane 1, intact DNA; lane 2, A reaction; lane 
3, G reaction; lane 4, DNase I control lane to which no polyamide was added; lanes 5-18, 
0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM, 50 nM, 0.1 ).!M, 0.2 J..!M, 0 .5 )lM, 1 J..!M, 2 
J..!M, 5 J..!M, 10 ).!M Im-(PykDp, respectively. 
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Figure 2.9. Data for the quantitative DNase I footprint titration experiments for Im-(Py)2_ 
6
-Dp in complex with the five to nine base pair match sites, respectively. The enonn points 
were obtained using photostimulable storage phosphor autoradiography and processed as 
described in the experimental section. The data points for Im-Py2-Dp, Im-Py3-Dp, Im-
Py 
4
-Dp, Im-Py 5-Dp and Im-Py 6-Dp are represented by filled circles, open diamonds, filled 
squares, open triangles and filled triangles, respectively. The curve through each set of data 
points is the best-fit cooperative Langmuir binding titration isotherm (n = 2) obtained from 
a nonlinear least-squares algorithm using eq. 2. 
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Table I. Apparent First-Order Binding Affinities (M-1 t ·b 
Polyamide 
Binding Site 
Match Mismatch Specificityc Size (b ) 
Im-(Pyk Dp 5 L3 X 105 (0_3) < 2 X 104 d > 6 .5 e 
Im-(Pyk Dp 6 8.5 X 106 (L3) 1.6 X 106 (0.2) 5.3 (0.5) 
Im-(Py)4-Dp 7 4.5 X 10
7 (L1) 7.9 X 106 (1.8) 5.7 (0.8) 
Im-(Py)s-Dp 8 5.3 X 107 (0.5) < 2 X 107 d > 2.7 e 
Im-(Pyk Dp 9 4.7 X 107 (0.4) 1.7 X 107 (0.7) 2.8 (0.7) 
Im-(Pyh-Dp 10 < 2 X 106 d < 2 X 106 d - 1 
a Values reported are the mean values from at least three footprint titration 
experiments. Numbers in parentheses indicate the standard deviation for each data set. 
b The assays were performed at 22 °C, pH 7.0 in the presence of 10 mM Tris•HCl, 10 mM 
KCI, 10 mM MgCI2, and 5 mM CaC12. c Defined as the ratio of the match site binding 
affinity to the binding affinity of the single base pair mismatch site. Numbers in 
parentheses indicate the uncertainty calculated using the standard deviations of the 
measured binding affinities. d Represents an upper limit for the binding affinity as the 
quality of fit for this data set was poor. • This value represents a lower limit on the 
specificity. 
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seven base pair site. Binding affinity drops dramatically for Im-(PykDp binding to a ten 
base pair 5'-TGTTTAAACA-3' site (Ka < 2 x 106 M-1 ). 
Sequence Specificity. Comparison of the apparent first-order binding affinities for 
the match and the single base pair mismatch site for each polyamide demonstrates that the 
specificity of 2:1 polyamide-DNA complex formation, defined as the ratio of match site 
binding affinity to the affinity for the single base pair mismatch site, generally decreases 
with increasing polyamide length (Table I). Im-(Py )2- Dp prefers binding the 5'-TGACA-
3' site over the 5'-TGGCA-3' site by a factor of at least 6 .5. Im-(PykDp and Im-(Pyk 
Dp bind the mismatch sites with five- and six-fold lower affinity, respectively. Im-(Pyk 
Dp displays at least a three-fold preference for the match site while Im-(PykDp binds the 
mismatch site with 2.7-fold lower affinity. At concentrations below 1 ).lM Im-(Py)7-Dp 
shows no binding to DNA. At concentrations I ).lM and above, equal protection from 
cleavage by DNase I of both the match and mismatch sites are observed indicating that the 
specificity as defined here is approximately one. However, cleavage protection is also 
observed at all positions on the restriction fragment suggesting that Im-(PykDp is binding 
DNA in a non-specific manner. The binding affinities reported for Im-(PykDp at 5 ' -
TGGCA-3 ', Im-(PykDp at 5'-TGTGAACA-3', and Im-(PykDp at the match and 
mismatch sites represent upper limits since the quality of fits for these data sets were poor. 
Discussion 
Binding Site Size. The MPE•Fe(II) footprinting experiments demonstrate that the 
polyamides Im-(PykDp, Im-(PykDp, Im-(PykDp, Im-(Py)5-Dp, Im-(Pyk Dp and Im-
(PykDp containing three to eight rings, respectively, recognize DNA binding sites five to 
ten base pairs in length, respectively. These results suggest that the added 
pyrrolecarboxarnide/ pyrrolecarboxamide pairs in the side-by-side dimers recognize the 
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additional A•T or T•A base pairs in the core of the binding sites as predicted by the model 
for 2:1 polyamide-DNA complex formation. 10. 15 The MPE•Fe(II) protection patterns 
suggest that the polyamides form specific complexes with the binding sites with no 
apparent slippage of the ligands in the intermolecular antiparallel dimers. 
Binding Affinity and Sequence Specificity. The 66-fold enhancement in 
apparent first-order binding affinity for Im-(PykDp binding to a six base pair 5'-
TGTACA-3' (Ka = 8.6 x 106 M"1) site compared to lm-(Pyk Dp binding to a five base 
pair 5'-TGACA-3' (Ka = 1.3 x 105 M"1 ) site corresponds to an increase in the free energy 
of binding (MG) of 2.4 kcal/mol (22 oq (Figure 2.10). This apparent increase in the free 
energy of binding is likely a result of the additional pyrrolecarboxarnide/ 
pyrrolecarboxarnide pair in the Im-(Py)3-Dp intermolecular dimer recognizing the T•A 
base pair in the context of the 5'-TGT ACA-3' sequence. A significant fraction of the 
increase in binding affinity for Im-(Pyk Dp presumably results from the hydrogen bonds 
and van der Waals contacts that likely form when the additional pyrrolecarboxarnides in the 
ligand bind the additional T•A base pair in the core of the binding site. The five-fold 
enhancement in affinity oflm-(PykDp for the seven base pair 5'-TGTAACA-3' site (Ka = 
4.5 x 107 M"1) over Im-(Pyk Dp binding to 5'-TGTACA-3' corresponds to an increase in 
the free energy of binding of 1.0 kcallmol. This relatively modest change in binding free 
energy suggests that the addition of a pyrrolecarboxarnide moiety to Im-(Pyk Dp in order 
to recognize an additional A•T base pair in the seven base pair 5'-TGTAACA-3' site is less 
favorable than the addition of a pyrrolecarboxarnide to Im-(PykDp to recognize the 
additional T•A base pair in the six base pair 5'-TGTACA-3' site. The observation that the 
affinities of Im-(Py)s-Dp (Ka = 5.3 x 107 M-1) and Im-(Py\-Dp (Ka = 4.7 x 107 M-1 ) for 
the eight and nine base pair 5'-TGTTAACA-3' and 5'-TGTTAAACA-3' sites, respectively, 
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Figure 2.10. Plot of apparent first order binding affinity (K.) for polyamides Im-(Py)2-
Dp-Im-(Py)7-Dp for the five to ten base pair match sites. The binding affinities are plotted 
on a logarithmic scale where the error bar heights represent the standard deviation of the 
average binding affinity determined for each polyamide. The value of 2 x 106 M-1 for Im-
Py7-Dp represents an upper limit of the binding affinity and is shown without error bars. 
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the polyamides from five to seven rings and the DNA binding site from seven to nine base 
pairs has no effect on the observed binding free energies of Im-(Py)s-Dp and Im-(Py)6-Dp. 
The dramatic decrease in binding affinity of Im-(PykDp for the ten base pair 5'-
TGTTTAAACA-3' site (Ka < 2 x 106 M"1) suggests that the presence of an additional 
pyrrolecarboxamide in the ligand is making an unfavorable contribution to the binding free 
energy of Im-(PykDp for the 5'-TGTTTAAACA-3' site. 
One explanation for these observations is that three and four ring polyamides Im-
(Py)z-Dp and Im-(PykDp, respectively, are in phase with their DNA binding sites. High-
resolution NMR and molecular modeling of a related (Im-(Py)2-Dp)2•5'-TGACT-3' 
complex showed that the curvature of the ligand closely matched the curvature of the minor 
groove of the five base pair binding site. 12b Similar observations were made for the four 
ring polyamide Im-Py-Im-Py-Dp binding to a 5'-AGCGCT-3' sequence. 14a For the 
longer polyamides beginning with Im-(PykDp where binding affinities level off at Im-
(Py)s-Dp and ultimately decrease at Im-(PykDp, the ligands may be falling out of register 
with the DNA binding sites.20 In these 2:1 complexes the curvature of the polyamides 
would likely not match the curvature of the minor groove surfaces of the longer binding 
sites. One likely consequence would be that the energetic benefit of the hydrogen bonds 
and van der Waals interactions that stabilize the 2: 1 complexes would decrease as the lack 
of correspondence between the binding surfaces of the polyarnides and the DNA sites 
became more pronounced. 21 The trend in the observed binding affinities for the six 
polyarnides studied here would be adequately explained if the degree of register mismatch 
between the polyamides and the DNA increased with polyamide length beyond Im-(Py)3-
Dp. Register mismatch in the larger polyamide-DNA complexes may explain the decrease 
in sequence specificity observed for the longer polyamides (Figure 2.11 ). In the mismatch 
sites a G•C base pair replaces an A•T or T•A base in the core of the binding site. The 2-
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amino group of guanine protrudes from the floor of the minor groove and therefore is 
expected to introduce a bump on the surface of the binding sites that may interfere with the 
hydrogen bonding of the pyrrolecarboxamide NH of the polyamides to N3 of the guanine 
base.4• If the longer polyamides are out of register with the DNA then the effect of this 
unfavorable interaction on the free energy of binding at the mismatch site may become less 
significant. This would lower the overall free energy difference between binding the match 
and mismatch sites and thereby reduce specificity. 
We note that sequence-dependent DNA structural features such as intrinsic minor 
groove width, minor groove flexibility, and inherent curvature may differ between each of 
the binding sites and could therefore contribute to the measured difference in the binding 
affinities of the six polyarnides. 22 One possibility is that as the length of the A, T -tract in the 
binding sites increases the minor groove width and/or flexibility may decrease which 
would likely impose an energetic penalty for 2:1 polyamide-DNA complex formation and 
lower the apparent binding affinities for these sites. These effects may also contribute to 
the lower sequence specificity observed for the longer polyamides in the series. Insertion 
of G•C base pairs into an A •T tract may increase the minor groove width and/or flexibility 
which may reduce the difference in binding free energy between the match and mismatch 
sites thereby lowering specificity.23 These considerations of sequence-dependent DNA 
structure suggest that the sequence of the putative DNA target site may be an important 
factor in determining polyamide affinity and specificity in the 2:1 motif. For example, 
although A •T and T• A base pairs are partially degenerate in the minor groove it remains an 
open question as to whether imidazole-pyrrole polyamides show a preference for one base 
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Figure 2.11. Plot of the observed specificity for a match site over a single base pair 
mismatch site for polyamides Im-(Py)z-Dp-Im-(Py)7-Dp. Error bar heights represent the 
uncertainty in the specificity calculated using the standard deviations of the apparent first-
order binding affinities of the match and mismatch sites. The specificity values for Im-
(Py)z-Dp and Im-(Py)s-Dp represent lower limits and are shown without error bars. The 
apparent specificity of 1 for Im-(Py)7-Dp is approximate and is shown without error bars. 
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Implications for the Design of Minor Groove Binding Polyamides. The results 
of this study demonstrate that DNA sequences up to nine base pairs in length can be 
specifically recognized by imidazole-pyrrole polyarnides containing three to seven rings by 
2:1 polyamide-DNA complex formation in the minor groove. Recognition of a nine base 
pair site defines the new lower limit of the binding site size that can be recognized by 
polyamides containing exclusively imidazole and pyrrolecarboxamides. We note that 
binding affinity reaches a maximum value (Ka - 5 x 107 M"1 ) for the five ring polyamide 
Im-(PykDp and that addition of up to two additional pyrrolecarboxamides has no effect 
on the observed binding affinity. These results and the failure of an eight ring polyamide to 
specifically recognize a ten base pair site suggests that a new class of polyamides is needed 
for extension of the 2:1 polyamide-DNA motif to sequences longer than nine base pairs. 
Perhaps polyamides in which the rigid imidazole or pyrrole rings are replaced by more 
flexible moieties will match the curvature of longer DNA sites and bind with high affinity. 
The affinities observed for the six to nine base pair sites are significant considering that the 
polyamides in the 2:1 complexes are unlinked. Covalently linking the individual 
polyamides in a head-to-tail fashion with y -aminobutyric acid (GABA) to afford hairpin 
polyamides or with two GABA moieties to afford cyclic polyamides may afford new 
polyamides that bind DNA sites up to nine base pairs with higher affinity and sequence 
specificity _24-25 Finally, the relatively modest sequence specificities of the polyamides 
studied here suggest that increasing the free energy difference between match and 
mismatch sites is an important goal in the design of nonnatural ligands that bind DNA with 
high affinity and sequence specificity. 
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Experimental Section 
Polyamide Synthesis. 1H NMR were recorded on a General Electric QE-300 
spectrometer with chemical shifts reported in parts per million relative to residual solvent 
signal. High-resolution mass spectra (HRMS) were recorded using fast atom 
bombardment (FAB) techniques at the High-Resolution Mass Spectrometry Facility at the 
California Institute of Technology or the Mass Spectrometry Laboratory at the University 
of California, Riverside. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectra (MALDI-TOF MS) were recorded in the Biomolecule Analysis Facility at the 
California Institute of Technology. Ultraviolet-visible (UV) spectra were recorded on a 
Hewlett Packard 8452A diode array spectrophotometer. Reactions were executed under an 
atmosphere of argon unless otherwise noted. Im-(Py)z-Dp and 1-methylirnidazole-2-
carboxylic acid were prepared as previously described.12a Reagent grade chemicals were 
used as received unless noted otherwise. Dimethylformamide (DMF), 
dimethylsulfoxide/N-methylpyrrolidone (DMSO/NMP) and diisopropylethylarnine 
(DIEA) were purchased from Applied Biosystems. Di-tert-butyl dicarbonate ((Boc2)0), 
2-( lH-benzotriazol-1-yl)-1, 1 ,3,3-tetramethyl-uronium hexafluorophosphate (HBTU), 
dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt) were purchased from 
Peptides International which is the reccomended supplier for these reagents. 
Dichloromethane was purchased from EM Science. Trifluoroacetic acid (TFA) was 
purchased from Halocarbon. Flash column chromatography was carried out using EM 
Science K.ieselgel 60 (230-400 mesh).26 Thin-layer chromatography was performed on 
EM Reagents silica gel plates (0.5 mm thickness). All compounds were visualized at 254 
nm. Preparative reverse phase high-performance liquid chromatography (RP-HPLC) was 
performed on a Beckman HPLC system using a Waters Delta-Pak Prep-Pak C18 column 
(25 mm x 10 em, 15 !1- , 100 A) equipped with a Delta-Pak Guard-Pak column. 
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Compounds were eluted with a gradient of 0-60% CH3CN/0.1% TFA over 120 min with a 
flow rate of 8-10 mL/min and detected using a Beckman 167 dual wavelength detector at 
254 and 340 nm. Fractions were collected and analyzed by analytical reverse phase HPLC 
on a Beckman Gold HPLC system using a Rainin Microsorb-MV C18 column (4.6 mm x 
30 em, 5 !J., 100 A). Compounds were eluted with a gradient of 0-60% CH3CN/O.l% 
TF A over 60 min with a flow rate of 1 mL/min and detected using a dual wavelength 
detector at 254 and 340 nm. The desired fractions were pooled and lyophilized. 
4-tert-Butoxycarbonylamino-tri-N-methylpyrrole-2-carboxylic acid methyl 
ester (8). To a solution of 4-amino-bis-N-methylpyrrole-2-carboxylic acid methyl ester 
hydrochloride (7) (1.0 g, 3.2 mmol) and DIEA (2.23 g, 17.2 mmol) in DMF (8 mL) was 
added 4-tert-butoxycarbonylamino-N-methylpyrrole-2-carboxylic acid hydroxy-
benzotriazole ester ( 1.1 g, 3.0 mmol). After stirring overnight at room temperature the 
solution was added slowly to 400 mL H20 . The resulting light brown powder was 
isolated by vacuum filtration, washed with cold H20 , dried in vacuo, and purified by flash 
chromatography (2-5% CH30H/CH2Cl2) to afford ester 8 (1.32 g, 83%) as a tan solid. 
1H 
NMR (DMSO-d6) 8 9.97 (s, 1 H), 9.90 (s, 1 H), 9.08 (s, 1 H), 7.42 (s , 1 H), 7.19 (s, 1 
H), 7.01 (s, 1 H), 6.82 (s, 2 H), 6.80 (s, 1 H), 3.82 (s, 6 H), 3.72 (s, 3 H), 3.68 (s, 3 H), 
1.44 (s, 9 H); FAB-HRMS mJe 498.2258 (M+, 498.5425 calcd. for C24H30N60 6). 
4-tert-Butoxycarbonylamino-tri-N-methylpyrrole-2-carboxylic acid (9). To a 
slurry of 4-tert-butoxycarbonylamino-tri-N-methylpyrrole-2-carboxylic acid methyl ester 8 
(1.32 g, 2.65 mmol) in 95% EtOH (125 mL) was added 1 M NaOH (125 mL) and the 
mixture heated at 60 oc for 1 h. Ethanol was removed under reduced pressure and the 
resulting solution was cooled to room temperature before acidifying to pH 3 with 1 M 
KHS04. The resulting white solid was collected by vacuum filtration, washed with cold 
H
2
0 , and dried in vacuo to afford carboxylic acid 9 (938 mg, 73%) as a tan powder. 1H 
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NMR (DMSO-d6 ) 8 9.90 (s, 1 H), 9.84 (s, 1 H), 9.06 (s, 1 H), 7.38 (d, 1 H, J = 1.0 Hz), 
7 .20 (d, 1 H , J = 1.3 Hz), 7.01 (d, 1 H, J = 1.3 Hz), 6.87 (s 1 H), 6.81 (d, 1 H, J = 1.3 
Hz), 6.80 (s, 1 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 1.43 (s, 9 H); FAB-HRMS 
m/e 484.2071 (M+, 484.5154 calcd. for C23~N606). 
4-tert-Butoxycarbonylamino-tri-N-methylpyrrole-2-(3-dimethylamino-
propyl)-carboxamide (10). To a solution of 4-tert-butoxy-carbonylamino-tri-N-
methylpyrrole-2-carboxylic acid 9 (2.0 g, 4.13 mmol) and DIEA (556 mg, 4 .3 1 mmol) in 
DMF (10 mL) was added HBTU (1.6 g, 4.22 mmol). After stirring 10 h at room 
temperature 3-dimethylaminopropylamine (506 mg, 4.96 mmol) was added and the 
solution stirred 2 h at room temperature. The solution was concentrated in vacuo and the 
resulting residue was purified by flash chromatography (0-1% NH40H/CH30H) to afford 
10 (1.04 g, 44%). 1H NMR (DMSO-d6) 8 9.88 (s, 1 H), 9.87 (s, 1 H), 9.12 (s, 1 H), 8.09 
(t, 1 H, J = 4.7 Hz), 7.62 (m, 1 H), 7.47 (m, 1 H), 7.19 (m, 1 H), 7 .06 (m, 2 H), 6.82 (m, 
1 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.22 (m, 2 H), 2.24 (t, 2 H, J = 7.0 Hz), 
2.13 (s, 6 H), 1.60 (q, 2 H, J = 7.0 Hz), 1.44 (s, 9 H); FAB-HRMS m/e 568.3202 (M +, 
568.6810 calcd. for C28H40N80 5) . 
4-Amino-tri-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
bistrifluoroacetate (11). Trifluoroacetic acid (14 mL, 182 mmol) was added to 4-tert-
butoxycarbonylamino-tri-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 10 
(500 mg, 0.88 mmol) and stirred at room temperature. After 20 min excess TFA was 
removed under reduced pressure and the resulting residue dried in vacuo to afford 11 (517 
mg, 84%) as a yellow solid. 1H NMR (DMSO-d6) 8 10.04 (s, 1 H), 9.93 (s, 1 H), 9.74 
(br s, 3 H), 9.35 (br s, 1 H), 8. 17 (t, 1 H, J = 5.8 Hz), 7 .23 (d, 1 H, J = 1.7 Hz), 7 .1 5 (d, 1 
H, J = 1.7 Hz), 7. 11 (d, 1 H, J = 1.8 Hz), 7.05 (d, 1 H, J = 1.8 Hz), 6.94 (d, 2 H, J = 1.7 
Hz), 3.88 (s, 3 H), 3.84 (s? 3 H), 3.80 (s, 3 H), 3.24 (m, 2 H), 3.06 (m, 2 H), 2.78 (s, 6 
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H), 1.82 (m, 2 H); FAB-HRMS mle 469.2642 (M+ H (- 2 TFA), 469.5712 calcd. for 
CnH32Ns03). 
1-Methylimidazole-2-carboxamide-4-tri-N-methylpyrrole-2-(3-dimethyl-
aminopropyl)-carboxamide trifluoroacetate (lm-(Py)3-Dp) (2). To a solution 1-
methylirnidazole-2-carboxylic acid (35 mg, 0.277 mmol) and DIEA (48.2 mg, 0.373 
mmol) in DMSO/NMP (0.4 mL) was added HBTU (103 mg, 0.272 mmol). The 
resulting solution was stirred 1 h at room temperature when 4-amino-tri-N-methylpyrrole-
2-(3-dimethylarninopropyl)-carboxarnide trifluoroacetate 11 (16 mg, 0.017 mmol), DIEA 
(30 mg, 0.23 mmol), and DMSO/NMP (0.2 mL) were added. The solution was shaken at 
37 oc for 4 h. Purification by RP-HPLC afforded Im-(PykDp (2) as the trifluoroacetate 
salt (5.55 mg, 48%). UV (H20) Amax (£) 246 (22,900), 314 (31400) nm; 
1H NMR 
(DMSO-d6) o 10.51 (s, 1 H), 9.98 (s, 1 H), 9.93 (s, 1 H), 9.26 (br s, 1 H), 8.17 (t, 1 H, 1 
= 4.7 Hz), 7.41 (s, 1 H), 7.29 (d, 1 H , 1 = 1.5 Hz), 7.23 (d, 1 H, 1 = 1.5 Hz), 7.17 (s, 2 H) , 
7.06 (s, 2 H), 6.94 (d, 2 H, 1 = 1.6 Hz), 3.99 (s, 3 H), 3.84 (s, 3 H), 3.84 (s, 3 H), 3.80 (s, 
3 H), 3.23 (m, 2 H), 3.06 (m, 2 H), 2.78 (d, 6 H, 1 = 4.8 Hz), 1.82 (m, 2 H); FAB-
HRMS m/e 577.3330 (M + H (- TFA), 577.6716 calcd. for C28H37 N 100 4). 
4-tert-Butoxycarbonylamino-bis-N-methylpyrrole-2-carboxylic acid (12). To a 
solution of 4-arnino-bis-N-methylpyrrole-2-carboxylic acid methyl ester hydrochloride 7 
(5.0 g, 16 mmol) and DIEA (16.5 g, 8 mmol) in DMF (20 mL) was added (Boc2)0 (17.5 
g, 80.2 mmol) . After stirring 2.5 hat room temperature the solution was added slowly to 
400 mL H
2
0 . The resulting light brown powder was isolated by vacuum filtration, 
washed with cold H20 , dried in vacuo, to afford the corresponding 4-tert-
butoxycarbonylarnino-bis-N-methylpyrrole-2-carboxylic acid methyl ester (5.0 g, 83%) 
which was used immediately. The ester (5.0 g, 13.3 mmol) was slurried in 95% EtOH 
(250 mL) and 1 M NaOH (125 mL) was added. The mixture heated at 60 °C for 4 h, 
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cooled to room temperature, and extracted with ether (100 rnL). The pH of the solution 
was adjusted to 2 with 1 M KHS04 and the resulting tan solid was collected by vacuum 
filtration, washed with cold H20 , and dried in vacuo to carboxylic acid 12 (4.38 g, 91 %) as 
a tan solid. 1H NMR (DMSO-d6 ) 8 9.92 (s, 1 H), 9.10 (s, 1 H), 7.40 (s, 1 H), 6.87 (s, 1 
H), 6.81 (s, 2 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 1.44 (s, 9 H); FAB-HRMS m/e 362.1593 
(M+, 362.3880 calcd. for C17~2N405). 
4-tert-Butoxycarbonylamino-tetra-N-methylpyrrole-2-carboxylic acid methyl 
ester (13). To a solution of 4-tert-butoxycarbonylamino-bis-N-methylpyrrole-2-carboxylic 
acid 12 (637 mg, 1.76 mmol) and DIEA (0.3 rnL, 1.7 mmol) in DMF (4 rnL) was added 
HBTU (670 mg, 1.77 mmol). After stirring 30 min at room temperature 4-amino-bis-N-
methylpyrrole-2-carboxylic acid methyl ester hydrochloride 7 (500 mg, 1.60 mmol), 
DIEA (1.11 g, 8.61 mmol) and DMF (2 rnL) were added. The solution was stirred 6 hat 
room temperature and poured into 400 rnL cold H20 and the resulting precipitate was 
collected by vacuum filtration. Flash column chromatography (5% CH30H/CH2Cl2) 
afforded 13 (620 mg, 63%) as a brown solid. 1H NMR (DMSO-d6) 8 9.94 (s, 2 H), 9.87 
(s, 1 H), 9.10 (s, 1 H), 7.47 (d, 1 H, J = 1.8 Hz), 7.23 (m, 2 H), 7.06 (m, 2 H), 6.90 (d, 1 
H , J = 1.9 Hz), 6.89 (d, 1 H, J = 0.6 Hz), 6.83 (s 1 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.80 
(s, 3 H), 3.73 (s, 3 H), 1.45 (s, 9 H); FAB-HRMS m/e 620.8864 (M+, 620.6698 calcd. for 
~H36Ns07). 
4-tert-Butoxycarbonylamino-tetra-N-methylpyrrole-2-carboxylic acid (14). To 
a slurry of 4-tert-butoxycarbonylamino-tetra-N-methylpyrrole-2-carboxylic acid methyl 
ester 13 (615 mg, 0.903 mmol) in 95% EtOH (250 rnL) was added I M NaOH (125 mL) 
and the resulting mixture was heated at 60 oc for 4 h. The solution was cooled to room 
temperature and ethanol was removed under reduced pressure before acidifying to pH 2 
with 2M KHS0
4
. The precipitate was collected by vacuum filtration, washed with cold 
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H20, and dried in vacuo to afford carboxylic acid 14 (600 mg, 99%) as a tan powder. 1H 
NMR (DMSO-d6) 8 9.94 (s, 1 H), 9.91 (s, 1 H), 9.87 (s, 1 H), 9.10 (s, 1 H), 7.42 (d, 1 H, 
J = 1.4 Hz), 7.23 (s, 2 H), 7.05 (s, 2 H), 6.89 (s, 1 H), 6.83 (s, 2 H), 3.84 (s, 6 H), 3.81 (s, 
3 H), 3.80 (s, 3 H), 1.45 (s, 9 H); FAB-HRMS m/e 606.9305 (M+, 606.6428 calcd. for 
C29H34Ns07). 
4-Amino-tetra-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
bistrifluoroacetate (15). To a solution of 4-tert-butoxycarbonylarnino-tetra-N-
methylpyrrole-2-carboxylic acid 14 (50 mg, 0.0824 mmol) and DIEA (14.8 mg, 0.115 
mmol) in DMF (0.12 mL) was added HBTU (31 mg, 0.0817 mmol). The resulting 
solution was stirred 30 min at room temperature when 3-dimethylarninopropylarnine (49 
mg, 0.477 mmol) was added to afford the correponding carboxarnide which was used 
immediately without isolation. After stirring 4 h at room temperature TFA (10 mL, 130 
mmol) was added and the solution stirred 1 h at room temperature. Excess TF A was 
removed under reduced pressure and the resulting residue was purified by RP-HPLC to 
afford 15 (25 mg, 37%) as a yellow solid. 1H NMR (DMSO-d6) 8 10.05 (s, 1 H), 9.96 (s, 
1 H), 9.95 (s, 1 H), 9.68 (br s, 3 H), 9.23 (br s, 1 H), 8.18 (t, 1 H, J = 4.6 Hz), 7.27 (d, 1 
H, J = 1.7 Hz), 7.21 (d, 1 H, J = 1.7 Hz), 7.17 (d, 1 H, J = 1.7 Hz), 7.12 (d, 1 H, J = 1.7 
Hz), 7.08 (m, 2 H), 6.95 (m, 2 H), 3.89 (s, 3 H), 3.86 (s, 3 H), 3.84 (s, 3 H), 3.81 (s, 3 
H), 3.21 (m, 2 H), 3.08 (m, 2 H), 2.78 (s, 6 H), 1.81 (m, 2 H); FAB-HRMS m/e 
590.3076 (M+ (- 2 TFA), 590.6906 calcd. for C29H38 N100 4). 
1-Methylimidazole-2-carboxamide-4-tetra-N -methylpyrrole-2-(3-dimethyl-
aminopropyl)-carboxamide trifluoroacetate (lm-(Py)4-Dp) (3). To a solution 1-
methylirnidazole-2-carboxylic acid (35 mg, 0.277 mmol) and DIEA (48.2 mg, 0.373 
mmol) in DMSO/NMP (0.4 mL) was added HBTU (103 mg, 0.272 mmol). The 
resulting solution was stirred 1 h at room temperature when 4-amino-tetra-N-
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methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide trifluoroacetate 15 (16 mg, 0 .017 
mmol), DIEA (30 mg, 0.23 mmol), and DMSO/NMP (0.3 mL) were added. The 
solution was shaken at 37 oc for 4 h. Purification by RP-HPLC afforded Im-(PykDp (3) 
as the trifluoroacetate salt (1.22 mg, 9%). UV (H20) A.max (£) 246 (28,500), 314 (39,100) 
nm; 1H NMR (DMSO-d6 ) 8 10.51 (s, 1 H), 9.99 (s, 1 H), 9.96 (s, 1 H), 9.93 (s, 1 H) , 
9.25 (br s, 1 H), 8.17 (t, 1 H, J = 5.8 Hz), 7.41 (s, 1 H), 7.31 (s, 1 H), 7.23 (s, 2 H), 7.17 
(s, 2 H), 7.08 (m, 3 H), 6.95 (s, 1 H), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.80 (s, 3 
H), 3.24 (m, 2 H), 3.07 (m, 2 H), 2.78 (d, 6 H, J = 4.8 Hz); FAB-HRMS m/e 698.3387 
(M+ (- TFA), 698.7910 calcd. for C34H42N12 0 5). 
4-tert-Butoxycarbonylamino-penta-N-methylpyrrole-2-carboxylic acid methyl 
ester (16). To a solution of 4-tert-butoxycarbonylamino-bis-N-methylpyrrole-2-carboxylic 
acid 12 (400 mg, 1.1 mmol) and DIEA (171 mg, 1.32 mmol) in DMF (3 mL) HBTU 
(450 mg, 1.2 mmol) was added and the resulting solution was allowed to stir at room 
temperature for 30 min. Separately, 4-tert-butoxycarbonylamino-tri-N-methyl-pyrrole-2-
carboxylic acid methyl ester 8 (499 mg, 1.0 mmol) was treated with TFA (10 mL, 130 
mmol) at room temperature for 30 min. Excess TFA was removed under reduced 
pressure and the corresponding amine trifluoroacetate was dissolved in DMF (2 mL) and 
added to the activated acid along with additional DIEA (2 mL, 8.61 mmol). After stirring 
overnight at room temperature the solution was added slowly to ether (100 mL) and the 
resulting precipitate was collected by vacuum filtration. Flash column chromatography 
(5% CH30H/CH2Cl2) afforded 16 (622 mg, 84%) as a brown solid. 
1H NMR (DMSO-d6) 
8 9.98 (s, 1 H), 9.96 (s, 3 H), 9.89 (s, 1 H), 9.11 (s, 1 H), 7.47 (s, 2 H), 7.24 (s, 2 H), 7.22 
(s, 1 H), 7.06 (s, 2 H), 6.90 (m, 2 H), 6.84 (s, 1 H), 3.84 (br s, 9 H), 3.83 (s, 3 H), 3.81 (s, 
3 H), 3.73 (s, 3 H), 1.45 (s, 9 H) ; FAB-HRMS m/e 743.1017 (M+, 742.7972 calcd. for 
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4-tert-Butoxycarbonylamino-penta-N-methylpyrrole-2-carboxylic acid (17). 
To a slurry of 4-tert-butoxycarbonylamino-penta-N-methylpyrrole-2-carboxylic acid 
methyl ester 16 (622 mg, 0.837 mmol) in 95% EtOH (20 mL) was added 1 M NaOH (20 
mL) and the resulting mixture was heated at 60 oc for 6 h. The solution was cooled to 
room temperature and ethanol was removed under reduced pressure before acidifying to 
pH 2 with 2 M KHS04 • The solid was collected by vacuum filtration, washed with cold 
H20, and dried in vacuo to afford carboxylic acid 17 (560 mg, 93%) as a tan powder. 
1H 
NMR (DMSO-d6) 8 9.96 (s, 2 H), 9.91 (s, 1 H), 9.88 (s, 1 H), 9.11 (s, 1 H), 7.43 (s, 1 
H), 7.24 (m, 3 H), 7.04 (m, 3 H), 6.88 (s, 1 H), 6.84 (s, 2 H), 3.84 (br s, 9 H), 3.81 (br s, 
6 H), 1.45 (s, 9 H); FAB-HRMS m!e 729.1034 (M+, 728.7702 calcd. for C35 H40N100 8). 
4-Amino-penta-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
bistrifluoroacetate (18). To a solution of 4-tert-butoxycarbonylamino-penta-N-
methylpyrrole-2-carboxylic acid 17 (50 mg, 0.0686 mmol) and DIEA (14.8 mg, 0 .11 5 
mmol) in DMSO/NMP (0.4 mL) was added HBTU (26 mg, 0.0686 mmol). The 
resulting solution was stirred 1 h at room temperature when 3-dimethylaminopropylamine 
(41 mg, 0.397 mmol) and DIEA (30 mg, 0.23 mmol) were added to afford the 
corresponding carboxamide which was used immediately without isolation. After stirring 
4 hat room temperature TFA (10 mL, 130 mmol) was added and the solution stirred 1 hat 
room temperature. Excess TF A was removed under reduced pressure and the resulting 
residue was purified by RP-HPLC to afford bistrifluoroacetate 18 (30 mg, 46%) as a 
yellow solid. 1H NMR (DMSO-d6) 8 10.05 (s, 1 H), 9.98 (s, 1 H), 9.96 (s, 1 H), 9.92 (s, 
I H), 9.70 (br s, 1 H), 9.47 (br s, 1 H), 8.17 (t, 1 H, J = 5.6 Hz), 7 .28 (s, 1 H), 7.24 (s, 1 
H), 7 .22 (s, 1 H), 7 .17 (s, 1 H), 7.13 (s, 1 H), 7.08 (m, 2 H), 6.92 (s, 3 H), 3.89 (s, 3 H), 
3.86 (s, 3 H), 3.84 (s, 3 H), 3.81 (s, 3 H), 3.22 (m, 2 H), 3.18 (m, 2 H), 2.78 (s, 6 H) , 
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1.84 (m, 2 H); FAB-HRMS mle 713.3633 (M+ (-2 TFA), 712.8180 calcd. for 
C3sH44NJ20s)· 
1-Methylimidazole-2-carboxamide-4-penta-N-methylpyrrole-2-(3-
dimethylaminopropyl)-carboxamide trifluoroacetate (lm-(Py)s-Dp) (4). To a solution 
1-methylimidazole-2-carboxylic acid (35 mg, 0.277 mmol) and DIEA (48.2 mg, 0.373 
mmol) in DMSO/NMP (0.4 mL) was added HBTU (1 03 mg, 0.272 mmol). The 
resulting solution was stirred 1 h at room temperature when 4-amino-penta-N-
methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide trifluoroacetate 18 (16 mg, 0.017 
mmol), DIEA (30 mg, 0.23 mmol), and DMSO/NMP (0.3 mL) were added. The 
solution was shaken at 37 oc for 4 h. Purification by RP-HPLC afforded Im-(Py)s-Dp (4) 
asthetrifluoroacetatesalt(2.0mg, 13%). UV (H20) A.max (£) 246 (34,100), 314 (50,900) 
nm; 1H NMR (DMSO-d6 ) 8 10.51 (s, 1 H), 9.98 (s, 1 H), 9.96 (s, 2 H), 9.91 (s, 1 H), 
9.20 (br s, 1 H), 8.17 (t, 1 H, J = 5.2 Hz), 7.40 (s, 1 H), 7.29 (d, 1 H, J = 1.6 Hz), 7.24 
(m, 3 H), 7.18 (s, 1 H), 7.17 (s, 1 H), 7.07 (m, 3 H), 7.04 (d, 1 H, J = 1.6 Hz), 6.94 (d, 1 
H , J = 1.5 Hz), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.80 (s, 3 H), 3.08 (m, 2 H), 
2.78 (d, 6 H, J = 4.8 Hz), 1.80 (m, 2 H); FAB-HRMS m/e 821.3993 (M+ (- TFA), 
820.9184 calcd. for C40H48 N140 6. 
4-tert-Butoxycarbonylamino-hexa-N-methylpyrrole-2-(3-dimethylamino-
propyl)-carboxamide (19). To a solution of 4-tert-butoxycarbonylamino-tri-N-
methylpyrrole-2-carboxylic acid 9 (1.037 g, 1.82 mmol) and DIEA (297 mg, 2.30 mmol) 
in DMF (6 mL) was added HBTU (760 mg, 2.0 mmol). After stirring 4 h at room 
temperature 4-amino-tri-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
trifluoroacetate 11 (1.27 g, 1.82 mmol), DIEA (2.23 g, 17.2 mmol) and DMF (2 mL) 
were added. The solution was stirred overnight at room temperature and poured into ether 
(400 mL) and the resulting precipitate was collected by vacuum filtration and washed with 
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cold ether. Flash column chromatography (1: 1 CH30H/CH2Cl2 to CH30H to 1% 




9.96 (s, 4 H), 9.91 (s, 1 H), 9.88 (s, 1 H), 9.11 (s, 1 H), 8.10 (t, 1 H, J = 5.0 Hz), 7.71 (d, 
1 H, J = 6.2 Hz), 7.48 (d, 1 H, J = 4.6 Hz), 7.22 (m, 5 H), 7.07 (m, 3 H), 6.89 (s, 1 H), 
6.85 (s, 1 H), 3.82 (m, 18 H), 3.22 (m, 2 H), 2.31 (s, 6 H), 1.65 (m, 2 H), 1.44 (s, 9 H), 
1.30 (m, 2 H); FAB-HRMS m/e 935.4677 (M+, 935.0632 calcd. for C46H58 N 140 8) . 
4-Amino-hexa-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
bistrifluoroacetate (20). To a slurry of 4-tert-butoxycarbonylamino-hexa-N-
methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 19 (500 mg, 0.542 mmol) was 
added TFA (20 mL, 260 mmol) and the resulting solution was allowed to stir 1.5 h at 
room temperature. Excess TF A was removed under reduced pressure and the resulting 
solid slurried in H20 (5 mL), frozen, and lyophilized to afford 20 (400 mg, 69%) as a 
yellow solid. 1H NMR (DMSO-d6) 8 10.05 (s, 1 H), 9.96 (s, 3 H), 9.91 (s, 1 H), 9.76 (br 
s, 3 H), 9.30 br s (1 H), 8.17 (t, 1 H, J = 5.8 Hz), 7.24 (d, 1 H, J = 1.8 Hz), 7.23 (s, 3 H) , 
7.16 (d, 1 H, J = 1.8 Hz), 7.12 (d, 1 H, J = 1.8 Hz), 7.08 (m, 4 H), 6.95 (s, 2 H), 3.90 (s, 3 
H), 3.86 (s, 12 H), 3.84 (s, 3 H), 3.81 (s, 3 H), 3.22 (m, 2 H), 3.05 (m, 2 H), 2.78 (d, 6 H, 
J = 4.8 Hz), 1.82 (m, 2 H); FAB-HRMS m/e 835.4131 (M+ (- 2 TFA), 834.9454 calcd. 
for c41 H50 NI4 06). 
1-Methylimidazole-2-carboxamide-4-hexa-N-methylpyrrole-2-(3-dimethyl-
aminopropyl)-carboxamide trifluoroacetate (lm-(Py)6-Dp) (5). To a solution of N-
methyl-imidazole-2-carboxylic acid (100 mg, 741 J.lmol) and hydroxybenzotriazole (72 
mg, 500 J.lmol) in DMF (0.5 mL) was added DCC. The solution was allowed to stand 12 
hat room temperature and then filtered to remove precipitated DCU. To the solution was 
added 4-amino-hexa-N-me thy lpyrrole-2-(3-dimethy laminopropy 1)-carboxamide as the 
bistrifluoroacetate salt 20 (10 mg, 9.4 J..Lmol) and DIEA (100 J..Ll, 576 J.lmol) and the 
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resulting mixture was allowed to stand 2 hat room temperature. Purification by RP-HPLC 
afforded Im-(PykDp (5) (6.3 mg, 62%) as the trifluoroacetate salt. UV (H
2
0) !..max (e), 
246 (34,100), 304 (56,600) nm; 1H NMR (DMSO-d6) b 10.46 (s, 1 H), 9.55 (s, 1 H), 
9.94 (m, 3 H), 9.90 (s, 1 H), 9.20 (br s, 1 H), 8,14 (t, 1 H, J = 7.2 Hz), 7.38 (s, 1 H), 7 .28 
(d, 1 H, J = 1.4 Hz), 7.26 (d, 1 H, J = 1.4 Hz), 7.23 (m, 4 H), 7.08 (m, 5 H), 7.04 (s, 1 H, 
J = 1.2 Hz), 6.93 (d, 1 H, J = 1.6 Hz), 3.98 (s, 3 H), 3.84 (m, 15 H), 3.83 (s, 1 H), 3.30 
(q, 2 H, J = 7.4 Hz), 3.21 (t, 2 H, J = 7.1 Hz), 2.77 (d, 6 H, J = 4.1 Hz), 1.74 (m, 2 H); 









MALDI-TOF MS 944.212 (M+H (- TFA), 944.04 calcd. for C46lis5 N16 0 7). 
4-Amino-septa-N-methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide 
bistrifluoroacetate (21). To a solution of 4-amino-hexa-N-methylpyrrole-2-(3-
dimethylaminopropyl)-carboxamide bistrifluoroacetate 20 (20 mg, 0.0214 mmol) and 
DIEA (37 .1 mg, 0.287 mmol) in DMSO/NMP (0.35 mL) was added 4-tert-
butoxycarbonylamino-N-methylpyrrole-2-carboxylic acid hydroxybenzotriazo1e ester (16 
mg, 0.43 mmol). The solution was shaken at 37 oc for 4 h and then diluted to 2 mL with 
DMF. The resulting precipitate was isolated by centrifugation, washed with cold DMF (2 
x 250 IlL), slurried in CH2Cl2 (0.4 mL) and treated with TFA (8 mL, 104 mmol). After 
1.5 h at room temperature excess TFA was removed under reduced pressure and the 
resulting residue purified by RP-HPLC to afford 21 (20 mg, 79%). 1H NMR (DMSO-d6) 
o 10.05 (s, 1 H), 9.98 (s, 5 H), 9.95 (s, I H), 9.82 (br s, 3 H), 9.42 (br s , I H), 8.17 (t, 1 
H, J = 5.8 Hz), 7.24 (m, 6 H), 7.15 (d, 1 H, J = 1.8 Hz), 7.10 (m, 6 H), 6.97 (d, 1 H , J = 
1.8 Hz), 3.98 (s, 3 H), 3.85 (s, 12 H), 3.80 (s, 3 H), 3.24 (m, 2 H), 3.I1 (m, 2 H), 2.78 (d, 
6 H, J = 4.8 Hz), 1.82 (m, 2 H); FAB-HRMS m/e 957.2256 (M+ -(2 TFA), 957.0728 
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1-Methylimidazole-2-carboxamide-4-septa-N-methylpyrrole-2-(3-dimethyl-
aminopropyl)-carboxamide trifluoroacetate (lm-(Py)7-Dp) (6). To a solution of 1-
methylimidazole-2-carboxylic acid (35 mg, 0.277 mmol) and DIEA (48.2 mg, 0.373 
mmol) in DMSO/NMP (0.4 mL) was added HBTU (103 mg, 0.272 mmol). The 
resulting solution was stirred 1 h at room temperature when 4-amino-septa-N-
methylpyrrole-2-(3-dimethylaminopropyl)-carboxamide bistrifluoroacetate 21 (20 mg, 
0.017 mmol), DIEA (30 mg, 0.23 mmol), and DMSO/NMP (0.3 mL) were added. The 
solution was shaken at 37 ac for 4 h. Purification by RP-HPLC Im-(Py)7-Dp (6) as the 
trifluoroacetate salt (6.1 mg, 31%). UV (H20) "-max (E) 246 (38,600), 304 (62,500) nm; 
1H NMR (DMSO-d6) 8 10.49 (s, 1 H), 9.98 (s, 1 H), 9.97 (s, 5 H), 9.92 (s, 1 H), 9.24 (br 
s, 1 H), 8.17 (t, 1 H, 1 = 5.2 Hz), 7.40 (s, 1 H), 7.29 (d, 1 H, 1 = 1.8 Hz), 7.27 (s, 1 H), 
7.24 (s, 4 H), 7.17 (s, 2 H), 7.08 (s, 4 H), 7.05 (s, 1 H), 6.94 (m, 2 H), 3.99 (s, 3 H), 3.84 
(s, 15 H), 3.83 (s, 3 H), 3.80 (s, 3 H), 3.22 (m, 2 H), 3.08 (m, 2 H), 2.78 (d, 6 H, 1 = 4.8 
Hz), 1.82 (m, 2 H); MALDI-TOF MS 1066.1 (M + H (- TFA), 1066.2 calcd. for 
CszH6rNrsOs). 
DNA Reagents and Materials. RNase free water was obtained from U .S. 
Biochemicals and used in all manipulations. Eco RI, Bam HI, Hind Ill, Pvu II, the 
Klenow fragment of DNA polymerase I, calf alkaline phosphatase, and T4 polynucleotide 
ldnase were purchased from Boehringer-Mannheim and used according to the supplier's 
recommended protocol in the buffers provided. T4 DNA ligase was obtained from New 
England Biolabs and used with the buffer provided. Nucleotide triphosphates were 
Pharmacia Ultra-Pure grade and were used as supplied. Nucleotide triphosphates labeled 
with 32P (> 3000 Ci/mmol) were obtained from Amersham. NICK columns were 
purchased from Pharmacia and used according to the suggested protocol. Glycogen was 
obtained from Boehringer-Mannheim as a 20 mg/mL aqueous solution. Cerenkov 
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radioactivity was measured with a Beckman LS 2801 scintillation counter. DNase I was 
purchased from Boehringer-Mannheim. Sonicated, deproteinized calf thymus DNA was 
purchased from Pharmacia and dissolved in H20 to a final concentration of 2 mM in base 
pairs and stored at -20 oc. Chemical sequencing reactions were performed according to 
published procedures.27•28 General manipulations of DNA were performed according to 
established procedures. 29 
Plasmid Preparation. Plasmids pJK5, pJK6, pJK7, pJK8, pJK9, and pJK10 
were prepared by established procedures.28 Briefly, oligonucleotides containing the desired 
insert sequences were synthesized, deprotected, and purified by 12-15% denaturing 
polyacrylamide gel electrophoresis (5% cross-linked, 7 M urea). The oligonucleotides 
were then annealed by slow-cooling from 90 oc to afford the desired insert duplex. The 
oligonucleotide duplex (1 pmol) was then added to Bam HI/Hind III restricted pUC19 
plasmid DNA and the resulting solution was treated overnight with T4 DNA ligase. The 
ligation mixture was then used to transform Epicurean Coli XL1-Blue Supercompetent 
cells (Stratagene) according to the manufacturer's protocol. Transformants containing an 
insert were identified by a-complementation, selected and grown overnight in 5 rnL LB 
media containing 50 mg/rnL ampicillin. The plasmids were isolated using a Quiagen 
miniprep kit (Tip 20) and sequenced using a Sequenase 2.0 kit (U.S. Biochemicals). Large 
scale plasmid preparation was accomplished using a Quiagen maxiprep kit (Tip 500). The 
sequences of the isolated plasmids were confirmed by sequencing. Plasmid yields were 
determined at 260 nm using the relation 1 OD unit = 50 J..Lg/mL duplex DNA Plasmids 
were stored in 1 mL 10 mM Tris•HCl, pH 7.0, 0.5 mM EDTA at -20 C. 
Labeled Restriction Fragment Preparations. The Eco RII Pvu II fragments 
from plasmids pJK5, pJK6, pJK7, pJK8, pJK9, and pJK10 3'-32P-end labeled at the Eco 
RI site were prepared by digesting each plasmid (3-5 J..Lg) with Eco RI, followed by 
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treatment with a-32 P-dATP and a -32P-TTP in the presence of the Klenow fragment of 
DNA polymerase I. Following the addition of unlabeled dATP and TIP unincorporated 
nucleotides were removed using a NICK column. The linearized, 32P-labeled plasmid was 
then digested with Pvu II, followed by separation of the resulting DNA fragments on a 
nondenaturing 5% polyacrylamide gel ( 1: 19 crosslinked). The desired fragment was 
located by autoradiography and excised. The gel slice was crushed and soaked in 25 mM 
Tris·HCl pH 7.0, 2 mM EDTA for 8-12 hat 37 oc. The resulting suspension was then 
filtered through an Isolab Quik-Sep polypropylene filter and the filtrate was ethanol 
precipitated using glycogen (1 ~L). The DNA pellet was washed with 70% EtOH, dried in 
vacuo, and resuspended in 10 mM Tris·HCl pH 7.0, 0.5 mM EDTA. The solution was 
then extracted with phenol (3 x 100 ~L), 24: 1 phenol:CHC13 (3 x 100 ~L), and 24:1 
CHC13:isoamyl alcohol (2 x 100 ~L). The solution was then passed through a NICK 
column equilibrated with 10 mM Tris·HCI pH 7.0, 0.5 mM EDTA buffer and the eluate 
stored at -20 oc after measuring Cerenkov radioactivity. Typical yields of Cerenkov 
radioactivity were 5-10 x 106 cpm. The restriction fragments 5'-32 P-end labeled at the Eco 
RI site was prepared by digesting the corresponding plasmids (5 ~g) with Eco RI followed 
by dephosphorylation with calf alkaline phosphatase. The linearized plasmid was then 
labeled by treatment with y-32P-ATP in the presence of polynucleotide kinase. 
Unincorporated y-32P-ATP was removed using a NICK column. The DNA was then 
digested with Pvu II and isolated as described above. Typical yields of radioactivity were 
2-5 x 106 cpm. 
MPE•Fe(II) Footprinting Experiments. For each experiment a cocktail 
containing Tris·AcOH pH 7.0, NaCl, calf thymus DNA, and 32P-end labeled DNA 
restriction fragment was prepared To separate 1.7 mL microfuge tubes were added 28 ~L 
of cocktail. Stock solutions of each polyamide were prepared and the concentrations were 
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verified by the UV absorbance at 316 nm before making serial dilutions. A 4 j..i.L aliquot of 
each 1 Ox ligand solution was added to the appropriate tubes and the solutions were allowed 
to equilibrate for 1-6 h at 22 oc. A 50 j..i.M solution of MPE·Fe(II) was prepared by 
mixing 100 j..i.L of a 100 j..i.M MPE solution with a freshly prepared 100 j..i.M ferrous 
ammonium sulfate solution and allowing to equilibrate for 15 min at 22 oc. A 4 j..i.L 
aliquot of 50 j..i.M MPE·Fe(II) was added to the appropriate tubes and incubated 15 min at 
22 oc. Cleavage was initiated by the addition of 4 j..i.L of 50 mM DTT. Final 
concentrations were 25 mM Tris·AcOH pH 7.0, 10 mM NaCI, 100 j..i.M-bp calf thymus 
DNA, 5 j..i.M MPE·Fe(II), and 5 mM DTT in a total volume of 40 j..i.L containing 1-3 x 105 
cpm of 32P-labeled restriction fragment. Cleavage was allowed to proceed for 15 min and 
then stopped by ethanol precipitation using 5 j..i.L of glycogen. The precipitated DNA was 
washed with 70% EtOH, dried in vacuo and resuspended in formamide-TBE loading 
buffer. After heating at 90 oc for 3 min and cooling on ice the samples were 
electrophoresed on 0.4 mm thick 8% denaturing polyacrylamide gels (5% cross-link, 7 M 
urea) at 2000 V until the bromophenol blue tracking dye reached the bottom of the gel. 
The gels were transferred to filter paper, dried, and quantitated using storage phosphor 
technology as described below. Histograms were constructed by comparing the cleavage 
intensity in lanes containing polyamide to an MPE•Fe(II) control lane to which no ligand 
was added. 
Quantitative DNase I Footprint Titration Experiments. For each experiment a 
cocktail containing Tris·HCl, pH 7.0, KCl, MgC12, CaC12, and 3'-
32P-end labeled restriction 
fragment was prepared. To separate 1.7 mL microfuge tubes was added a 32 j..i.L aliquot of 
the cocktail solution. Stock solutions of each polyamide were prepared and the 
concentrations were verified by the UV absorbance at 3 16 nm before making serial 
dilutions. To the appropriate tubes containing cocktail were added 4 j..i.L of 1 Ox ligand 
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solution and the solutions were allowed to equilibrate at 22 °C. Final ligand concentrations 
were 5 nM to 50 11M for Im-(PykDp, 50 pM to 10 J.LM for Im-(PykDp, 20 pM to 1.5 
J.LM for Im-(PykDp, 1 pM to 0.2 J.LM for Im-(Py)s-Dp, 10 pM to 1 J.LM for Im-(PykDp, 
and 1 nM to 20 J.LM for Im-(Py)7-Dp. The equilibration times were 1 h and 3 h for Im-
(PykDp, 36 hand 65 h for Im-(Py)3-Dp, 36 h and 65 h for Im-(Py)4-Dp, 60 h and 84 h 
for Im-(Py)s-Dp, 36 h and 65 h for Im-(Py)6-Dp, and 8 h for Im-(PykDp. Mter 
equilibration, cleavage was initiated by the addition 4 J.LL of a solution of DNase I (0.04 
units/mL) containing 1 mM DTT. Final concentrations were 10 mM Tris·HCl pH 7.0, 10 
mM KCl, 5 mM MgC12, and 5 mM CaC12 in a total volume of 40 J.LL containing 1-2 x 105 
cpm of 3'-32P-end labeled restriction fragment. We note explicitly that binding affinities 
were determined in the absence of unlabeled carrier DNA. Cleavage was allowed to 
proceed for 6 min at 22 oc and then stopped by the addition of 12.8 J.LL of a 3 M 
NaOAc/50 mM EDT A/glycogen solution (1.2/1/1) followed by ethanol precipitation. The 
precipitated DNA was washed with 70% EtOH, dried in vacuo and resuspended in 
formarnide-TBE loading buffer. After heating at 90 oc for 3 min and cooling on ice the 
samples were electrophoresed on 0.4 mm thick 8% denaturing polyacrylamide gels (5% 
cross-link, 7 M urea) at 2000 V until the bromophenol blue tracking dye reached the 
bottom of the gel. The gels were transferred to filter paper, dried, and quantitated using 
storage phosphor technology as described below. 
Apparent first-order binding constants were determined as previously described. 17 
The data were analyzed by performing volume integrations of the match and single base 
pair mismatch sites on each restriction fragment as well as a 5' -GAGC-3' reference site at 
which DNase I cleavage was invariant. The apparent DNA target site saturation, eapp' was 
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where 1101 and ~r are the integrated volumes of the target and reference sites, respectively, 
and 1101o and ~ero correspond to those values from a DNase I control lane lane to which no 
polyamide has been added. At concentrations higher than 50 l.l-M of Im-(Py)2-Dp, 5 l.l-M 
Im-(PykDp, 1 f.LM Im-(PykDp, 0.1 f.LM Im-(Py)s-Dp and 1 f.LM Im-(PykDp the 
reference site becomes partially protected, resulting in low e.PP values. For this reason, 
polyamide concentrations higher than these values were not used. The ([L]
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, e.PP) data 
points were best fit to cooperative Langmuir binding isotherms (n = 2) consistent with 2:1 
polyamide-DNA complex formation by minimizing the difference between e app and efit 
using the modified Hill equation: 
8fir = 8m,·n + (()max - 8m,·n ) K an [L t tot 
1 + K a n [L]n "" (2) 
where [L]
10 1 
corresponds to the total polyamide concentration, Ka corresponds to the 
apparent monomeric association constant, n represents the Hill coefficient, and emax and entin 
represent the experimentally determined site saturation values when the site is unoccupied 
or saturated, respectively. We note explicitly that treatment of the data in this manner does 
not represent an attempt to model a binding mechanism. Rather, we have chosen to 
compare values of the apparent first-order association constant, because this parameter 
represents the concentration of polyamide at which the binding site is half-saturated. Data 
were fit using a non-linear least-squares fitting procedure of Kaleidagraph software 
(version 3.0.1; Abelbeck Software) running on a Power PC Macintosh 6100/60 computer 
with Ka, emax' and emin as the adjustable parameters. The goodness of fit is evaluated by the 
correlation coefficient, with R > 0.98 as the criterion for an acceptable fit. The binding 
affinities reported for Im-(Py)z-Dp at 5'-TGGCA-3' , Im-(Py)s-Dp at 5'-TGTGAACA-3', 
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and Im-(PykDp at the match and mismatch sites represent upper limits since the quality 
of fits for these data sets were poor. The specificity of each polyamide represents the ratio 
of the binding affinity of the match side to the affinity for the single base pair mismatch 
site. The uncertainty of each specificity value was calculated using the standard deviations 
for the match and mismatch site binding affinities.30 The specificities of Im-(Py)z-Dp and 
Im-(Py)s-Dp represent a lower limit due to the fact that the mismatch site binding affinities 
are upper limits. At least three sets of acceptable data were used in determining each 
association constant. All lanes from each gel were used unless visual inspection revealed a 
data point to be obviously flawed relative to neighboring points. The data were normalized 
using the following equation: 
ll _ 8app - 8rrun 
onorm -
8max - 8rrun 
(3) 
Quantitation by Storage Phosphor Autoradiography. Photostimulable storage 
phosphor imaging plates (Kodak Storage Phosphor Screen S0230 obtained from 
Molecular Dynamics) were pressed flat against dried gels and exposed in the dark for 12-
24 h at 22 oc. A Molecular Dynamics 400S Phosphorlmager was used to obtain all data 
from the storage screens. The data were analyzed by performing volume integrations of all 
bands using ImageQuant v. 3.3 software running on a Gateway 2000 486/66 computer. 
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Chapter 3 
Recognition of 5'-(A,T)GCGC(A,T)-3' Sequences 
by a Hairpin Polyamide 
Introduction 
2:1 Polyamide-DNA Complexes. The discovery that the three ring synthetic 
polyamide Im-Py-Py-Dp containing imidazole (lm) and pyrrole (Py) carboxamides binds 
the DNA sequence 5' -(A,T)G(A,T)C(A,T)-3 ' as an anti parallel dimer offers a new model 
for the design of ligands for specific recognition of sequences in the minor groove 
containing both G,C and A,T base pairs. 1-6 The 2: I model allows specific contacts with 
each DNA strand on the floor of the minor groove where the side-by-side combination of 
an imidazole ring on one ligand and a pyrrole carboxamide on the second ligand recognizes 
G·C, while a pyrrole carboxarnide-imidazole pair targets a C·G base pair. A pyrrole 
carboxarnide-pyrrole carboxamide pair is partially degenerate and binds to either A·T or T·A 
base pairs. 
Recognition of 5'-(A,T)GCGC(A,T) Sequences. Recently, it was 
demonstrated by footprinting, affinity cleaving, and NMR studies that the alternating four-
ring polyamide Im-Py-lm-Py-Dp 1 binds a family of six base pair sites 5' -
(A,T)GCGC(A,T)-3' containing a four base pair G,C core as an antiparallel dimer in the 
minor groove representing a reversal of the A,T specificity of the natural product 
distamycin (Figure 3.1 ).5 Remarkably, despite the novel specificity of polyamide 1 for 5'-
(A,T)GCGC(A,T)-3 ' sites, the overall affinity was modest (K. = 4 x 105 M·', pH 7.0, 22 
0 C). This suggests that there is an energetic price for forming four specific hydrogen bonds 
between the imidazole rings on the polyamide dimer and the guanine amino groups 
protruding from the 
5' 3' 
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Figure 3.1. Model of the (lm-Py-lm-Py-Dp)2•5 '-TGCGCA-3' complex derived from 
NMR data. Circles with dots represent lone pairs of N3 of purines and 02 of pyrimidines 
and circles containing a H represent the 2-amino group of guanine. Putative hydrogen 
bonds are indicated by dashed lines. 
floor of the minor groove. It is possible that the dimer of 1 does not sit deeply in the minor 
groove diminishing energetically favorable van der Waals contacts with the walls of the 
double helix. 
Experimental Design. A hairpin motif in which two crescent-shaped 
polyamides are linked head-to-tail by y-arninobutyric acid (GABA, y) offers a methodology 
for the preparation of polyamides that bind in the minor groove with enhanced affinity.7 
The question arises whether hairpin polyamides bind G,C core sequences with high affinity 
and specificity. Here we examine the energetics of the hairpin polyamide Im-Py-lm-Py-y-
Im-Py-Im-Py-Dp 2 binding at eight different six base pair sites on a 381 base pair DNA 
fragment containing three putative perfect matches 5'-(A,T)GCGC(A,T)-3' and five sites 
with one to two mismatches in the central 5' -GCGC-3' core (Figure 3.2). 
Ill 
1 2 
Figure 3.2. Structure of Im-Py-lm-Py-Dp 1 and hairpin polyamide Im-Py-Im-Py-y-lm-
Py-lm-Py-Dp 2. 
Results 
Hairpin Polyamide Synthesis. The hairpin polyamide Im-Py-lm-Py-y-lm-Py-
Im-Py-Dp 2 was synthesized in nine steps from methyl 4-nitro-N-methylpyrrole-2-
carboxylate (3) (Figure 3.3). Reduction of 3 followed by coupling with 4-nitro-N-
methylimidazole-2-acyl chloride affords 4 that was similarly reduced and treated with 4-
nitro-N-methylpyrrole-2-acyl chloride to afford the three ring polyamide 5. Reduction of 5 
and coupling with 1-methylimidazole-2-carboxylic acid (DCC, HOBt) affords ester 6 
which is converted to acid 7 by saponification (LiOH, H20 , EtOH). Reduction of 5 and 
coupling with 4-( 4-amino-N-t-butoxycarbony 1-butyramido )-N-me thy !imidazole-2-
carboxylic acid (12) , available in three steps from ethyl-4-nitro-1-methylimidazole-2-
carboxylate (11) (Figure 3.4), affords polyamide 9 containing the GABA linker in 
protected form. Saponification (LiOH, H20 , EtOH) of 9 affords acid 10 that can be 
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Figure 3.3. Synthesis of hairpin polyamide 2 . Reagents: (a) H 2, Pd-C; (b) 4-nitro-1-
methylimidazole-2-carboxylic acid, oxalyl chloride; (c) 4-nitro-N-methylpyrole-2-
carboxylic acid, SOC12 ; (d) 1-methylimidazole-2-carboxylic acid, DCC, HOBt; (e) LiOH, 
H 20 , EtOH; (f) N,N-carbonyldiimidazole, N,N-dimethylaminopropylamine, NEt3; (g) 







Figure 3.4. Synthesis of afford 4-( 4-N-t-butoxy-aminobutyramido )-1-methylimidazole-
2-carboxylic acid (12). Reagents: (a) (i) H 2, Pd-C; (ii) Boc-GABA, DCC, HOBt; (b) 
LiOH, EtOH, H20. 
converted to the corresponding imidazolide with 1,1'-carbonyldiimidazole and condensed 
with 3-dimethylamino-propylamine to afford Boc-protected amine 10 containing the 
dimethylamino group at the C-terrninus of the polyamide. Removal of the Boc group with 
TF A in the presence of 0.5 M thiophenol yields primary amine 11. Conversion of acid 7 
to the corresponding HOBt ester and coupling with amine 11 affords the hairpin polyamide 
Im-Py-Im-Py-y-Im-Py-Im-Py-Dp 2 which was purified by reverse phase HPLC. 
MPE•Fe(II) Footprinting. MPE•Fe(II) footprinting experiments with the Eco 
RIJBam HI restriction fragment from pBR322 32P-labeled at each end reveal that the hairpin 
polyamide Im-Py-Im-Py-y-Im-Py-Im-Py-Dp is specific for 5'-GCGC-3' sequences 
(Figures 3.5, 3.6).8 Strong footprints are observed at the match sites 5'-TGCGCT-3', 5'-
TGCGCA-3', and 5'-AGCGCT-3' at 2 !1M concentration of Im-Py-Im-Py-y-Im-Py-Im-
Py-Dp (Figure 3.7). Weaker protection is observed at the mismatched 5'-TGCGGT-3', 
5 '-AACGCA-3' , and 5'-TGCGIT-3' sites (base pair mismatches are underlined). No 
protection is observed at the mismatched 5'-TCGGCA-3' and 5'-ACCGCT-3' sites. 
Quantitative DNase I Footprint Titration Experiments. DNase I 
footprinting experiments on the 32P-labeled 381 base pair restriction fragment reveal that 
both Im-Py-
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5 '-GCTTT GTTTATCACAGTTAAATTGCT TCAGGCA 









Figure 3.5. Illustration of the 381 base pair Eco RJJBam HI restriction fragment from 
pBR322 used in this study. The fragment was 32P-end labeled at both restriction sites in 
order to analyze six eight base pair sites which are indicated by boxes. The relative 
position and nucleotide sequence of the restriction fragment resolved by gel electrophoresis 
are shown. 
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Figure 3.6. MPE•Fe(II) footprinting experiment with hairpin polyamide Im-Py-Im-Py-
y-Im-Py-lm-Py-Dp 2 on the Eco RJJBam HI restriction fragment from pBR322 5 ' -32P end-
labeled at the Eco RI restriction site. Autoradiogram of an 8% denaturing denaturing 
polyacrylamide gel. All reactions contain 10 kcpm labeled restriction fragment, 25 mM 
Tris•AcOH, 10 mM NaCl, and 100 )lM calf thymus DNA at 22 °C, pH 7.0. Lane 1, intact 
DNA, lane 2, A reaction, lane 3, G reaction, lane 4, MPE•Fe(II), lanes 5-6, 1 and 2 )1M 
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Im-Py-Dp and Im-Py-Im-Py-y-Im-Py-lm-Py-Dp bind the six base pair sites in the relative 
order 5'-TGCGCT-3', 5 '-TGCGCA-3', 5'-AGCGCT-3' > 5'-AACGCA-3', 5 ' -
TGCGIT-
3' > 5'-TGCGGT-3' , 5'-ACCGCT-3' , 5'-TCGGCA-3' (Figure 3.8).9 From quantitative 
footprint titration experiments Im-Py-Im-Py-Dp binds the match sites 5 '-TGCGCT -3 ', 5 '-
TGCGCA-3', and 5'-AGCGCT-3' with an apparent first order binding affinities of 3 .7 x 
105 M·1, 3.4 x 105 M·1, and 3.9 x 105 M·1, respectively (Table 1). The unlinked polyamide 
1 binds the mismatch sites 5' -AACGCA-3' (K , = 1.7 x 105 M "1), 5'-TGCGIT-3 ' (K , = 
1.5 x 105 M"1) , 5' -TGCGGT-3' (K, < 105 M"1), 5' -ACCGCT-3' (K, < 105 M"1) , and 5' -
TCGGCA-3' (K, < 105 M"1) with 2-4 fold lower affinity. In contrast, hairpin polyamide 2 
binds the match sites 5'-TGCGCT-3', 5'-TGCGCA-3', and 5'-AGCGCT-3' with an 
apparent first order binding affinities of 1.1 x 107 M -1, 1.1 x 107 M-1, and 1.0 x 107 M-1, 
respectively and the mismatch sites 5 '-AACGCA-3' (K , = 1.9 x 106 M"1) , 5'-TGCGTT-3' 
(K, = 1.7 x 106 M"1) , 5' -TGCGGT-3 ' (K. < 106 M"1) , 5'-ACCGCT-3' (K. < 106 M"1), and 
5'-TCGGCA-3' (K, < 106 M"1) with 5-10 fold lower affinity (Table 1). Like Im-Py-Im-
Py-Dp the hairpin polyamide Im-Py-Im-Py-y-lm-Py-Im-Py-Dp does not discriminate 
between A•T and T•A at the first and sixth positions of the binding site. Im-Py-lm-Py-y-
Im-Py-Im-Py-Dp binds three sites 5' -TGCGCT-3', 5'-TGCGCA-3 ' , and 5 '-AGCGCT-3' 
with similar binding affinities ( -1.0 x 107 M "1) (Table 1). However, it is specific for and 
discriminates between G·C and C·G base pairs in the 5' -GCGC-3' core as evidenced by 
lower affinities for the mismatched sites 5'-AACGCA-3 ' , 5 ' -TGCGIT-3', 5'-TGCGGT-
3', and 5 ' -ACCGCT-3' on the same DNA fragment. 
Discussion 
Binding Affinity for 5'-(A,T)GCGC(A,T)-3' Sequences. Covalently 
linking two Im-Py-lm-Py-Dp polyamides affords an eight ring polyamide Im-Py-Im-Py-y-
Im-
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Figure 3.8. Quantitative DNase I footprint titration experiment with hairpin polyamide 
Im-Py-Im-Py-y-Im-Py-Im-Py-Dp 2 on the Eco Rl/Bam HI restriction fragment from 
pBR322 3 ' -32P end-labeled at the Eco RI restriction site. Autoradiogram of an 8% 
denaturing denaturing polyacrylamide gel. All reactions contain 10 kcpm labeled restriction 
fragment, 10 mM Tris•HCl, 10 mM KCl, 10 mM MgC12, and 5 mM CaC12. Lane 1, intact 
DNA, lane 2, A reaction, lane 3, G reaction, lane 4, DNase I control, lanes 5-17, 0.1 nM, 
0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM, 50 nM, 0.1 ~M, 0.15 ~M, 0.25 ~M, 
0.5 ~M polyamide 2, respectively. 
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Table I. First Order Affinity Constants (M-1) for Im-Py-Im-Py-Dp 1 and 
Im-Py-Im-Py-y-Im-Py-Im-Py-Dp 2.a.b 
Site (5'-3') c 1 2 Mismatches 
TGCGCT 3.7 X 105 (0.2) 1.1 X 107 (0.3) 0 
AGCGCT 3.4 X 105 (0.3) 1.1 X 107 (0 .2) 0 
TGCGCA 3.9 X 105 (0.3) 1.0 X 107 (0.4) 0 
AACGCA 1.7 X 105 (0.7) 1.9 X 106 (0.9) 
TGCGIT 1.5 X 105 (0.9) 1.7 X 106 (0.8) 1 
TGCGGT d < 105 < 106 
ACCGCTd < 105 < 106 
TCGGCAd < 105 < 106 2 
a Values reported are the mean values determined from four footprint 
titration experiments, with the standard deviation for each data set indicated in 
parentheses. h The assays were performed at 22 oc at pH 7.0 in the presence 
of 10 mM Tris•HCI, 10 rnM KCI, 10 mM MgC12, and 5 mM CaCI2• c Base 
pair mismatches are underlined. d Upper limits for binding affinities are 
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Figure 3.9. Data for quantitative DNase I footprint titrations for Im-Py-lm-Py-Dp 1 and 
Im-Py-lm-Py-y-lm-Py-Im-Py-Dp 2 binding to the 5'-TGCGCT-3' site. The enorm points 
were obtained using photostimulable storage phosphor autoradiography. The data points 
for 1 are represented by open diamonds and for 2 by filled diamonds. The dashed curve is 
a best fit cooperative binding isotherm (n = 2) consistent with 2:1 polyamide-DNA complex 
formation with 1. The solid curve is a best fit Langmuir binding isotherm (n =1 ) consistent 
with 1:1 polyamide-DNA complex formation with 2. 
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Py-Im-Py-Dp that binds 5' -(A,T)GCGC(A,T)-3' sequences with 30-fold higher affinity 
(Figure 3.9). This 2.3 kcallmol increase in the free energy of binding of 2 is likely due to a 
more favorable translational entropy for a single polyamide versus dimeric binding of 1 at 
the six base pair sequences minus the entropic penalties due to restricted rotational freedom 
of the GABA linker in a hairpin conformation when bound in the minor groove as well as 
the loss of one of the two positive charges in proceeding from the 2:1 complex to the 1:1 
hairpin polyamide-DNA complex (Figures 3.10, 3.11). Future work must now define the 
sequence composition limitations as well as the upper limit for the binding site size which 
can accommodate hairpin polyamides in the minor groove of DNA. 
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Im-Py-Im-Py-y-Im-Py-lm-Py-Dp • TGCGCT 
Figure 3.10. Proposed binding of model the Im-Py-lm-Py-y-lm-Py-lm-Py-Dp•S'-
TGCGCA-3' complex derived from NMR data. Circles with dots represent lone pairs of 
N3 of purines and 02 of pyrimidines and circles containing a H represent the 2-amino 
group of guanine. Putative hydrogen bonds are indicated by dashed lines. 
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Figure 3.11. Space-filling model of Im-Py-lm-Py-y-Im-Py-Im-Py-Dp bound in the 
minor groove of a 5 '-TGCGCT -3' site. The hairpin polyamide is shown as a CPK model 
m blue with the imidazole rings, GABA linker, and positively charged 
dimethylaminopropyl group highlighted in yellow, red, and green, resepectively. The 
DNA is shown as a van der Waals surface in magenta with the model overlaid in white. 
This model was constructed from the model of the 2: 1 polyamide-DNA complex between 
Im-Py-Im-Py-Dp and 5'-TGCGCA-3' derived from NMR and molecular modeling data 
using the Insightii/Discover package (Biosym). The A•T base pair at the 3 '-end of the 
binding site was substituted with T•A. The hairpin polyamide was created by deleting a 
dimethylaminopropyl group from one peptide, replacing it with GABA, and bonding the 
carboxylate of the GABA linker to an amino group added to the N-terminal imidazole ring 
of the other polyamide in the 2: 1 complex. The conformation of the GABA linker was 




Polyamide Synthesis. 1H NMR were recorded on a General Electric QE-300 
spectrometer with chemical shifts reported in parts per million relative to residual solvent 
signal. High-resolution mass spectra (HRMS) were recorded using fast atom 
bombardment (FAB) techniques at the Mass Spectrometry Laboratory at the University of 
California, Riverside. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectra (MALDI-TOF MS) were recorded in the Biomolecule Analysis Facility at the 
California Institute of Technology. Ultraviolet-visible (UV) spectra were recorded on a 
Hewlett Packard 8452A diode array spectrophotometer. Reactions were executed under an 
atmosphere of argon. 1-Methylimidazole-2-carboxylic acid was prepared as described. 1a 
Reagent grade chemicals were used as received unless noted otherwise. Tetrahydrofuran 
(THF), dichloromethane, and dimethylformarnide (DMF) were purchased from Fluka over 
molecular sieves. Dicyclohexylcarbodiimide (DCC) and N-hydroxybenzotriazole (HOBt) 
were purchased from Peptides International. 4-N-t-Butoxy-aminobutyric acid was 
purchased from Novachem. Trifluoroacetic acid (TFA) was purchased from Applied 
Biosystems or Halocarbon. Thiophenol, thionyl chloride, 10% palladium on carbon 
(Pd/C), and triethylamine were obtained from Aldrich. Oxalyl chloride was purchased 
from Fluka. Flash column chromatography was carried out using EM Science Kieselgel 60 
(230-400 mesh). Thin-layer chromatography was performed on EM Reagents silica gel 
plates (0.5 mm thickness). All compounds were visualized at 254 nm. Preparative reverse 
phase high-performance liquid chromatography (RP-HPLC) was performed on a Beckman 
HPLC system using a Waters Delta-Pak Prep-Pak C18 column (25 mm x 10 em, 15 ).!., 100 
A) equipped with a Delta-Pak Guard-Pak column. Compounds were eluted with a gradient 
of 0-60% CH3CN/0.1 % TFA over 120 min with a flow rate of 8-10 mL/min and detected 
using a Beckman 167 dual wavelength detector at 254 and 340 nm. Fractions were 
collected and analyzed by analytical reverse phase HPLC on a Beckman Gold HPLC 
system using a Rainin Microsorb-MV C 18 column (4.6 mm x 30 em, 5 ).!. , 100 A). 
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Compounds were eluted with a gradient of 0-60% CH3CN/0.1% TFA over 60 min with a 
flow rate of 1 mL/min and detected using a dual wavelength detector at 254 and 340 nm. 
The desired fractions were pooled and lyophilized. 
Dimer 4. To a slurry of 4-nitro-1-methylimidazole-2-carboxylic acid (4.73 g, 
27.3 mmol) in THF (20 mL) cooled to 0 °C was added oxalyl chloride (20 mL, 0.229 mol) 
and the resulting solution was heated at reflux for 2 h. The solution was cooled and 
concentrated under high vacuum. The resulting white solid was dissolved in DMF (10 mL) 
and cooled to 0 °C. Separately, a solution of methyl 4-nitro-1-methylpyrrole-2-carboxylate 
(3) (2.0 g, 1.97 mmol) in DMF (15 mL) and 10% Pd/C (670 mg) was hydrogenated in a 
Parr bomb appartus (350 psi H2) for 6 h at 22 oc. The solution was filtered through celite, 
triethylamine (12 mL, 86 mmol) was added, and the solution was added dropwise to acid 
chloride at 0 oc. The ice bath was removed and the solution allowed to stir 24 h at 22 oc. 
DMF was removed under high vacuum and the remaining solid was dissoved in CH2Cl2 
(250 mL), washed with H20 (2 x 100 mL), dried (Na2S04) , and concentrated under 
reduced pressure to afford 4 (2.0 g, 6.5 mmol, 60%) as a yellow solid that was used 
without further purification. 'H NMR (300 MHz, CDC13) o 9.02 (s, 1 H), 7 .8 (s, 1 H) , 
7.4 (d, 1 H, J = 3.2 Hz), 6.8 (d, I H, J = 3.2 Hz), 4 .3 (s, 3 H), 3.9 (s, 3 H), 3.8 (s, 3 
H). EI MS m/e (relative intensity) 307.0912 (1.0, M+, 307.2680 calcd. for C 12H 13N50 5) . 
Trimer 5. To a flask equipped with a reflux condenser were added 4-nitro-N-
methylpyrrole-2-carboxylic acid (4.4 g, 26 mmol) and thionyl chloride (30 mL, 0.411 mol) 
and the resulting slurry was heated at reflux for 4 h. Excess SOC12 was removed under 
high vacuum and the resulting solid was dissolved in DMF (I 0 mL) and cooled to 0 °C. 
Separately, a solution 3 (2.0 g, 6.5 mmol) in DMF (80 mL) and 10% Pd/C (670 mg) was 
hydrogenated in a Parr bomb appartus (350 psi H2) for 6 h at 22 °C. The solution was 
filtered through celite, triethylamine (12 mL, 86 mmol) was added, and the solution was 
added dropwise to the acid chloride at 0 oc. The ice bath was removed and the solution 
allowed to stir at 24 h at 22 oc for. The solution was filtered through celite and methanol 
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( 10 rnL) was added. Solvents were removed under high vacuum and the remaining solid 
was dissoved in 1:1 CH2Cl2:CH30H (100 mL) and cooled to ·20 octo precipitate a white 
solid which was collected by vacuum filtration and washed with cold CH2Cl2 to afford N-
acyl irnidazolium derivative 13 (Figure 3 .12) (1 .6 g, 3.73 mmol, 57%). 1H NMR (300 
MHz, DMSO-d6) o 10.7 (s, 1 H), 10.2 (s, 1 H), 8.20 (dd, 2 H, J = 2.5 Hz), 7.20 (d, 1 H, 
J = 2.4 Hz), 7.62 (s, 1 H), 7.53 (d, 1 H , J = 5 .1 Hz), 7.25 (d, 1 H, J = 2.3 Hz) 6.98 (d, 
1 H, J = 5.0 Hz), 3.94 (s, 3 H), 3 .92 (s, 3 H), 3.82 (s, 3 H), 3.75 (s, 3 H), 3.70 (s, 3H) . 
This material was slurried in 1:1 CH30H:H20 (100 mL) containing 3 drops 50% NaOH 
and stirred vigorously for 20 min. Extraction with CH2Cl2 ( 4 x 100 mL) afforded trimer 5 
( 1.1 g, 2.56 mmol, 39%) as a light yellow solid that was used without further purification. 
1H NMR (300 MHz, DMSO-d6) o 10.7 (s, 1 H), 10.2 (s, 1 H), 8.20 (d, 1 H, J = 2.5 Hz) , 
7.20 (d, 1 H , J = 2.4 Hz), 7.62 (s, 1 H), 7.53 (d, 1 H, J = 5.1 Hz), 6.98 (d, 1 H, J = 5.0 
Hz), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.75 (s, 3 H), 3.70 (s, 3H). EI MS m/e (relative 
intensity) 429.1377 (1.0, M, 429.3954 calcd. for C 18H 19N70 6). 
13 
Figure 3.12. Putative structure of N-acyl imidazolium derivative 13. 
Ester 6. To a solution of 1-methylirnidazole-2-carboxylic acid (177 mg, 1.4 
mmol) and HOBt (190 mg, 1.41 mmol) in DMF (5 mL) was added DCC (288 mg, 1.40 
mmol) and the resulting solution stirred 4.5 h at 22 °C. Separately, a solution of 5 (220 
mg, 0.51 mmol) and 10% Pd/C (75 mg) in DMF (8 mL) was hydrogenated in a Parr bomb 
appartus (350 psi H 2) for 5 h at 22 oc. The solution was filtered through celite, 
triethylamine (2.5 mL, 18 mmol) was added, and the solution was added dropwise to the 
HOBt ester. The solution was allowed to stir 24 hat 22 oc and then quenched with H 20 (5 
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mL). The solution was concentrated to dryness under high vacuum. The resulting solid 
was purified by flash chromatography (2% CH30H/CH2Cl2) to afford ester 6 (50 mg, 
0.098 mmol, 19%). 1H NMR (300 MHz, CDC13) o 9.39 (s, 1 H), 8 .83 (s, 1 H), 8.04 (s, 
1 H), 7.47 (s, 1 H) , 7.41 (d, 1 H, J = 5.2 Hz), 7.32 (d, 1 H , J = 5.2 Hz), 7.08 (d, 1 H, J 
= 3.1 Hz), 7.05 (d, 1 H, J = 3.1 Hz), 6.84 (d, 1 H, J = 6.5 Hz), 6.82 (d, 1 H, J = 6.5 
Hz), 4.13 (s, 3 H), 4.06 (s, 3 H), 3.97 (s, 3 H), 3.92 (s, 3 H), 3.82 (s, 3 H). FABMS 
m/e 508.3327 (508.5210, M + H, calcd. for C23H 26N90 5). 
Acid 7. To a solution of ester 6 (50 mg, 0.098 mmol) in ethanol (3 mL) was 
added 1.0 M LiOH (3 mL) and the solution was heated at reflux for 2 h. The solution was 
cooled to room temperature and acidified to pH 3 with 1 M NaHS04 . A solid precipitated 
that was isolated by centrifugation. The solid was washed with H20 (2 x 15 mL), 
resuspended in H20 (5 mL), and dried in vacuo to afford 7 (32 mg, 0.065 mmol, 66%) as 
a tan solid. 1H NMR (300 MHz, DMSO-d6) o 10.4 (s, 1 H ), 10.3 (s, 1 H), 7.53 (s, 1 H ) , 
7.38 (m, 3 H) , 7.14 (d, 1 H, J = 4.2 Hz), 7.03 (d, 1 H, J = 3.1 Hz), 6.83 (d, 1 H , J = 
2.2 Hz). FABMS m/e 494.5019 (494.4940, M + H, calcd. for C22H 24N90 5). 
4-( 4-N -t-bu toxy-aminobutyramido )-1-methy limidazole-2-carboxylic 
acid (12). To a solution of 4-N-t-butoxy-aminobutyric acid (4.54 g, 20.8 mmol) and 
HOBt (2.9 g, 20.5 mrnol) in 2:1 CH2Cl2:DMF (30 mL) cooled to 0 oc was added DCC 
(4.23 g, 20.5 mmol) in DMF (10 mL). The solution was stirred 15 min at 0 oc and then 
allowed to warm to room temperature and stirred an additional 3 h. The solution was 
filtered, concentrated under reduced pressure to remove CH2Cl2 , and cooled to 0 oc_ 
Separately, a solution ethyl4-nitro-1-methylimidazole-2-carboxylate (2.0 g, 10.0 mrnol) in 
DMF (15 mL) and 10% Pd/C (670 mg) was hydrogenated in a Parr bomb appartus (300 
psi H
2
) for 5 hat 22 °C. The solution was filtered through celite, triethylamine (12 mL, 86 
mrnol) was added, and the solution was added drop wise to the HOBt ester. After 10 min 
the solution was allowed to warm to room temperature and stirred an additional 24 h. 
Water (5 mL) was added and the solution was concentrated to dryness under high vacuum. 
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The resulting solid was purified by flash chromatography (10% CH30H/CH2Cl2) to afford 
ethyl-4-( 4-N-t-butoxy-aminobutyramido )-1-methylirnidazole-2-carboxylate (2.25 g, 64%) 
as a light yellow solid. 1H NMR (300 MHz, CDC13) 8 8.43 (s, 1 H), 7.50 (s, 1 H), 4.68 
(br, s, 1 H), 4.35 (q, 2 H, J = 12Hz), 3.99 (s, 3 H), 3.29 (m, 2 H), 2.38 (t, 2 H , J = 10 
Hz), 1.77 (quintet , 2 H, J = 10Hz), 1.42 (s, 9 H) 1.41 (t, 3 H, J = 12Hz). EI MS mle 
(relative intensity) 355.1967 (0.24, M + H, 355.4170 calcd. for C 16H27N40 5). To a slurry 
of ethyl-4-( 4-N-t-butoxy-arninobutyramido )-1 -methylimidazole-2-carboxylate (2.0 g, 5 . 6 
mrnol) in ethanol (30 mL) was added 1 M LiOH (30 mL) and the resulting solution was 
heated at reflux for 3 h. The solution was cooled to room temperature and concentrated 
under reduced pressure to remove EtOH. The solution was cooled to 0 oc and acidifed to 
pH 3 with 15% citric acid. The solution was filtered and the white solid was washed with 
cold H20 and dried in vacuo to afford 4-(4-N-t-butoxy-aminobutyrarnido)-1-
methylirnidazole-2-carboxylic acid (12) (1.6 g, 4.9 mrnol, 88%). 1H NMR (300 MHz, 
DMSO-d6) 8 10.52 (s, I H), 7.48 (s, 1 H) 6.75 (br, s, 1 H), 3.85 (s, 3 H), 2.85 (m, 2 H), 
2.22 (m, 2 H), 1.65 (m, 2 H), 1.35 (s, 9 H). FABMS mle 327.1653 (M + H, 327.3630 
calcd. for C14H 23N40 5) . 
Ester 8. To a solution of 4-( 4-N-t-butoxy-arninobutyramido )-1-methylirnidazole-
2-carboxylic acid (12) (304 mg, 0.93 mrnol) and HOBt (200 mg, 1.48 mrnol) in DMF (7 
mL) was added DCC (290 mg, 1.41 mmol) and the resulting solution stirred 4 h at 22 °C. 
Separartely, a solution of 5 (400 mg, 0.93 mrnol) in DMF (15 mL) and 10% Pd/C (145 
mg) was hydrogenated in a Parr bomb apparatus (400 psi H2) for 4.5 h at 22 oc. The 
solution was filtered through celite, triethylamine (4.5 mL, 32 mrnol) was added, and the 
solution was added dropwise to the HOBt ester. The solution was allowed to stir 24 h at 
22 °C and then quenched with H20 (5 mL). The solution was concentrated to dryness 
under high vacuum and the residue was dissolved in CH2Cl2 (300 mL). After filtering 
through celite the solution was washed with H20 (50 mL), 5% NaHS04 (50 mL), 2% 
NaHC03 (50 mL), and H20 (50 mL). The solution was dried (N~S04) and concentrated 
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under reduced pressure. Flash column chromatography (0-4% CH30H/ CH2Cl2) afforded 
ester 8 (361 mg, 0.51 mmol, 55%) as an orange solid. 1H NMR (300 MHz, CDC13) 8 
9.05 (br, s, 1 H), 8.98 (s, 1 H), 8.80 (s, 1 H), 8.30 (s, 1H), 7.46 (s, 1 H), 7.43 (d, 2 H), 
7.42 (d, 1H), 7.29 (d, 1 H, J = 3.5 Hz), 6.87 (br, s, 1 H), 6.81 (br, s, 1 H) 4 .05 (s, 3 
H), 4.02 (s, 3 H), 3.93 (s, 3 H), 3.89 (s, 3 H), 3.81 (s, 3 H), 3.20 (m, 2 H), 2.42 (m, 2 
H), 1.85 (m, 2 H), 1.48 (s, 9 H). FABMS m/e (relative intensity) 708.3229 (0.23, M + 
H, 707.7522 calcd. for C32H48Nu0 8). 
Acid 9. To a slurry of ester 8 (361 mg, 0.51 mmol ) in ethanol (15 mL) was 
added 1 M LiOH (15 mL) and the resulting solution was heated at reflux for 2.5 h. The 
solution was cooled to room temperature and concentrated under reduced pressure to 
remove EtOH. The solution was cooled to 0 °C, acidifed to pH 3 with 1 M NaHS04 , and 
extracted with ethyl acetate (4 x 25 mL). The combined organics were dried (N~S04) and 
concentrated under reduced pressue to afford 9 (260 mg, 0.37 mmol, 73%). 1H NMR 
(300 MHz, CD30D) 8 7.43 (s, 1 H), 7.39 (s, 1 H), 7.36 (d, 1 H, J = 5.5 Hz), 7.25 (d, 1 
H , J = 5.0 Hz), 7.02 (d, 1 H, J = 5.5 Hz), 6.78 (d, 1 H, J = 5.0 Hz), 4.06 (s, 3 H), 4.03 
(s, 3 H), 3.94 (s, 3 H), 3.91 (s 3 H), 3.15 (t, 3 H, J = 8.2 Hz), 2.35 (m, 2 H) , 1.85 (t, 2 
H, J= 8.2 Hz), 1.46 (s, 9 H). FABMS m/e 608.6317 (M + H, 608.6188 calcd. for 
C 27H 33Nio0 7). 
Boc-Protected Amine 10. To a solution of 9 (130 mg, 0.21 mmol) in DMF (1 
mL) was added 1, 1 ' -carbonyldiimidazole (320 mg, 1.97 mmol) and the solution was 
stirred 4 hat 22 °C. 3-Dimethylaminopropylamine (650 mg, 6.4 mmol) was added and the 
solution was stirred 30 min at 22 oc. The solution was diluted to 10 mL with H 20 and 
acidified to pH 4 with 1 N HCI. The solution was purified by preparative reverse phase 
HPLC to afford 10 (50 mg, 0 .062 mmol, 30%) as the trifluoroacetate salt. 1H NMR (300 
MHz, CD30D) 8 7.39 (s, 1 H), 7.37 (s, 1 H), 7.29 (br, s, 1 H), 7.23 (br, s, 1 H), 6.94 
(d, 1 H, J = 3.2 Hz) 6.82 (d, 1 H, J = 3.2 Hz), 4.02 (s, 3 H), 3.99 (s, 3 H), 3.87 (s, 3 
H), 3.84 (s, 3 H), 3.42 (t, 2 H, J = 7.5 Hz), 3.19 (t, 2 H, J = 7.4 Hz), 3.12 (t, 2 H , J = 
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7.5 Hz), 2.35 (t, 2 H, J = 7 .2 Hz), 1.98 (t, 2 H, J = 7.5 Hz), 1.81 (t, 2 H, J = 7.5 Hz), 
1.46 (s, 9H). FABMS mle 692.7785 (M + H, 692.7844 calcd. for C32H44N 120 6). 
Amine 11. Bee-protected amine 10 (50 mg, 0.062 mmol) was treated with TFA 
containing 0.5 M thiophenol (5 mL) for 30 min at 22 oc. Excess TFA was removed under 
high vacuum to afford amine 11 (26 mg, 0.037 mmol) that was used immediately without 
further purification. 1H NMR (CD30D) S 7.43 (s, 1 H), 7.41 (s, 1 H), 7.31 (d, 1 H, J = 
3.6 Hz) , 7.24 (d, 1 H, J = 3.7 Hz), 7 .08 (d, 1 H, J = 4.6 Hz), 6.95 (d, 1 H, J = 4 .6 Hz) , 
4 .08 (s, 3 H), 4 .08 (s, 3 H), 3.95 (s, 3 H), 3.93 (s, 3 H), 3.42 (t, 2 H, J = 7 .7 Hz), 3.18 
(t, 2 H, J = 7.7. Hz), 3.03 (t, 2 H, J = 7.5 Hz), 2.57 (t, 2 H, J = 7.5 Hz), 2.97 (s, 6 H) , 
2.0 (m, 4 H). 
Im-Py-Im-Py-y-Im-Py-lm-Py-Dp (2) (p. 70). To a solution of acid 7 (21 
mg, 23.5 11mol) and HOBt (13 mg, 96 11mol) in DMF (80 11L) was added DCC (10.6 mg, 
51 11mol) and the solution vigorously stirred 6 h at 22 °C. A solution of amine 11 (26 mg, 
37 11mol) in DMF (70 IlL) was added to the HOBt ester followed by triethylamine (7 11L, 50 
f..LIDOl) . The solution was stirred for 24 h at 22 oc and then diluted to 2 mL with H20 and 
concentrated under high vacuum. The residue was dissolved in 10 mL 0.1% TFAIH20, 
filtered (0.45 !l), and purified by preparative reverse phase HPLC to afford 2 as the 
trifluoroacetate salt. The solid was dissolved in 2 mL 0.1 N HCl and concentrated under 
high vacuum, dissolved in H 20 ( 1 mL) and concentrated under high vacuum to afford 2 
(1.25 mg) as the hydrochloride salt. 1H NMR (CD30D) o 7.38 (s, 1 H), 7.35 (s, 1 H ) , 
7.28 (d, 1 H, J = 1.8 Hz), 7.25 (d, 1 H, J = 1.9 Hz), 7.22 (br s, 2 H), 7.21 (s, 1 H) , 
7.16 (d, 1 H, J = 1.9 Hz), 7 .07 (d, 1 H, J = 1.7 Hz), 6.93 (d, 1 H, J = 1.9 Hz), 6.89 (d, 
1 H, J = 1.8 Hz), 6 .87 (d, 1 H, J = 1.9 Hz), 6.63 (d, 1 H, J = 1.8 Hz), 4.05 (s, 3 H ) , 
4.04 (br s, 6 H), 3.99 (s, 3 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 (s, 3 H), 3,87 (s, 3 H), 
3.40 (t, 2 H, J = 7.0 Hz), 3.18 (m, 4 H), 2.93 (s, 6 H), 2.42 (t, 3 H, J = 6.5 Hz), 2.05 




38,000 M·1cm·1; MALDI-TOF MS mle: 1154.2 (M + H, 1154.3 
calcd. for C53H65N220 9) . 
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DNA Reagents and Materials. RNase free water was obtained from U .S. 
Biochemicals and used in all manipulations. Plasmid pBR322 was obtained from 
Boehringer-Mannheim. Eco RI, Bam HI, the Klenow fragment of DNA polymerase I, calf 
alkaline phosphatase, and T4 polynucleotide kinase were purchased from Boehringer-
Mannheim and used according to the supplier's recommended protocol in the buffers 
provided. Nucleotide triphosphates were Pharmacia Ultra-Pure grade and were used as 
supplied. Nucleotide triphosphates labeled with 32P (> 3000 Ci/mmol) were obtained from 
Amersham. NICK columns were purchased from Pharmacia and used according to the 
suggested protocol. Glycogen was obtained from Boehringer-Mannheim as a 20 mg/mL 
aqueous solution. Cerenkov radioactivity was measured with a Beckman LS 2801 
scintillation counter. DNase I was purchased from Boehringer-Mannheim. Sonicated, 
deproteinized calf thymus DNA was purchased from Pharmacia and dissolved in H20 to a 
final concentration of 2 mM in base pairs and stored at -20 oc. Chemical sequencing 
reactions were performed according to published procedures. General manipulations of 
DNA were performed according to established procedures. 
Labeled Restriction Fragment Preparations. The Eco RJJBam HI fragment 
of pBR322 3' -32P-end labeled at the EcoRI site was prepared by digesting the plasmid (5-
1 0 1-1g) with Eco RI, followed by treatment with a.-32P-dATP and a.-32P-TIP in the 
presence of the Klenow fragment of DNA polymerase I. Following the addition of 
unlabeled dATP and TTP unincorporated nucleotides were removed using a NICK column. 
The linearized, 32P-labeled plasmid was then digested with Bam HI, followed by separation 
of the resulting DNA fragments on a nondenaturing 5% polyacrylamide gel (1 : 19 
crosslinked) . The desired 381-bp fragment was located by autoradiography and excised. 
The gel slice was crushed and soaked in 25 mM Tris·HCl pH 7 .0, 25 mM NaCl, 2 mM 
EDTA for 8-12 hat 37 oc. The resulting suspension was then filtered through an Isolab 
Quik-Sep polypropylene filter and the filtrate was ethanol precipitated using glycogen (1 
!1-L). The DNA pellet was washed with 70% EtOH, dried in vacuo, and resuspended in 10 
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mM Tris·HCl pH 7.0, 0.5 mM EDTA. The solution was then extracted with phenol (3 x 
100 JlL), 24:1 phenol:CHC13 (3 x 100 JlL), and 24:1 CHC13:isoamyl alcohol (2 x 100 JlL). 
The solution was then passed through a NICK column equilibrated with 10 mM Tris·HCl 
pH 7.0, 0 .5 mM EDTA buffer and the eluate stored at ·20 oc after measuring Cerenkov 
radioactivity. Typical yields of Cerenkov radioactivity were 5-l 0 x 106 cpm. The same 
restriction fragment 3' -32P-end labeled at the Bam HI site was prepared as described above 
except that the plasmid was first digested with Bam HI, a-32P-dATP, a - 32P-TTP, a -32P-
dCTP and a -32P-dGTP were used in the labeling reaction, and Eco RI was used in the 
second digestion. The restriction fragment 5' -32P-end labeled at the Eco RI site was 
prepared by digesting pBR322 (1 0 Jlg) with Eco RI followed by treatment with calf alkaline 
phosphatase. The linearized plasmid was then labeled by treatment with y-32P-ATP in the 
presence of polynucleotide kinase. Following the addition of unlabeled ATP 
unincorporated nucleotides were removed using a NICK column. The DNA was then 
digested with Bam HI and isolated as described above. Typical yields of radioactivity were 
2-5 x 106 cpm. The restriction fragment 5'-32P-end labeled at the Bam HI site was 
prepared in the same manner except that Bam HI and Eco RI were used in the first and 
second digestions, respectively. 
MPE•Fe(II) Footprinting Experiments. For each experiment a cocktail 
containing Tris·AcOH pH 7.0, NaCl, calf thymus DNA, and 32P-end labeled DNA 
restriction fragment was prepared. To separate 1.7 mL microfuge tubes were added 28 ~ 
of cocktail. A 50 11M stock solution of Im-Py-Im-Py-y-Im-Py-Im-Py-Dp was prepared by 
dissolving 2 nmol in 40 f.lL H20 and diluted serially to 20 JlM. A 4 f.lL aliquot of each lOx 
ligand solution was added to the appropriate tubes and the solutions were allowed to 
equilibrate for 12-24 hat 22 °C. A 50 11M solution of MPE·Fe(II) was prepared by mixing 
100 ~of a 100 J1M MPE solution with a freshly prepared 100 J1M ferrous ammonium 
sulfate solution and allowing to equilibrate for 15 min at 22 oc. A 4 JlL aliquot of 50 J1M 
MPE·Fe(II) was added to the appropriate tubes and incubated 15 min at 22 °C. Cleavage 
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was initiated by the addition of 4 ~ of freshly prepared 50 mM DTI solution. Final 
concentrations were 25 mM Tris·AcOH pH 7.0, 10 mM NaCl, 100 1-LM-bp calf thymus 
DNA, 5 f.!M MPE·Fe(ll), and 5 mM DTT in a total volume of 40 ~containing 1-3 x 105 
cpm of 32P-labeled restriction fragment. Cleavage was allowed to proceed for 20 min and 
then stopped by ethanol precipitation using 5 ~ of glycogen. The precipitated DNA was 
washed with 70% EtOH, dried in vacuo, resuspended in 1x TBE-formamide loading 
buffer, and electrophoresed on 8% denaturing polyacrylamide gels (5% cross-link, 7 M 
urea) at 2000 V for 1-2 h. The gels were transferred to filter paper, dried, and quantitated 
using storage phosphor technology as described below. 
Quantitative DNase I Footprint Titration Experiments. For each 
experiment a cocktail containing Tris·HCl, pH 7.0, KCl, MgC12, CaC12, and 3' -
32P-end 
labeled restriction fragment was prepared. To separate 1.7 mL microfuge tubes was added 
a 32 ~ aliquot of the cocktail solution. A 100 f.!M solution of Im-Py-Im-Py-Dp was 
prepared by dissolving a 10 nmol aliquot in 100 ~of H20. A 5 1-lM solution of Im-Py-
Im-Py-y-Im-Py-Im-Py-Dp was prepared by dissolving a 2 nmol aliquot in 400 ~of H20 . 
These solutions were then serially diluted to the appropriate concentrations. To the 
appropriate tubes were added 4 f.!L of 1 Ox ligand solution and the solutions were allowed to 
equilibrate for 8-24 h. Final ligand concentrations were 0.2 nM to 10 1-lM for Im-Py-lm-
Py-Dp and 10 pM to 0.5 1-LM for Im-Py-Im-Py-y-Im-Py-Im-Py-Dp. Cleavage was initiated 
by the addition 4 f.!L of a solution of DNase I (0.04 units/mL) containing 1 mM DTT. Final 
concentrations were 10 mM Tris·HCl pH 7.0, 10 mM KCl, 5 mM MgC12, and 5 mM 
CaC12 in a total volume of 40 ~ containing 1-2 x 10
5 cpm of 32P-end labeled restriction 
fragment. Cleavage was allowed to proceed for 6 min at 22 °C and then stopped by the 
addition of 12.8 ~of a 3 M NaOAc/50 mM EDT A/glycogen solution (1.2/111) followed 
by ethanol precipitation. The DNA pellets were washed with 70% EtOH, dried in vacuo, 
resuspended in formamide-TBE loading buffer, and electrophoresed on 8% denaturing 
polyacrylamide gels (5% cross-linked, 7 M urea) at 2000 V for 1 h . The gels were 
137 
transferred to filter paper, dried, and quantitated using storage phosphor technology as 
described below. 
Apparent first-order binding constants were determined as previously described. 9 
The data were analyzed by performing volume integrations of the target sites and 5'-
GACA-3' and 5'-ACCA-3' reference sites for experiments with the restriction fragment 
labeled at the Eco RI and Bam HI sites, respectively. The apparent DNA target site 
saturation, e•PP' was calculated for each concentration of peptide using the following 
equation: 






where Itat and ~er are the integrated volumes of the target and reference sites, respectively, 
and Ita•o and I.ero correspond to those values from a DNase I control lane to which no 
polyamide had been added. At concentrations higher than 10 ~ Im-Py-Im-Py-Dp and 0.5 
~ Im-Py-Im-Py-y-Im-Py-Im-Py-Dp the reference sites become partially protected, 
resulting in low eapp values. For this reason, peptide concentrations of than 10 !1M Im-Py-
Im-Py-Dp and 0.5 ~ Im-Py-Im-Py-y-Im-Py-Im-Py-Dp were not used. The ([L]tw e.PP) 
data points were fit to Langmuir binding isotherms by minimizing the difference between 
e app and etit using the modified Hill equation: 
8fir = 8m,·n +(()max - 8m,·n) Ka n [Lr tot 
1 + Ka n [L]" '"' (2) 
where [L]
10
t corresponds to the total polyamide concentration, K. corresponds to the 
apparent monomeric association constant, n represents the Hill coefficient, and emax and emin 
represent the experimentally determined site saturation values when the site is unoccupied 
or saturated, respectively. Data were fit using a non-linear least-squares fitting procedure 
of Kaleidagraph software (version 3 .0.1; Abel beck Software) running on a Power 
Macintosh 6100/60 computer with K., emax ' and emin as the adjustable parameters. The 
goodness of fit is evaluated by the correlation coefficient, with R > 0.98 as the criterion for 
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an acceptable fit. All lanes from each gel were used unless visual inspection revealed a data 
point to be obviously flawed relative to neighboring points. The data were normalized 
using the following equation: 
8norrn = 8app - 8nun 
8max - 8min 
(3) 
Quantitation by Storage Phosphor Autoradiography. Photostimulable 
storage phosphor imaging plates (Kodak Storage Phosphor Screen S0230 obtained from 
Molecular Dynamics) were pressed flat against dried gels and exposed in the dark for 8-24 
h at 22 oc. A Molecular Dynamics 400S Phosphor Imager was used to obtain all data from 
the storage screens. The data were analyzed by performing volume integrations of all 
bands using ImageQuant v. 3.3 software running on a Gateway 2000 486/66 computer. 
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Studies Towards the Sequence Specific Hydrolysis 
of HIV-1 TAR RNA 
Introduction 
Challenge of Sequence-Specific RNA Hydrolysis. The design and synthesis of 
reagents capable of sequence-specific DNA or RNA hydrolysis is one of the most 
challenging problems in bioorganic chemistry. The phosphodiester backbone of the 
nucleic acids is extremely well-suited for its biological function.1 Phosphodiesters are 
negatively charged and are therefore extremely resistant to nucleophilic attack in aqueous 
solution. The half life of DNA and RNA at pH 7 .0, 37 oc in the absence of any catalysts 
has been estimated to be 200 million years and 2000 years, respectively.2 The uncatalyzed 
rate of RNA hydrolysis is faster than DNA hydrolysis due to the presence of the 2'-
hydroxyl group in RNA which can serve as an intramolecular nucleophile to cause strand 
scission via transesterification. In addition to the fact that phosphodiester hydrolysis is an 
inherently slow reaction, another challenge in the design of synthetic reagents capable of 
sequence-specific hydrolysis of DNA and RNA is the fact that the catalysts must be 
delivered to the target phosphodiester with the proper geometry for hydrolysis to occur. 
This requirement severely tests our ability to design molecules capable of simultaneous 
recognition and hydrolysis of RNA. Despite the fact that there are several naturally 
occurring protein and RNA catalysts for site-specific phosphoryl transfer in RNA 
molecules, there are few examples of designed artificial catalysts that perform these 
functions. 3 
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1 10 20 
Met G1u Pro Va1 Asp Pro Arg Leu G1u Pro Trp Lys His Pro Gly Ser Gln Pro Lys Thr 
21 30 40 
A1a Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln Va1 Cys Phe I1e Thr 
41 47 so 57 60 
Lys A1a Leu G1y Ue Ser Tyr Glyl #_~,;;,f.¥-:i(~ ~:'~~.:~'-GJ._il 11%-~:-.A.rg)~rgl Pro Pro Gln 
61 70 72 80 
Gly Ser Gln Thr His G1n Va1 Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp 
81 86 
Pro Thr Gly Pro Lys Glu 
Figure 4.1. Sequence of the HIV -1 Tat protein. The basic RNA binding domian IS 
highlighted. 
The IDV-1 Tat-TAR Complex. The HIV-1 Tat protein is 86 residues in length 
and functions as an activator of HIV -1 gene expression by binding to the trans-activation 
response element (TAR) RNA sequence located at the 5 ' -end of all viral mRNAs (Figure 
4.1 ).4 TAR is a stable 58-nucleotide hairpin structure containing a trinucleotide bulge 
(Figure 4.2). 5 A Tat protein fragment spanning residues 49-72 containing an arginine and 
lysine-rich basic subdomain has been shown to bind TAR with sub-micromolar affinity.6 
Chemical modificaton interference experiments suggest that Tat( 49-72) binds TAR in the 
major groove proximal to the pyrimidine bulge and interacts with several bases and 
phosphates flanking the bulge. 6 The electrostatic contribution to Tat( 49-72) recognition of 
TAR is highlighted by recent two-dimensional NMR experiments which suggest that TAR 
contains a specific binding site for the guanadinium moiety of an arginine residue.7-8 These 
experiments suggest that L-argininamide and presumably Tat peptides bind on the 5 ' side 
of the bulge and make specific contacts with G23 and two adjacent phosphates in the major 
groove and perturb the structure of TAR upon binding. In the absence of ligand the 
pyrimidine bases in the bulge are partially stacked between the two adjacent helical stem s 
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Figure 4.2. Predicted secondary structure of the HIV -1 TAR RNA sequence. 
with A27·U38 in the major groove. Loret and coworkers have proposed a model for the 
structure of the Tat(47-72)-TAR complex based on difference circular dichroism 
experiments with Tat(47-72) and molecular dynamics calculations.9 In this model residues 
47-58 of Tat bind in the major groove of TAR in an extended conformation with the N-
terminus of the peptide positioned on the 5' -side of the bulge with the C-terminus oriented 
towards the hairpin loop and residues 59-67 forming an a-helix which makes additional 
contacts with the RNA. A recent NMR study of a Tat(47-57) peptide fused to a IS-residue 
activation domain from the Tat protein of equine infectious anemia virus suggests that the 
Tat(47-57) peptide forms a stable a-helix in solution in the absence of TAR RNA. 10 All of 
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these models are highly speculative and must await confirmation by high-resolution NMR 
or x-ray structural data from a Tat-TAR complex. 
RNA Hydrolysis by Lanthanides. Lanthanide ions have been known for over 
thirty years to hydrolyze RNA at neutral pH, 37 °C. 11 For folded RNA structures the rates 
of reaction can differ by several orders of magnitude (e.g. single-stranded > double-
stranded) and, in a formal sense, this kinetic specificity is one example of site-specific 
RNA cleavage.12 Recently, hexa-aza macrocyclic Schiff base complexes of lanthanide ions 
(Ln(L)3+ ) have been shown to be effective catalysts for RNA hydrolysis at neutral pH, 37 
oc and are remarkably stable to metal ion release (Figure 4.3). 13• 15 
Figure 4.3. Structure of the hexa-aza Schiff base lanthanide ion macrocycle, Ln(L)3+. 
Experimental Design. In order to test whether catalysts could be designed for 
site-specific cleavage ofT AR RNA, we have covalently attached a kinetically inert hexa-aza 
lanthanum complex La(L/+ to a Tat(49-72) peptide at three different cysteine residues via a 
disulfide bond to afford Tat(48-72, Cys48 -La(L)3+) 1, Tat(49-72, Cys54 -La(L)3+) 2, and 
Tat(49-72, Cys72 -La(L)3+ ) 3 (Figure 4.4). Although these three metallo-peptides cleave 
TAR site-specifically in the hexanucleotide loop to afford products consistent with 
hydrolysis, a series of control experiments suggests that the observed cleavage is not 
caused by a sequence-specifically bound Tat(49-72)-La(L)3+ peptide. 
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Figure 4.4. Structure of Tat-La(L)3+ peptides 1-3. 
Results 
Synthesis of Tat(49-72)-La(L)3+ Peptides. Lanthanum(ill)-directed 
condensation of dialdehyde 4, synthesized in eight steps from commercially available 
chelidamic acid (5), with excess 2,6-diformylpyridine and ethylenediamine afforded the 
mono-functionalized lanthanum macrocycle La(L)3+ 13 which was purified by ion 
exchange chromatography after removal of the trifluoroacetamide group (Figures 4.5, 
4.6).16-17 Acylation of the resulting amine 13 with N-succinimidyl-3-(2-
pyridyldithio)propionate (SPDP) afforded pyridyl disulfide 14 which was purified by 
reverse-phase HPLC. Treatment of Tat(48-72, Cys48 ), Tat(48-72, Cys54), and Tat(48-72, 
Cys72 ) peptides with pyridyl disulfide 14 afforded the synthetic metallo-peptides Tat(48-72, 


































Figure 4.5. Synthesis of dialdehyde 4 from commercially available chelidarnic acid (5). 
Reagents: (a) CH30H, H2S04 ; (b) dihydropyran, p-toluene sulfonic acid, CH2Cl2 ; (c) (i) 
NaBH4, EtOH; (ii) triisopropylsilyl triflate, NEt3, CH2Cl2; (d) oxalic acid, CH30H; (e) 
BrCH2C02Et, Ag2C03, DMF; (f) ethylenediamine; (g) (i) tetrabutylammonium fluoride, 
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Figure 4.6. Synthesis of Tat-La(L)3+ peptides 1-3. Reagents: (a) (i) CH30H, AcOH; (ii) 
NH/H20; (iii) Sephadex SP-C25 resin, 100 mM to 500 mM NH40Ac, pH 4.75; (b) N-
succinimidyl 3-(2-pyridyldithio)propionate (SPDP), 100 mM NEt30Ac, pH 7.5; (c) 20 
mM Tris·HCI pH 8.0. 
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respectively, which were purified by reverse-phase HPLC and characterized by amino acid 
analysis. 
Cleavage of TAR RNA by Tat-La(L)3+ Peptides. The 58 nucleotide TAR RNA 
sequence labeled at the 5 '-end with 32 P was allowed to react for 10 h with Tat( 48-72, Cys48 -
La(L)3+) 1 (0.5 J..LM) at 37 oc (70 mM NaCl, 10 mM Tris·HCl, pH 7.2). Separation of the 
RNA cleavage products by high resolution denaturing gel electrophoresis reveals that 
Tat( 48-72, Cys48 -La(L)'+) cleaves TAR in the loop with strongest cleavage at G32 and less 
efficient cleavage at U31, G33, G34, and A35 (Figures 4.7, 4.8). Minor cleavage is 
observed at C24 and U25 in the trinucleotide bulge and at G 16 adjacent to the predicted 
single base bulge at Al7. The same cleavage specificity was observed with Tat(49-72, 
Cys48 -La(L)3+ ) 2 and Tat(49-72, Cys72-La(L)3+) 3 although with slightly lower cleavage 
yield. After treatment of TAR with 1 for 10 h the overall cleavage yield was 8%. A plot of 
ln([RNAlnrac/[RNA],
0
,a1) is linear in target RNA concentration with an initial pseudo-first-
order rate constant of 5.5 x 10·3 h-1• This corresponds to a half-life of 96 h assuming that 1 
undergoes no decomposition at 37 °C, pH 7.2. Control experiments with La(L)3+ and 
La(N03) 3 at 0.5 J..LM concentration show no cleavage of TAR in the presence or absence of 
the unfunctionalized Tat(49-72) peptide (Figure 4.7, lanes 10-13). 
End-Product Analysis. The nature of the termini of the TAR cleavage products 
resulting from reaction with Tat(48-72, Cys48 -La(L)3+ ) were determined by comparing the 
electrophoretic mobility of the fragments with standards of known chemical composition. 
TAR 32P-labeled at the 3' -end was treated with Tat(48-72, Cys48 -La(L)3+) (0.5 J..LM). 
Analysis of the RNA cleavage products by 20% denaturing gel electrophoresis reveals that 
they have the same electrophoretic mobility as cleavage products generated by alkaline and 
RNase Tl digestions, both of which are known to afford 5'-hydroxyl termini (Figure 
4.9a). The cleavage products were treated with T4 polynucleotide kinase and ATP which 
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Figure 4.7. Cleavage of HIV-1 TAR RNA by Tat(48-72, Cys48 -La(L)3+). Autoradiogram 
of a denaturing polyacrylamide gel of cleavage products from the reaction of Tat(48-72, 
Cys48 -La(L)3+) with 32 P 5' -end-labeled HIV-1 TAR, pH 7.2, 37 °C. Lane 1, TAR 
incubated for 10 h. Lane 2, limited alkaline hydrolysis. Lane 3, products of an G-specific 
RNase T1 digestion. Lanes 4-9 contain Tat(48-72, Cys48 -La(L)3+) which was allowed to 
react for 0, 2, 4, 6, 8, and 10 h, respectively. Lanes 10 and 11 contain 0.5 rnM La(L)3+ 
which was allowed to react for 10 h in the absence and presence of unmodified Tat(49-72) 
peptide, respectively. Lanes 12 and 13 contain 0.5 mM La(N03) 3 which was allowed to 
react for 10 h in the absence and presence of unmodified Tat( 49-72) peptide, respectively. 
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Figure 4.8. Sequence and predicted secondary structure of HIV -1 TAR RNA showing the 
phosphodiesters cleaved by Tat(48-72, Cys48 -La(L)3+) after 10 h, 37 °C, pH 7.2. Arrow 
heights are proportional to cleavage intensities at the indicated phosphodiesters. 
results in phosphorylation of 5 ' -terminal hydroxyl groups.18 Treatment of the RNA 
cleavage products generated by Tat(48-72, Cys48 -La(L)3+) and RNase Tl with 
polynucleotide kinase in the presence of ATP produces TAR fragments with an identical 
increase in electrophoretic mobility demonstrating that the 5' -end-products of TAR 
cleavage by Tat(48-72, Cys48 -La(Li+) are hydroxyl groups. 
The identity of the 3 ' -end-product was determined by treating TAR 32 P-labeled at 
the 5 ' -end with Tat( 48-72, Cys48 -La(L)3+) (0.5 1-1M). Analysis of the cleavage products by 
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Figure 4.9. Analysis of the termini of the TAR cleavage products resulting from treatment 
with Tat(48-72, Cys48 -La(L)3+). (A) Autoradiogram of a denaturing polyacrylamide gel 
analyzing the 5 ' -end products of TAR cleavage by Tat(48-72, Cys48-La(L)3+). Lane 1, 
intact TAR. Lane 2, limited alkaline digestion. Lanes 3 and 4 contain RNase T1 digestions 
without and with treatment with kinase and ATP, respectively. Lanes 5 and 6 contain 
Tat(48-72, Cys48 -La(L)3+) cleavage reactions without and with treatment with kinase and 
ATP, respectively. (B) Autoradiogram of a denaturing polyacrylamide gel analyzing the 
3 ' -end products ofT AR cleavage by Tat( 48-72, Cys48 -La(Li+). Lane 1, intact TAR. Lane 
2, limited alkaline digestion. Lanes 3 and 4 contain RNase T1 digestions without and with 
kinase treatment, respectively. Lanes 5 and 6 contain Tat(48-72, Cys48 -La(L)3+) cleavage 
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20% denaturing gel electrophoresis reveals that they have the same electrophoretic mobility 
as cleavage products RNase Tl digestion which produces products cleavage products with 
phosphorylated 3'-ends (Fig. 4.9b). The cleavage products were treated with T4 
polynucleotide kinase which removes phosphate groups at the 3' -termini of RNA 
molecules.19 Kinase treatment of the RNA cleavage products generated by Tat(48-72, 
Cys48 -La(L)3+) and RNase Tl produces TAR fragments with an identical decrease in 
electrophoretic mobility indicating that cleavage with Tat( 48-72, Cys48 -La(L)3+) produces 
cleavage products with phosphates at the 3' -termini. Since polynucleotide kinase has been 
shown to hydrolyze both 2 '- and 3' -monophosphates as well as 2' ,3' -cyclic phosphates the 
3' -end-products of TAR cleavage by Tat(48-72, Cys48-La(L)3+) may be 2',3'-cyclic 
phosphates, 2' -monophosphates, or 3' -monophosphates.20-21 
The presence of 5' -hydroxy I and 3 ' -phosphate end-products indicates that the RNA 
cleavage pattern observed with Tat(48-72, Cys48 -La(L)3+) is not due to oxidative scission of 
the ribose backbone ofT AR. 23-24 These data are consistent with TAR cleavage by Tat( 48-
72, Cys48 -La(L)3+) occurring by transesterification involving attack of the 2' -hydroxyl 
group at the adjacent phosphodiester to afford 5 ' -hydroxyl products and 2 ' ,3' -cyclic 
phosphates.25 We estimate that Tat(48-72, Cys48-La(L)3+) accelerates the rate of 
transesterification by four orders of magnitude above the background rate of RNA 
tranesterification in the absence of catalysts.26 With regard to mechanism we cannot yet 
distinguish possible energetic contributions from the La(L)3+ moiety of Tat( 48-72, Cys48 -
La(L)3+) in the TAR cleavage reaction beyond a likely contribution from charge 
neutralization of the phosphodiesters. 
TAR Cleavage with La(N03) 3 and La(L)
3
+. At higher concentrations both 
La(L)3+ and La(N03\ cleave TAR. At 100 f.!M concentration (70 mM NaCl, 10 mM 
Tris·HCl, pH 7.2, 37 oq both catalysts preferentially cleave the bulged nucleotides with 
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most efficient cleavage observed at C24 in the center of the trinucleotide bulge (Figure 
4 .10). Both species also cleave the hairpin loop although with lower efficiency than the 
bulge. Some reactivity in the double-stranded regions of TAR was observed with 
La(N03) 3 although these structural elements are generally much less susceptible to cleavage 
than the single-stranded bulge and hairpin (Figure 4 .11 ). Differences between the two 





roughly a factor of five. Also, there is a difference in cleavage specificity in the hairpin 
loop with maximal cleavage observed at U31 and G32 with La(N03) 3 and La(L)
3+ , 
respectively. The differences in cleavage rates and specificity between the two catalysts is 
most likely due to complexation of the La3+ ion by the hexa-aza macrocyclic ligand. The 
coordinating nitrogen groups in the ligand may attenuate the Lewis acidity of the metal ion 
which would be expected to reduce the reaction rate relative to uncomplexed La3+. The 
slight difference in cleavage specificity between the two species may reflect a change in the 
coordination geometry around the La3+ ion in the complex making G32 more susceptible to 
cleavage than U31. 
TAR Cleavage with La(N03) 3 and La(L)3+ in the Presence of Tat(49-72) 
Peptides. In order to examine the effect of Tat peptides on the selectivity and efficiency of 
La3+ -catalyzed hydrolysis, 5' -end-labeled TAR was treated with 50 f..LM La(N0) 3 in the 
presence of increasing concentrations of Tat( 49-72). The specificity of La3+ -induced 
hydrolysis ofT AR changes in the presence of the peptide (Figure 4.12). The main site of 
cleavage shifts from C24 to U23 with weaker cleavage observed at C24 and eight 
additional phosphodiesters in the presence of Tat( 49-72). Since the rate of metal-catalyzed 
hydrolysis of a phosphodiester is dependent on its accessibility to the catalyst and inherent 
chemical reactivity, the enhancement in cleavage at U23 in the presence of Tat( 49-72) 
indicates that the RNA has adopted a conformation that makes this position more 
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Figure 4.10. Cleavage ofT AR by La(N03) 3 and La(L)3+. Autoradiogram of a denaturing 
polyacrylamide gel of cleavage products from the reaction of La(N01) 1 and La(L)3+ with 
32P 5'-end-labeled HIV-1 TAR, pH 7.2, 37 oc. Lane 1, TAR incubated for 80 min in the 
absence of lanthanides. Lane 2, limited alkaline hydrolysis. Lane 3, products of an G-
specific RNase T1 digestion. Lanes 4-7 contain 100 J..LM La(N03) 3 which was allowed to 
react for 20, 40, 60, and 80 min, respectively. Lanes 8-11 contain 100 J..LM La(L)3+ which 
was allowed to react for 20, 40, 60, and 80 min, respectively. 
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La(N03b + + + + - - - -
La( L)3+ - - - - + + + + 
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Figure 4.11. Sequence and predicted secondary structure of HIV-1 TAR RNA showing 
the phosphodiesters cleaved by La(N03) 3 after 1 h, 37 °C, pH 7 .2. Arrow heights are 
proportional to cleavage intensities at the indicated phosphodiesters. 
susceptible to hydrolytic cleavage in the Tat(49-72)-TAR complex. A similar change in 
cleavage specificity was also observed in experiments with La(L)3+. Similar footprinting of 
the Tat(48-72, Cys48-La(L)3+)-TAR complex with 100 j..LM La(N03) 3 and La(Ll+ also 
showed the shift in the primary cleavage site from C24 to U23 upon peptide binding 
indicating that the functionalized peptide is binding to TAR. 
Competition Experiments. Experiments in which 5' -32P end-labeled TAR was 
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Figure 4.12. Sequence and predicted secondary structure of HIV-1 TAR RNA showing 
the phosphodiesters cleaved by La(N03) 3 in the presence of 100 J.LM Tat(49-72) after 1 h, 
37 °C, pH 7.2. Arrow heights are proportional to cleavage intensities at the indicated 
phosphodiesters. 
of Tat(48-72, Cys48 -La(L)3+) (0.25 J.LM) did not reveal any inhibition of cleavage of the 
TAR loop phosphodiesters by the Tat-La(L)3+ peptide (Figure 4 .13). We expected that at 
high concentrations of Tat( 49-72) TAR would be saturated with unmodified peptide and 
therefore metallo-peptide 1 would not be able to bind and direct cleavage of the loop 
phosphodiesters. This result suggests that the cleavage of TAR by Tat( 48-72, Cys48 -
La(L)3+) is not a result of site-specific binding of the peptide to the Tat binding site 
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Figure 4.13. Cleavage of TAR by Tat(48-72, Cys48 -La(L)3+) (70 mM NaCl, 10 mM 
Tris•HCl, pH 7.2, 37 oc, 10 h) in (A) the absence and (B) the presence of unfunctionalized 
Tat( 49-72) at 100 J..LM concentration. Arrow heights are proportional to cleavage intensities 
at the indicated phosphodiesters. 
of bound 1. In order to test this idea further, a derivative of TAR RNA which is lacking 
the trinucleotide bulge (15) was prepared by chemical synthesis (Figure 4.14a). 
Experiments have shown that the binding affinity of Tat peptides for this RNA is reduced 
by a factor of 120 compared to the corresponding RNA possessing the 5 ' -UCU-3 ' bulged 



































Figure 4.14. Cleavage of a bulgeless derivitve of TAR RNA by Tat(48-72, Cys48 -La(L)3+) 
at pH 7.2, 37 oc_ (A) Predicted secondary structure of RNA 15. (B) Cleavage pattern 
observed with 0.5 11M Tat(48-72, Cys48 -La(L)3+) after 10 h. Arrow heights are 
proportional to cleavage intensities at the indicated phosphodiesters. 
!lM) (70 mM NaCI, 10 mM Tris·HCl, pH 7.2, 37 oq for 10 h resulted in cleavage of the 
loop with the same specificity and yield at the same concentration of Tat-La(L/+ as 
observed with full-length native TAR (Figure 4.14b). Preincubation of RNA 15 with up to 
200 11-M had no effect on the observed cleavage efficiency with Tat(48-72, Cys48-La(L)3+). 
Discussion 
TAR Cleavage by Tat-La(L)3+ Peptides. In spite of the fact that TAR cleavage 
with Tat-La(L)3+ peptides 1-3 occurs at the kinetically less reactive loop nucleotides to 
afford reaction products consistent with a transesterification/hydrolysis mechanism, we do 
not believe this observed cleavage is a result of a bound Tat-La(L)3+ peptide. The fact that 
peptides 1-3 show the same cleavage specificity and yield is surprising given that the 
La(L)3+ moiety is attached to the peptide at three quite different positions in the amino acid 
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sequence. Furthermore, the results of the cleavage inhibition experiments with TAR and 
bulgeless RNA 15 are inconsistent with models invoking RNA cleavage from a sequence-
specifically bound Tat-La(L)3+ peptide. 
The TAR cleavage experiments with La(N03) 3 and La(L)3+ in the presence and 
absence of Tat( 49-72) peptides rule out metallo-peptide decomposition as a possible 
explanation for the observed loop cleavage. Decomposition of the Tat-La(L)3+ peptides by 
either hydrolysis of the metal complex imines to afford free La3+ ion or by disulfide bond 
reduction to afford the corresponding untethered La(L? + complex. In either case, however, 
we would see cleavage in the bulge and not the loop since La3+ and La(L)3+ complexes are 
highly specific for the bulge in both unliganded TAR and in the Tat( 49-72)-TAR complex. 
We note explicitly that in all of our experiments with untethered lanthanide salts or (L)3+ 
complexes we observe highly specific bulge cleavage. The only reagents that display a 
preference for the loop phosphodiesters are Tat-La(L)3+ peptides 1-3. 
One explanation for the observed TAR cleavage is that coupling a Tat(49-72) 
peptide to a La(L)3+ complex inhibits binding to and hence cleavage of the phosphodiesters 
in the TAR trinucleotide bulge affording the observed specificity for the loop for pep tides 
1-3. This would explain the fact that RNA 15 is cleaved by peptide 1 in spite of the fact 
that the pyrimidine bulge has been deleted. Another possibility involves initial binding of 
Tat-La(L)3+ peptide to the Tat binding site proximal to the pyrimidine bulge (Figure 4.15). 
Although the Tat-TAR complex forms we propose that no RNA cleavage results from this 
interaction. Another equivalent of Tat-La(L)3+ approaches a Tat-bound TAR molecule in 
solution. The inherent specificity of the La(L)3+ moiety for the bulge is altered in the Tat-
La(L)3+ reagent because of repulsive electrostatic interactions between the positively 
charged Tat(49-72) fragments of the sequence-specifically bound and the free Tat-La(L)3+ 
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Figure 4.15. One explanation for the loop-specific cleavage of TAR by peptides 1-3. (A), 
(B) A Tat-La(L)3+ peptides binds the RNA to form the Tat-TAR complex but the bound 
metallo-peptide does not direct cleavage of the RNA. (C) Another equilvalent of a Tat-
La(Li+ peptide approaches the Tat-TAR complex. Repulsive electrostatic interactions 
between the free and bound Tat-La(L)3+ peptides disfavors interaction of the La(L)3+ moiety 
of the free Tat-La(L)3+ with the trinucleotide bulge and cleavage is only observed in the 
loop. 
cleavage of the loop phosphodiesters is observed. As the observed cleavage of TAR RNA 
by peptides 1-3 was not sequence-specific our interest in this project was terminated and 
the mechanism of loop cleavage by peptides 1-3 was not further characterized. 
Sequence Specific RNA Hydrolysis by Artificial Catalysts. Since the 
completion of this work several reports of sequence specific RNA hydrolysis by designed 
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catalysts have appeared in which metal complexes are covalently tethered to a 
deoxyribonucleotide and used to cleave a complementary RNA (Figure 4.16). Bashkin 
and coworkers report that a terpyridyl•Cu2+ complex tethered to C-5 of a thymidine base 
can cleave a complementary RNA (18-25% yield, 45 oc, 72 h).27 Komiyama and 
coworkers report that an iminodiacetate-Lu3+ complex can be used to direct the hydrolysis 
of a complementary RNA in modest yield (17%, 37 °C, 8 h).28 The utility of both of these 
approaches may be limited as they require the use of kinetically unstable metal complexes 
to effect RNA hydrolysis. In a significant advance, Magda and coworkers report that a 
kinetically stable expanded porphyrin complex (texaphyrin) of Eu3+ was capable of site-
directed RNA hydrolysis when tethered to the 5' end of a deoxynucleotide (30%-60% 
yield, 37 oc, 18-24 h).29 More recently, Haner and coworkers disclosed that kinetically 
stable octa-aza macrocyclic Eu(III) complexes are capable of near-quantitative yield of 
complementary RNA hydrolysis at physiological pH and temperature.30 These results 
clearly demonstrate that stable complexes of lanthanide ions can be covalently attached to 
RNA-binding ligands to effect sequence-specific RNA hydrolysis. It is not understood 
why hexa-aza Schiff base lanthanide macrocycles tethered to Tat(49-72) or 










Figure 4.16. Designed catalysts for sequence-specific RNA hydrolysis. (A) Terpyridyl 
•Cu(II) complex reported by Bashkin and coworkers.27 (B) Iminodiacetate•Lu(ill) 
complex reported by Komiyama and coworkers.28 (C) Texaphyrin derivitive reported by 




Organic Synthesis. 1H and 13 C NMR spectra were recorded at 300 MHz on a 
General Electric-QE 300 NMR spectrometer. High-resolution mass spectra (HRMS) 
were recorded using electron ionization (EI) or fast atom bombardment (FAB) techniques 
at the Mass Spectrometry Laboratory at the University of California, Riverside. 
Ultraviolet-visible spectra were recorded on a Hewlett-Packard 8452 A diode array 
spectrophotometer. All reactions were conducted under an atmosphere of argon unless 
noted otherwise. Pyridine-sulfur trioxide complex and DMSO were purchased from 
Fluka. N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) was purchased from Pierce. 
Tetrahydrofuran (THF) was distilled under nitrogen from sodium/ benzophenone ketyl. 
Dichloromethane and triethylamine were distilled from calcium hydride. All other reagents 
were purchased from Aldrich. Sephadex-SP C25 resin was obtained from Aldrich and 
stored in 100 mM NH40Ac, pH 4.75 for 8 h before use. Flash column chromatography 
was carried out using EM Science Kieselgel 60 (230-400 mesh).32 Thin-layer 
chromatography was performed on EM Reagents silica gel plates (0.5 mm thickness). All 
compounds were visualized at 254 nm. 
Dimethyl ester (6). A slurry of 25 g (124 mmol) of chelidamic acid (5) in 250 
mL of methanol was treated with 15 mL concentrated sulfuric acid (caution: exothermic) 
and heated at reflux for 8 h. After cooling to ambient solution 750 mL of dichloromethane 
were added and the resulting solution was washed with water (3 x 500 mL), dried with 
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 
11.94 g (26%) of diester 6 that was used immediately. 
Tetrahydropyranyl Ether (7). A solution of 11.94 g (52.1 mmol) of dimethyl 
ester 6 in 360 mL dichloromethane was treated with 20.4 g (243 mmol, 4.65 eqiv.) of 
dihydropyran, and 570 mg ( 3.0 mmol, 0.06 eqiv.) p-toluenesulfonic acid. After stirring 5 
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h at ambient temperature the reaction mixture was partitioned between 200 mL of saturated 
aqueous sodium bicarbonate and 200 mL of ether. The layers were separated and the 
aqueous phase was extracted with ether (3 x 100 mL) and the combined organic layers 
were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated 
under reduced pressure. Purification by chromatography on silica gel (2: 1 hexane/ ethyl 
acetate) afforded 10.35 g (72%) of 7 as yellow oil. 1H NMR (300 MHz, CDC13) 7.90 (s, 2 
H, ArH), 5.65 (m, 1 H, CHO), 4.01 (s, 6 H, CH3), 3.78-3.65 (m, 1 H, CH20), 2.0-1.5 (m, 
6 H, CH2) . 
Bis-Silyl Ether (8). A solution 10.35 g (37.3 mmol) of diester 7 in 400 mL of 
ethanol was treated with 14.1 g (373 mmol , 10 equiv.) of sodium borohydride. The 
solution was heated at reflux for 6 h before it was cooled and treated with 200 mL 1 N 
sodium tartrate. After removal of the ethanol under reduced pressure the resulting 
concentrate was partitioned between 200 mL 1 N KH2P04 and 200 mL dichloromethane. 
The layers were separated and the aqueous phase was extracted with dichloromethane (3 x 
100 mL) and the combined organic layers were washed with brine, dried over anhydrous 
sodium sulfate, filtered, concentrated under reduced pressure, and azeotroped with 
acetonitrile (2 x 50 mL) to afford the diol that was used without further purification. To a 
solution of the diol in 125 mL dichloromethane cooled to 0 oc were added 11.5 mL (82.2 
mmol, 3.0 equiv.) of triethyarnine and 16.9 g (54.4 mmol, 2.0 equiv.) and stirred 1 h at 0 
oc. The solution was quenched with 200 mL 1 N KH2P04 and 300 mL dichloromethane. 
The layers were separated and the aqueous phase was extracted with dichloromethane (3 x 
100 mL) and the combined organic layers were washed with brine (150 mL), dried over 
anhydrous sodium sulfate, filtered, concentrated under reduced pressure. Purification by 
chromatography on silica gel (2:1 hexane/ ethyl acetate) afforded 12.4 g (81.4%) of 8 as 
yellow oil. 1H NMR (300 MHz, CDC13) 7.15 (s, 2 H, ArH), 5.48 (m 1 H, OCHO), 4.85 
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(s, 4H, CH2), 3.90-3.82 (m, 1 H, CH2), 3.80-3.72 (m, 1 H, CH2), 2.05-1.35 (m, 6 H, 
CH
2
), 1.30-0.80 (m, 42 H, 0Si(CH(CH3) 2) 3) . 
Hydroxypyridine (9). A solution of 12.4 g (22.5 mmol) of 8 350 mL dry 
methanol was treated with 7 .88 g (113 mmol, 5 equiv.) of oxalic acid. The solution was 
stirred at ambient temperature 1.5 h during which time a white crystalline solid precipitated. 
The solid was collected by filtration, washed with ice-cold methanol and dried under 
reduced pressure to afford 9.31 g (88.4%) of hydroxypyridine 9. 'H NMR (300 MHz, 
CDC13) 6.75 (s, 2 H, ArH), 6.85 (s, 4 H, CH2), 1.2-1.9 (m, 42 H, 0Si(CH(CH3) 2) 3) . 
Ester (10). A suspension of 5.26 g Ag2C03 (38.2 mmol, 2.1 equiv.) and 9.31 g 
(19.1 mmol) ofhydroxypyridine 9 100 mL DMF at 70 oc was stirred for 10 min before 
9.1 mL of a-methyl bromoacetate was added. The mixture stirred 2 h at 70 oc before it 
was cooled to room temperature and filtered through celite. The filtrate was partitioned 
between 250 mL 1: 1 ether:dichloromethane and 250 mL water and filtered through celite. 
The layers were separated and the aqueous phase was extracted with ether (3 x 100 mL) 
and the combined organic layers were washed with brine (100 mL), dried over anhydrous 
sodium sulfate, filtered, concentrated under reduced pressure. Purification by 
chromatography on silica gel (2:1 hexane/ ethyl acetate) afforded 8.7 g (85%) of 10 as a 
clear, colorless liquid. 'H NMR (300 MHz, CDC13) 7 .0 (s, 2 H, ArH), 4.85 (s, 4 H, CH2) , 
3.80 (s, 3 H, OCH3), 1.20-1.00 (m, 42 H, 0Si(CH(CH3) 2) 3). 
13 C NMR (CDC13) 169, 166, 
104, 67, 64, 52, 18, 11. 
Diol (12). A solution of 920 mg (1.70 mmol) of ester 10 in 5 mL ethylenediamine 
was stirred 4 hat ambient temperature before it was partitioned between ether (30 mL) and 
water (30 mL). The layers were separated and the aqueous phase was extracted with ether 
(3 x 30 mL) and the combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 
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amine 11 as a pale yellow oil. A solution of unpurified 11 in 5 mL THF was treated with 
4 .25 rnL (4.25 mmol, 4.5 equiv.) of a 1 M solution of tetrabutylammonium fluoride in 
THF at 0 oc and stirred for 30 min. The solution was allowed to warm to ambient 
temperature and stir for an additional 2 h and then treated with 2 mL of ethyl 
trifluoroactetate and stirred for an additional 2 h. The solution was concentrated under 
reduced pressure and purified by chromatography on silica gel (1 0:1 CH3CN/ H20) to 
afford 339 mg (59%) of diol12 that was used immediately. 
Aldehyde (4). A solution of 339 mg (1.00 mmol) of diol 12 and 1.40 mL of 
triethylamine (10.0 mmol, 10.0 equiv.) in 5 mL DMSO and 5 mL dichloromethane at 0 oc 
was treated dropwise via cannula with a solution of 954 mg (6 mmol, 6.0 equiv.) of 
pyridine-sulfur trioxide complex in 5 mL DMSO. The solution was stirred at 0 oC for 2 h 
before it was partitioned between 10 mL of 0.1 NaHS04 and 20 mL of 3:1 
ether:dichloromethane. The aqueous layer was extracted with ether (3 x 20 mL) and the 
combined organic layers were washed with brine, dried over anhydrous sodium sulfate, 
filtered, and concentrated under reduced pressure. Purification by chromatography on 
silica gel (1 :1 CH2Cli ethyl acetate) afforded 200 mg (62%) of 4. 
1H NMR (300 MHz, 
CDC13) 10.1 (s, 2 H, CHO), 8.60 (br s, 1 H , NH), 8.05 (br s, 1 H, NH), 7.75 (s, 2 H, 
ArH), 4.80 (s, 2 H, CH2), 3.55-3.45 (m, 4 H, CH2). 
Amine (13). A solution of 20 mg (57.6 J.lmol) dialdehyde 4, 86 mg (636.5 J.lmol, 
11 equiv.) 1,6-pyridinedicarboxaldehyde, and 149.6 mg (345.6 j.lmol, 6 equiv.) of 
lanthanum nitrate hexahydrate in 10 mL methanol was treated with 40.8 mg (mmol, 
equiv.) of ethylenediamine and stirred 10 min during which time a white solid precipitated. 
Three drops of acetic acid were added and the solution was heated at reflux 4 h. After 
cooling to ambient temperature the solid was isolated by filtration and washed with cold 
methanol. The solid was dissolved in 3 mL of water and treated with 150 J..LL of 
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concentrated aqueous ammonium hydroxide. After 2 h the solution was concentated to 
dryness under reduced pressure, dissolved in 4 mL of water, and applied to a column of 
350 mg Sephadex-SP C-25 resin equilibrated with 100 mM NH40Ac, pH 4 .75. Using 
100 mM NH40Ac, pH 4.75 as the eluant, fractions were collected and monitored by UV 
as the unsubstituted La(L)3+ complex eluted from the column. Then a gradient of 180 to 
500 mM NH40Ac, pH 4.75 was used to isolate 20 mg (42.8%) of complex 13 after 
lyophilization. 1H NMR (D20) 8.82 (s, 2 H, NCH), 8.76 (s, 2 H , NCH), 8.37 (t, 1 H, 
ArH), 8.10 (d, 2 H, ArH), 7.63 (s, 2 H, ArH), 4.88 (s, 2 H, OCH2), 4.14 (s, 8 H, NCH2) 
3.62 (t, 2 H, NHCH2), 3.36 (s, 1 H, NH), 3.20 (t, 2 H, CH2NH/), 1.80 (s, 12 H, 
OCOCH3) . 
Pyridyl Disulfide (14). A solution of amine 54 mg (0.17 mmol) amine 13 in 450 
11L of 100 mM NEt30Ac, pH 7.5 was treated with a solution of 75 mg (0.44 mmol, 2 .5 
equiv.) SPDP in 225 11L CH3CN. The resulting solution was vigorously mixed for 3 h at 
ambient temperature when it was concentrated under reduced pressure. The resulting solid 
was dissolved in 6 mL 100 mM NH40Ac, pH 4.75 and purified in three portions by C8 
RP-HPLC. A gradient of 100% A to 80% B over 60 min (A:100 mM NH40Ac, pH 4.75, 
B: 40% 100 mM NH40Ac, pH 4.75/ 60% CH3CN) with a flow rate of 2 mL/min was 
used to isolate the desired disulfide 14 eluting at 50% B. Lyophilization afforded 16 mg 
(25%) of 14. 'H NMR (D20) 8.80 (s, 1 H NCH), 8.7 (a, 1 H, NCH), 8.38 (t, 2 H, ArH), 
8.34 (d, 1H, ArH), 8.08 (d, 2 H, ArH), 7.78 (m, 2 H, ArH), 7.58 (s, 2 H, ArH), 7.23 (br t, 
1 H, ArH), 4 .83 (s, 2 H, OCH2), 4.16 (br s, 8 H, NCH2) , 3.48 (m, 4 H, COCH2CH2S), 
3.04 (t, 2 H, NHCH2), 2.64 (t, 2 H, CH2NH3+), 1.82 (s, 9 H, OCOCH3) . 
Reagents for Peptide Synthesis. Protected amino acid derivatives were 
purchased from Peninsula Laboratories. t-Boc-L-His(DNP) was purchased from Fluka. 
Benzhydrylamine resin (BHA) was purchased from U .S. Biochemical Corp. N,N-
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Dimethylformamide (DMF) and diisopropylethylamine (DIEA), and trifluoroacetic acid 
(TF A) were purchased from Applied Biosystems. Dicyclohexylcarbodiimide (DCC) was 
purchased from Peptides International. N-Hydroxybenzotriazole (HOBt), p-cresol, and p-
thiocresol were from Aldrich. Dichloromethane (DCM) and methanol (HPLC grade) were 
purchased from Mallinkrodt. Diethyl ether (low peroxide content) was obtained from 
Baker. Mass spectrometry and quantitative amino acid analysis was performed at the 
Biomolecule Analysis Facility at the California Institute of Technology. 
Manual Peptide Synthesis. Manual peptide synthesis was carried out in 20-mL 
vessels fitted with coarse glass frits as described by Kent.33.34 Na-t-Boc-L-amino acids 
were used with the following side chain protecting groups: Arg(Tos), Lys(Cl-Z), Cys(p-
MeBzl), Thr(Bzl), and His(DNP). Manual assembly of the protected peptide on the solid 
support was carried out at 25 oc via a three-step reaction cycle. First the Boc protecting 
group was removed from the a.-amino group of the resin-bound amino acid by using TFA 
(65% TFA in DCM for 1 and 15 min). The deprotected peptide resin was then neutralized 
with 10% DIEA in DCM (2 x 1 min). All amino acids were coupled to the free a.-amino 
group as the HOBt esters. Coupling yields were determined by quantitative ninhydrin 
monitoring with acceptable values being 2:99.5%. Average coupling yields were 99.8%. If 
a second coupling was necessary, the resin was neutralized with 10% DIEA in DMF. The 
HOBt ester was formed outside the reaction vessel in an absolute minimum of 
DCM/DMF. The solution was filtered into the vessel to remove the dicyclohexylurea, 
topped off with DMF, and allowed to react for 1-2 hours. If the yield was not acceptable at 
this point, a third coupling was performed by the same protocol as the second coupling. 
Peptide Deprotection and Purification. Samples of the peptide resin (150-300 
mg) were deprotected using HF and p-cresol and p-thiocresol as scavengers as previously 
described.33·34 Crude peptides were purified by C8 semi-preparative RP-HPLC as 
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described using a 0-60% acetonitrile/H20/0.1% TFA gradient.
34 Purified peptides were 
quantitated using the BCA Protein Assay (Pierce) according to the manufacturer's 
instructions using BSA as a standard. 
Tat-La(L)3+ Peptide Synthesis. Tat(49-72)-La(L)3+ peptides 1-3 were all 
synthesized in the same manner. An aqueous solution containing 160 nmol of purified Tat 
peptide is concentrated under reduced pressure and redissloved in 225 f..LL of 22.2 mM 
Tris·HCl, pH 8.0. A aqueous solution of 568 nmol (3.55 equiv.) of pyridyl disulfide 4 in 
17 11-L is added and the resulting solution allowed to stand at ambient temperature. After 3 
h the solution is diluted with 3 mL of water and purified by RP-HPLC using a C8 semi-
prep coulrnn and a gradient of 100% A to 45% B over 90 min (A: 0.1% TFA in H 20 , B: 
0.1 % TFA,/40% H20/60% CH3CN) with a flow rate of 2 mL/min. Fractions were 
collected and analyzed by C8 anylytical RP-HPLC using a gradient of 100% A to 30% B 
over 30 min (A: 0.1% TFA in H20, B: 0.1% TFA,/40% H20/60% CH3CN) with a flow 
rate of 1 mL/min. Fractions containing the desired material were pooled, diluted with 500 
mM NH40Ac, pH 7.0 to a final concentration of 100 mM NH40Ac, frozen, and 
lyophilized. In order to ensure complete removal of NH40Ac, the solids were lyophilized 
3 times from 1.5 mL of water. Concentrations were determined by quantitative amino acid 
analysis . Peptides were stored as aqueous solutions at -20 oc. 
HIV-1 TAR RNA Preparation. HIV-1 TAR was synthesized by run-off 
transcription with T7 RNA polymerase using a DNA template and primer synthesized by 
automated synthesis using ~-cyanoethyl phosphoramidites as previously described.35 
Transcribed TAR was purified by denaturing polyacrylamide gel electrophoresis and stored 
as an aqueous solution at -70 °C. RNA concentrations were quantitated by UV 
spectroscopy using the following molar extinction coefficients: 15,400 (A), 11,700 (G), 
7,300 (C), 9900 (U) cm·1 M·1• After treatment with calf alkaline phosphatase to remove the 
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terminal triphosphate, TAR was labeled at the 5'-end with T4 polynucleotide kinase and 
[y-32P1-ATP as described and purified on a 15% denaturing polyacrylamide gel. TAR was 
3' -end labeled with cytidine 3' ,5' -[5' -32P]-bisphosphate and T4 RNA ligase as described.36 
End-labeled TAR was dissolved in 70 mM NaCI, 10 mM Tris·HCl, pH 7.5 (22 °C) and 
heated to 90 oc for 3 min and allowed to slowly cool to ambient temperature in order to 
form the proper secondary structure as described by Celander and Cech.37 End-labeled 
RNA was stored in 70 mM NaCI, 10 mM Tris-HCl, pH 7.5 at -20 oc. 
RNA Chemical Synthesis. Chemical RNA synthesis was performed on an 
Applied Biosystems 394 synthesizer using 2' -OTBDMS-[3 -cyanoethyl phosphorarnidites 
base protetced with the PAC (rR and rG) or Bz (rC) groups (Biogenix). Following 
automated synthesis base protecting groups were removed by treatment with ammonia-
saturated methanol for 24 hat room temperature. 2' -OTBDMS groups were removed by 
treatment with 0.1 M tetrabutylammonium fluoride in THF for 24 h at room temperature. 
THF was removed by lyophilization and the remaining residue was dissolved in 1 mL of 
water and lyophilized again to remove all traces of THF. The residue was dissolved in 3 
mL of water and dialyzed against 10 mM Tris• HCl, pH 7.2 for 24-48 h at 4 oc with buffer 
changes every 4-8 h. Following dialysis the solution was concentrated by lyophilization 
and dissolved in formamide-TBE loading buffer and elecrophoresed on a 1.4 mm thick 
20% denaturing polyacrylamide gel. The RNA was visualized by UV shadowing and 
excised. The gel slice was crushed and soaked in 500 mM NH40Ac, pH 7.0 at 37 "C for 
12-18 h. The isolated RNA was ethanol precipitated, dissolved in 400 mL of water and 
desalted using a NAP-5 column (Pharmacia). RNA concentrations were quantitated by 
UV spectroscopy using the following molar extinction coefficients: 15,400 (A), 11,700 
(G), 7,300 (C), 9900 (U) cm·1 M·1 • 
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RNA Cleavage Reactions. Reaction conditions were 70 mM NaCI, 10 mM Tris-
HCl, pH 7.2, 37 °C, and approximately 40,000 cpm of 5' end-labeled RNA in a total 
volume of 20 fl.L containing the appropriate concentration of cleaving reagent. Reactions 
were allowed to proceed for the appropriate length of time and terminated by ethanol 
precipitation. Samples were resuspended in formamide-EDT A loading buffer, heated to 
90 oc for 3 min, ice-cooled, and electrophoresed on a 15% or 20%, 1:20 cross-linked, 7 M 
urea denaturing polyacrylamide gel for 5-6 h at 40 V /em. Following electrophoresis gels 
were wrapped in plastic fim and quantitated by storage phosphor autoradiography. 
End-Product Analysis. Reaction conditions forT AR cleavage by Tat( 48-72, Cys48 -
La(L)3+) (0.5 f..LM) were 70 mM NaCI, 10 mM Tris·HCl, pH 7.2, and approximately 
200,000 cpm of end-labeled RNA in a total volume of 20 f..LL Cleavage reactions were 
incubated at 37 oc for 12 h and terminated by ethanol precipitation. The presence of 5'-
hydroxyl groups was assayed by dissolving the 3' -end-labeled TAR cleavage products in 
10 fl.L of buffer containing 10 mM ATP, 50 mM Tris·HCl, 10 mM MgC12, 5 mM DTT, 
100 mM spermidine, 100 mM EDTA, 5% glycerol, pH 9.5, and 5 units of 3'-
phosphatase-free T4 polynucleotide kinase. The reactions were incubated at 37 °C for 1 h 
and terminated by ethanol precipitation. The presence of phosphates at the 3' -termini was 
assayed by dissolving the 5'-end-labeled cleavage products in 10 mL of buffer containing 
20 mM Tris·HCl, 20 mM MgC12, 5 mM DTT, pH 6.8, and 20 units of T4 polynucleotide 
kinase. The reactions were incubated at 37 oc for 1 h and terminated by ethanol 
precipitation. For both 5' and 3' end product analyses the conditions for RNase T1 
digestion of TAR were 0.03 units RNase T1 , 35 mM NaCl, 3.5 M urea, 2 mM EDTA, 20 
mM sodium citrate, pH 5.0, and approximately 200,000 cpm of 32P end-labeled TAR in a 
total volume of 50 fl.L. After incubation at 37 oc for 20 min digestions were terminated by 
ethanol precipitation. All cleavage products were analyzed by electrophoresis on a 20%, 
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1:20 cross-linked, 7 M urea, 0.4 mm thick denaturing polyacrylamide gel at 45 V/cm for 
15 h. 
Quantitation by Storage Phosphor Technology Autoradiography. Following 
electrophoresis, gels were wrapped in plastic film and exposed to photostimulable 
phosphorimaging plates (Kodak Storage Phosphor Screen S0230) for 12-24 h in the dark 
at 22 oc. A Molecular Dynamics 400S Phosphorlmager was used to obtain all data from 
the storage screens. Cleavage intensities for each nucleotide were obtained by performing 
volume integrations of each band using the ImageQuant v. 3.0 software running on a AST 
Premium 386/33 computer. Individual arrow heights were obtained by subtracting 
background cleavage from the total cleavge intensity. 
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Addendum to Chapter 4 
Part 1 
Analysis of the Specificity of Lanthanide-Catalyzed Hydrolysis 
of a Designed, Folded RNA Structure 
Experimental Design. In the course of examining the specificity of TAR cleavage 
by La(N03) 3 and La(L)
3
+, RNA 16 was prepared by chemical synthesis and analyzed in a 
similar fashion (Figure 4.17). RNA 16 is a derivitive of TAR in which the double-helical 
stem below the trinucleotide pyrimidine bulge has been deleted and a single-stranded 
region has been inserted at the 5' end. The purpose of these experiments was to determine 
the specificity of lanthanides for cleaving different types of structural elements , i.e. duplex, 
bulge, loop, single-stranded, in a stable, folded RNA structure. RNA 16 was 5' 32P end-
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Figure 4.17. Predicted secondary structure of RNA 16. 
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labeled and treated with 100 !J.M La(N03) 3 for 30 min (70 mM NaCl, 10 mM Tris•HCl, 
pH 7.2, 37 oq and the cleavage products were analyzed by 20% denaturing gel 
electrophoresis. The single-sranded regions in RNA 16 are all cleaved with greater 
efficiency than the double helical stem regions (Figure 4.18). Within the single-stranded 
regions, the upaired nucleotides at the 5' end and the nucleotides in the pyrimidine bulge 
appear to be more reactive than the six nucleotides in the loop. These results underscore 
the importance of targeting single-stranded regions in an RNA moleclue with artificial 
catalysts for sequence-specific hydrolysis. 
Single-
Stranded Duplex I Bulge I Duplex I Loop Duplex 
Figure 4.18. Cleavage of RNA 16 by 100 !J.M La(N03) 3 after 30 min (pH 7.2, 37 oc). 
Bar heights are proportional to the extent of cleavage as measured by storage phosphor 
autoradiography. No data was obtained for the 5'-GGCC-3' sequence at the 3' end of the 
sequence as the bands corresponding to cleavage at these positions were located too close 
to intact RNA 16 in the autoradiogram for accurate quantitation. 
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Addendum to Chapter 4 
Part2 
Attempted Transesterification of Single-Stranded DNA by 
Nucleophile-Appended Lanthanide Complexes 
Experimental Design. Nucleophile-appended La(L)3+ complexes 17-22 were 
prepared and tested for their ability to hydrolyze single-stranded DNA (Figure 4.19). The 
hydroxyl groups were designed to mimic the 2' -hydroxyl group of RNA. Binding of the 
complex to a DNA phosphodiester was designed to activate it for attack by the appended 
nucleophile, effecting strand cleavage by transesterification. A 20mer oligodeoxy-
nucleotide 32 P labeled at the 5' end was treated with complexes 17-22 (50 mM NaCl, 10 
mM Tris•HCl, pH 7-9, 12-48 h, 37-55 °C) and analyzed for cleavage by 20% denaturing 
gel electrophoresis. No cleavage above background levels was observed with any of the 
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Figure 4.19. Structure of nucleophile-appended lanthanide complexes designed for DNA 
transesterification. 
